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It is essential for an organism’s viability to ensure that the correct sets of 
genes are expressed in the right place and at the right time. There are several 
mechanisms by which cells regulate the amount of protein produced from 
genes under different conditions. One of the most basic is transcriptional 
regulation. By controlling the recruitment of RNA polymerase and associated 
factors to gene promoters, and the assembly of the transcription initiation 
complex, transcription factors regulate the transcriptional process, and 
therefore the expression of particular genes. A large number of human diseases 
are caused by malfunctions in transcriptional regulation, highlighting the 
importance of this system.
Here I present a computational study of transcriptional regulation 
in the human genome. First I identify and analyse the properties of 1,369 
sequence-speciﬁc DNA-binding transcription factors in the human genome. 
We show that: (i) 80% of transcription factors belong to just three protein 
families, with the C2H2-Zn ﬁnger family being the most common; ii) 40% 
of factors are spatially clustered in speciﬁc chromosomal regions, and as a 
result may function in a co-ordinated manner; iii) transcription factors either 
function speciﬁcally in one or two tissues or ubiquitously across the whole 
body, giving rise to a two-tier organisation of global and local regulators; and 
iv) groups of transcription factors have arisen in the human lineage at key 
events during evolution (such as the appearance of mammalian organisms).
Secondly, I examine how sequence variation in the human genome, and 
in particular single nucleotide polymorphisms (SNPs), disrupt the normal 
function of the transcriptional regulatory system. I predict functional 
nucleotide sequence motifs (such as transcription factor binding sites and 
exonic splicing enhancers) inside or in the proximity of genes, and identify 
SNPs that overlap with them. Despite the simplicity of the approach, many 
of the predicted disruptive SNPs have been validated experimentally and 
have been associated with diseases.
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Finally, none of the above results could have been obtained without the 
development of methods and tools required to perform a robust analysis of 
the data. In the past ten years the tandem development of high-throughput 
technology along with the sequencing of numerous genomes have produced 
a ﬂood of data describing biological systems from a global perspective. These 
new data types often require special statistical or mathematical treatment in 
order to interpret them. I have devoted a large part of this dissertation towards 
creating methods and web-tools to analyse genomic data. These include 
approaches for: (i) cDNA microarray normalisation and quality control; (ii) 
identifying differentially expressed genes; (iii) building sets of genes with 
class prediction properties; (iv) performing transcription factor annotation of 
microarray experiments; (v) assessing the sensitivity and speciﬁcity of gene 
level measurements for Affymetrix GeneChips; (vi) detecting tissue-speciﬁc 
expression from microarray data; and (vii) detecting binding signal for ChIP-
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1. Introduction
“The discovery of regulator and operator genes, and of repressive regulation of 
the activity of structural genes, reveals that the genome contains not only a series 
of blue-prints, but a co-ordinated program of protein synthesis and the means of 
controlling its execution.” 
- Jacob and Monod 1961 
Cellular life must recognise and respond appropriately to diverse internal 
and external stimuli. By ensuring the correct expression of speciﬁc genes, the 
transcriptional regulatory system plays a central role in controlling many 
biological processes ranging from cell cycle progression and maintenance of 
intracellular metabolic and physiological balance, to cellular differentiation 
and developmental time-courses.
Proteins are produced based on the information contained in the DNA 
through a series of very tightly controlled phases (Figure 1.1). The ﬁrst step 
is called transcription, the process by which a section of the DNA molecule 
is used as a template to produce a precursor RNA messenger molecule. This 
is enzymatically processed to a mature mRNA molecule which acts as an 
intermediary for protein synthesis (Crick et al., 1961; Crick, 1970; reviewed 
2in Alberts et al., 2002).
The second phase is called translation, a process by which the mRNA 
is used as a template that determines the sequence of amino acids linked 
together in a polypeptide protein chain. The amino acid type is inferred 
from a translation code, in which triplets of nucleotide bases correspond to 


















Figure 1.1 | Schematic diagram of protein synthesis from DNA. (A) Genes encoded 
in genomic DNA are transcribed to a mRNA molecule via transcription. This process 
is controlled by chromatin condensation, transcriptional regulation mediated by 
transcription factors and pre-mRNA processing among other mechanisms. (B) 
Mature mRNA molecules are used as templates to produce amino acid chains via 
translation. This is regulated by the mRNA transport outside of the nucleus, mRNA 
degradation, translational efﬁciency and post-translational processing.
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3The newly manufactured protein chain folds into a three-dimensional 
structure, and can be processed further in a third phase via post-translational 
modiﬁcations: different chemical reactions can modify the protein structure 
and therefore its activity or cellular localisation (reviewed in Lodish et al, 
2004; Walsh and Jefferis, 2006).
The amount of protein and its activity are controlled through multiple 
mechanisms at the transcriptional, translational and post-translational stages. 
The transcriptional stage includes chromatin condensation, polymerase 
recruitment or inhibition and RNA processing. During the translational 
and post-translational phases mechanisms include mRNA export from the 
nucleus, RNA degradation, translation efﬁciency, and post-translational 
modiﬁcations (Darnell, 1982). Although all these mechanisms contribute to 
determining protein concentration and activity, transcriptional regulation is 
one of the most important. It controls whether or not a gene is expressed and 
at what level, and therefore the total amount of mRNA that will feed the rest 
of the process. 
In this thesis, I apply genomic and computational biology techniques to 
further our understanding of transcriptional regulation in humans.
1.1 How transcription is controlled
RNA polymerase is the enzyme responsible for the production of RNA 
molecules from a DNA template. Although there are variants of this 
enzyme between prokaryotes and eukaryotes, the molecular mechanisms of 
transcription are quite conserved and well understood (Bushnell el at., 2004; 
Cramer et al., 2001; Gnatt et al., 2001; reviewed in Boeger et al., 2005).
Transcription initiates preferentially from speciﬁc locations in the 
upstream region of each gene. These are called gene promoters and are 
locations where the polymerase and other associated proteins assemble the 
transcription pre-initiation complex (PIC) (Gross and Oelgeschlager, 2006; 
How transcription is controlled
4Smale and Kadonaga, 2003). RNA polymerases do not display sequence 
speciﬁcity in their DNA-binding; however in order to control transcription 
of speciﬁc genes they must bind preferentially to certain promoters (Brodsky 
et al., 2005).
This is of particular importance in higher eukaryotes, as a great majority 
of their genomes is non-coding (eg, around 98% of the human genome; 
International Human Genome Sequencing Consortium, 2004). How does the 
RNA polymerase detect those genes that should be expressed?
Selectivity for certain promoters is achieved through a set of proteins 
called transcription factors, which are responsible for recruiting the 
RNA polymerase to speciﬁc promoters and activating or repressing the 
transcriptional activity of genes based on the cell’s requirements (Figure 1.2). 
There are two broad classes of transcription factors:
i) General transcription factors. These are responsible for RNA 
polymerase assembly in core promoters and are associated with the pre-
initiation, initiation, elongation and termination of transcription. The general 
transcription factors are sufﬁcient for initiating basal levels of transcription 
in eukaryotic cells (Hampsey, 1998; Thomas and Chiang, 2006).
ii) Non-general or speciﬁc transcription factors. These are regulators 
that activate or repress transcription in different conditions or cell types. 
These proteins contain a DNA-binding domain that recognises speciﬁc 
binding site sequences or motifs in the DNA. They control the recruitment 
of the polymerase and general transcription factors thereby promoting or 
repressing transcription (Kadonaga, 2004). Additionally, they are sometimes 
associated with the recruitment of chromatin remodelling complexes, which 
in turn affect expression levels by changing the DNA conformation.
The protein-DNA interaction interface has been extensively studied (Jones 
et al., 1999; Marmorstein et al., 1992; Luscombe and Thornton, 2002; Suzuki 
et al., 1995; reviewed in Harrison, 1991; Luscombe et al., 2000) and more 
than 200 different DNA-binding protein domains have been identiﬁed so far 
(Mulder et al., 2007). The most common mechanism for sequence recognition 
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5involves the interaction of an alpha-helix of the DNA-binding domain with 
the DNA major groove (Luscombe et al., 2000).
Many other proteins also affect transcription without binding directly 
and speciﬁcally to DNA, such as co-factors and histone modiﬁers. Although 
many studies group these proteins with direct DNA-binding factors, I have 
excluded them from my work here, as the mechanism of transcriptional 
regulation is very different.
The importance of transcriptional regulation is underlined by the large 
number of diseases caused by a breakdown in the system. These include 
cancer (Darnell, 2002), and developmental (Boyadjiev and Jabs, 2000) and 
neurodegenerative diseases (Steffan et al., 2000). Therefore, it is very important 
to characterise and understand the different mechanisms that cells employ 
to regulate transcription, as well as the effects resulting from changes in the 





Figure 1.2 | Transcription factor mediated transcriptional regulation. The diagram 
represents the transcriptional regulatory mechanisms that control gene expression 
levels in eukaryotic organisms. The RNA polymerase II (light yellow) binds to the 
promoter of a gene along with the general transcription factors (small sub-units 
surrounding the polymerase) recruited by sequence-speciﬁc transcription factors 
(light blue) recognising transcription factor binding sites (TFBS).
How transcription is controlled
61.2 Genomics
Molecular biology has traditionally been based on a reductionistic approach 
in which complex biological systems are dissected into their simplest 
components in order to study them in great detail. Once the individual 
components are characterised they are then placed together in an attempt to 
explain the entire system. This method has worked very well in establishing 
the molecular function of many genes and deciphering the causes of 
diseases such as phenylketonuria (reviewed in Eisensmith and Woo, 1992), 
and haemophilia (reviewed in Bowen, 2002). However, the method relies 
on components retaining the same functionality in isolation and within a 
system. This is known to be untrue in many cases, as interactions with other 
components introduce new capabilities (Kitano, 2002). This is highlighted 
by the limited success of molecular biology in understanding systems such 
as cancer or development which involve the combined activity of numerous 
genes.
A complementary approach is to study biological systems as a whole, 
using a genomic approach. Genomics can be deﬁned as the analysis of the 
entire genome of an organism and the integration of the functionality of 
each component to create a global view of the system. This has required 
the development of new technologies in order to scale molecular biology 
techniques to work at much larger scale. Genomics has revolutionised the 
way in which we approach biological research as it allows us to evaluate the 
behaviour of whole systems, and so describe them using general principles.
An example of the way in which genomics has overturned our previous 
understanding of biology is the study of mammalian promoters (Carninci et 
al., 2006). The classical view of promoters derived from studies in prokaryotes, 
whose genes tipically include an AT-rich region called TATA-box, situated 
30 base pairs upstream of the transcription start site, at which the TATA-
box binding general transcription factor (TBP) binds and assembles the pre-
initiation complex (Alberts et al., 2002). Recent genomic studies, however, 
have shown that the majority of gene promoters lack a TATA-box and 
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eukaryotes. A further surprise is that non-TATA-box promoters appear to 
have multiple transcription start sites (see Sandelin et al., 2007 for a review). 
These results clearly highlight the importance of genomic approaches in 
allowing us to make general conclusions about systems without bias from 
individual observations.
While powerful, new genomic approaches create challenges not previously 
faced by biologists: the amount and complexity of the data demands robust 
mathematical and automatic treatment in order for them to be interpreted 
sensibly. This associates genomics unequivocally with bioinformatics and 
computational biology. Purely genomic analyses, however, cannot replace 
the traditional, careful examination of single components; results generated 
by computational approaches must be tested experimentally. Therefore, 
collaborations between experimentalists and bioinformaticians are essential 
as both approaches complement each other.
1.3 High-throughput data
The sequencing of more than 500 genomes (as of May 2007) including those of 
human, mouse, chimpanzee or yeast, represents a milestone in our biological 
knowledge (Lander et al., 2001; The Chimpanzee Sequencing and Analysis 
Consortium, 2005; Venter et al., 2001; Waterston et al., 2002). However, the 
availability of these sequences is only the initial step towards understanding 
the functionality encoded in them and many downstream analyses are still 
necessary.
First, gene ﬁnding algorithms were developed (reviewed in Burge and 
Karlin, 1998) which allowed us to determine the full set of components of a 
genome. Next, the identiﬁcation of genes fuelled the development of high-
throughput technologies such as microarrays, yeast-two-hybrid assays and 
RNAi screenings that allow us to gain information about their functionalities 
in different systems. Most of these techniques are based on traditional 
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8molecular biology assays for single gene analysis that have been scaled up to 
analyse thousands of genes at once.
1.3.1 Gene expression microarrays
The level of gene expression for single genes can be measured using the 
Northern blot. Here, single-stranded radioactive DNA molecules with 
particular sequences matching the gene of interest are used to measure the 
amount of transcripts of that gene in nuclear extracts. One of the ﬁrst high-
throughput technologies to be developed was microarrays (Schena et al., 
1995), which allowed the simultaneous interrogation of thousands of gene 
expression levels at once. This is achieved thanks to the availability of the 
genes’ sequences, which allow us to design speciﬁc probes assessing the 
level of expression at a genomic scale. These probes are physically attached 
to a device that allows us to track their individual signal.
The use of microarrays was pioneered for S. cerevisiae to measure global 
changes in gene expression for diverse cellular conditions (Cho et al., 1998; 
DeRisi et al., 1997; Lashkari et al., 1997; Spellman et al., 1998; Wodicka et al., 
1997) and to identify abnormally expressed genes in human cancer samples 
(DeRisi et al., 1996).
The scope of microarray use has greatly expanded since then, and 
microarrays are now routinely employed to determine the outcome of 
particular diseases (van ‘t Veer et al., 2002), classify samples in different 
groups based on their expression patterns (van de Vijver et al., 2002), explore 
expression across the whole genome (Bertone et al., 2004), detect sequence 
variation between individuals of the same species (Janne et al., 2004), or 
simply measure the expression levels of genes in normal and healthy tissues 
(Su et al., 2004).
Despite the individual protocol adjustments for different methods, 
microarrays can be broadly classiﬁed into two major groups: (i) printed 
oligonucleotide microarrays, and (ii) complementary DNA (cDNA) 
microarrays.
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called photolithography in which single-stranded nucleotide sequences 
are synthesised directly on the glass slides. The oligonucleotide probes are 
usually between 25 and 60 bases long. Gene expression levels are measured 
by extracting and fragmenting mRNA from cellular samples, and then 
transforming the RNA into biotinylated single-stranded complementary 
DNA sequences that are hybridised to the corresponding microarray probes. 
The biotinylated sequences are then stained using a ﬂuorescent streptavidin-
phycoerythrin antibody and the expression levels measured using a laser-
based scanner. The most commonly used arrays of this type are the Affymetrix 
GeneChips®.
ii) cDNA microarrays. Instead of using short oligonucleotides, these 
microarrays use long nucleic acid sequences as probes. The nucleic acids 
are manufactured by cloning the sequences into bacterial libraries and 
amplifying them by PCR. Probe lengths in this case vary from several 
hundred to thousands of base pairs. Once synthesised the probe sequences 
are physically attached to a glass slide using a robotic spotter or inkjet device. 
These microarrays are most commonly used for comparing hybridisations 
between two different mRNA samples, each labelled with a different 
ﬂuorescent dye attached to the transformed cDNA molecule. The microarrays 
are then scanned at two different wavelengths to measure the amount of 
hybridisation from each sample. Therefore, these microarrays are analysed as 
a comparison between the two samples analysed. These types of microarrays 
have been widely manufactured in-house using robotic spotters.
Each technology has its beneﬁts and drawbacks: recent studies 
have compared available technologies and suggested that commercial 
oligonucleotide microarrays, owing to their standardised manufacturing 
process and experimental protocols, and the higher probe density provide 
more reliable results. However it has also been reported that one the biggest 
reasons for discrepancies among platforms and laboratories arises from 
differences in post-experimental data processing and analysis (Bammler et 
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al., 2005; Irizarry et al., 2005; Larkin et al., 2005).
1.3.2 Chromatin immunoprecipitation followed by microar-
ray hybridisation
Chromatin immunoprecipitation is a long-standing technique to detect 
protein-DNA interactions. Cells are treated with formaldehyde to cross-link 
the proteins and DNA, so stabilising these complexes in in vivo conditions. 
The cellular components are extracted and sonicated to break down the 
chromatin into short fragments of around 200-500 bases in length. The 
sample is then treated with antibodies against speciﬁc transcription factors 
to immunoprecipitate the protein-DNA complexes. The DNA fragments are 
then dissociated from the proteins and assayed via Southerns or sequenced 
to identify the original DNA-binding sites.
The technique is now frequently coupled with microarrays to determine 
DNA-binding sites on a larger scale (Boyer et al., 2005; Cawley et al., 2004; 
Horak et al., 2002a,b; Iyer et al., 2001; Martone et al., 2003; Ren et al., 2000). 
The immunoprecipitated DNA is hybridised to microarrays containing 
probe sequences for intergenic regions. For smaller genomes it is possible 
to represent all intergenic regions; however for complex organisms such as 
mouse and humans, microarrays are usually restricted to promoter regions. 
The sample is compared against a control of genomic DNA or a mock-
immunoprecipitation. The analysis is similar to that for gene expression 
experiments (see below), except that enrichment is expected only for the 
immunoprecipitated sample.
1.3.3 Tiling arrays
Continuous improvements to the microarray production process have 
allowed manufacturers to increase the probe density of slides from several 
thousand to several millions. This makes it possible to design microarrays 
that cover not only speciﬁc genomic loci but entire genomes. These tiling 
arrays — so-called because probes “tile” across the whole genome — allow 
us to interrogate transcription for the genome in an unbiased fashion. Using 
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tiling arrays, several studies have detected unexpected regions of the human 
genome that appear to be actively transcribed (Bertone et al., 2004; Cheng et 
al., 2005; Kapranov et al., 2005). This contributed to the now-accepted view 
that the human genome contains thousands of non-coding RNA genes, many 
of them transcribed from the anti-sense strand of known protein coding genes. 
Tiling microarrays have also been used for chromatin immunoprecipitation 
experiments revealing widespread protein binding not limited to promoters 
(Lee et al., 2006).
1.3.4 Re-sequencing techniques
Sequencing technologies have improved in the past 30 years resulting in a 
dramatic rise in throughput. The increased capacity allows us to sequence 
many individuals of the same species as well as many other model organisms, 
in order to measure both intra- and inter-species genomic variation.
i) Intra-species variation. Although we have developed the tendency 
to conceptualise an organism’s genome as having a universal and ﬁxed 
genomic sequence, individuals in fact never share the exact same DNA 
sequence (unless they are identical twins). Such differences enable organisms 
to diversify and therefore adapt to changes in the environment more easily 
as a population. Different molecular mechanisms lead to intra-species 
variations, including recombination, segmental duplications, insertions 
or deletions, translocations and mutations. The most frequent types of 
variation for humans are point mutations, which consist of single nucleotide 
changes. These mutations propagate in a sub-population only if they are 
non-fatal and occur in the germ line. Mutations are ofﬁcially classiﬁed as a 
single nucleotide polymorphism (SNP) if they arise in more than 1% of the 
population (Chakravarti, 2001).
More than 12 million SNPs have been identiﬁed so far (dbSNP v.126; 
Sherry et al., 2001) through international collaborations such as the HapMap 
project (The International HapMap Consortium, 2003) which sequenced 
diverse human populations. These data are publicly available and enable us 




ii) Inter-species variation. The availability of the genome sequences of 
other model organisms provides valuable data describing how evolution has 
progressed over millions of years. Using comparative genomic techniques 
we can detect species-speciﬁc features as well as those that are conserved 
(Bejerano et al., 2004; reviewed in Boffelli et al., 2004; Ureta-Vidal et al., 
2003). Comparative genomics is an important area of research with many 
applications, but it is not the focus in the current thesis.
A.   Data acquisition B.   Normalisation & pre-processing
C.   Unsupervised
clustering
D.   Supervised classiﬁcation
& prediction
E.   Lists of signiﬁcant genes
F.   Functional annotation
Figure 1.3 | Microarray data analysis ﬂowchart. The diagram shows a common 
workﬂow for microarray data analysis. After (A) scanning, the microarray data must 
be (B) normalised and pre-processed to remove systematic non-biological variation 
from the data. The next steps consist either of (C) unsupervised clustering to detect 
genes or samples with similar expression patterns, or (D) perform supervised 
classiﬁcation techniques to identify differentially expressed genes or probes between 
groups of samples. Both approaches return (E) lists of genes that can be subsequently 
(F) functionally annotated using additional biological information such as genomic 
location or GO annotations.
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1.4 Gene expression microarray data analysis
Standard microarray experiments produce expression data for thousands of 
genes. Owing to the large quantity of data and the level of noise found in them, 
we need robust computational tools and statistical techniques to analyse and 
interpret the results. The most common workﬂow for analysing microarray 
data comprises: (i) data acquisition; normalisation and pre-processing; (ii) 
unsupervised class-discovery; (iii) differential gene expression, supervised 
classiﬁcation and prediction; and (iv) functional interpretation of the results 
(Figure 1.3). Of course the details of the workﬂow differ depending on the 
biological question being addressed.
i) Data acquisition, normalisation and pre-processing: This is the most 
variable step between microarray platforms. A scanner is used to detect the 
ﬂuorescence for each probe in order to measure the amount of hybridisation: 
a single wavelength laser is used for oligonucleotide microarrays, or two 
lasers of different wavelength for cDNA microarrays.
The scanned images are converted into numerical read-outs of 
ﬂuorescence levels with software such as GenePix. Ideally these values should 
directly reﬂect the expression level for genes, however ﬂuorescence values 
also contain biases because of the manufacturing or handling procedures 
employed (Quackenbush, 2002). To remove sources of systematic bias, 
several methods for data normalisation have been developed (Huber et al., 
2002; Irizarry et al., 2003; Smyth and Speed, 2003). Methods vary between 
microarray platforms, although the most common ones are based on the 
assumption that the majority of genes do not change in expression between 
samples.
ii) Unsupervised class-discovery or clustering: The aim of this step is to 
ﬁnd classes of genes or samples within the same experiment that behave 
in a similar fashion in their expression. The algorithms do not use any 
prior knowledge about the class membership of samples and therefore the 
detection of classes or clusters is based on the similarity in the behaviour 
of genes. Clustering was among the ﬁrst analysis techniques employed for 
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microarray data and has been used extensively, in, for example, a number 
of seminal research projects which identiﬁed genes with similar expression 
patterns across the yeast cell cycle and sporulation time courses (Chu et al., 
1998; Eisen et al., 1998; Spellman et al., 1998).
iii) Differential gene expression, supervised classiﬁcation and class 
prediction: This is an alternative approach to identify genes displaying 
interesting gene expression in which we utilise prior knowledge about the 
samples being analysed (eg, class membership). Most frequently we apply 
statistical techniques to highlight features that differ between distinct sets of 
samples that might be used as classiﬁers or predictors for class membership. 
Differential gene expression analysis has been widely employed to select 
genes behaving differently between various types of cancer, and therefore 
provide a list of candidate genes for follow-up studies (Clark et al., 2000). 
Similar approaches have been applied to numerous other biological problems 
ranging from detecting genes that are responsible for the pluripotency and 
self-renewing properties of the stem cells (Ivanova et al., 2002; Ramalho-
Santos et al., 2002) to the study of co-ordinated gene responses in plants 
(Schenk et al., 2000). The gene lists —often referred to as the ‘signature’ for a 
biological condition— can in turn be used to classify samples or predict the 
future outcome of the process under investigation (Ramaswamy et al., 2003; 
van ‘t Veer et al., 2002). Such gene signatures have been used to develop 
commercial microarray solutions; for example, the Mammaprint® (http://
www.agendia.com/common.asp?id=80) has been used to evaluate the risk of 
breast cancer relapse after surgery.
iv) Functional interpretation of the results: Almost all techniques 
above output lists of genes related to a particular outcome, behaviour, or 
temporal expression pattern. To gain insight into the biological implications 
of these results we can incorporate some of the vast amounts of biological 
information available from different databases. The most common types 
of analyses look at the functional annotations from the Gene Ontology 
database (GO; Ashburner et al., 2000), gene structure and protein domains 
from InterPro (Mulder et al., 2007), cellular pathways from databases such as 
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KEGG (Kanehisa et al., 2006), and putative transcription factor-binding sites 
upstream of differentially expressed genes from databases such as JASPAR 
(Sandelin et al., 2004), CisRED (Robertson et al., 2006) and TRANSFAC 
(Wingender et al., 2000).
1.5 Genomics and transcriptional regulation
Transcriptional regulation has been extensively studied from a genomic 
perspective in recent years. Most experimental studies have focused on yeast, 
as it is a relatively simple organism that is easy to experiment on, and yet has 
high levels of conservation relative to more complex organisms. These have 
used microarrays measuring gene expression under diverse conditions such 
as stages of the cell cycle, sporulation, diauxic shift, DNA damage, and stress 
response (Cho et al., 1998; Chu et al., 1998; DeRisi et al., 1997; Gasch et al., 
2001; Gasch et al., 2000). There are now over 120 microarray experiments for 
yeast (as of May 2007) in the ArrayExpress database (Parkinson et al., 2005).
To complement gene expression studies and computational approaches, 
high-throughput experimental methods have been developed to detect 
transcription factor binding sites in vivo. In yeast, these studies consisted 
of ChIP-chip experiments (Horak et al., 2002a; Lee et al., 2002), where the 
target genes of multiple factors, such as SBF or MBF, the major transcription 
factors controlling the G1/S phase transition, were determined. This allowed 
us to recreate the regulatory network and to show which parts of it are active 
under speciﬁc conditions (Luscombe et al., 2004).
In human however, the majority of studies involving genomics have 
focused on detecting differences between tumours and healthy tissues 
(Bhattacharjee et al., 2001; DeRisi et al., 1996; Golub et al., 1999; Ramaswamy et 
al., 2001). As experimental techniques have improved, however, there is now 
more and more interest in deciphering the logic controlling the transcriptional 
regulatory processes. The main reason behind this interest is the relationship 
between the malfunctioning in these control mechanisms and major diseases 
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such as cancer, and developmental or neurological disorders. Most of current 
research is directed towards understanding how combinations of multiple 
transcription factors regulate different processes (Lemon and Tjian, 2000). In 
order to achieve this goal, studies have identiﬁed different locations in the 
genome where particular transcription factors bind to regulate the expression 
of particular genes. The computational approaches developed to carry out 
this task vary from direct sequence analysis, ie, identiﬁcation of binding site 
consensus sequences in the genome, to phylogenetic footprinting, where 
evolutionary information is integrated in the analysis to restrict analysed 
regions to those conserved between particular species (Tompa et al., 2005). 
Unfortunately, these computational approaches generate results with false 
positive rates in the order of thousands for each right prediction (Wasserman 
and Sandelin, 2004).
These computational studies have been complemented in higher 
organisms with experimental approaches employing techniques such as 
ChIP-chip (Martone et al., 2003), DamID (Greil et al., 2006) or the gateway-
compatible one-hybrid system (Deplancke et al., 2006), although the 
outcome of these results in mammalian systems is still unclear mainly due 
to the quality of the data and the difﬁculties in their interpretation. It has 
not been until very recently, coinciding with the improvement on the data 
quality obtained from ChIP-chip experiments for human, that work has been 
devoted to understand the transcriptional regulatory network in human. This 
has involved the analysis of the binding sites for several key developmental 
transcription factors, such as OCT4, NANOG, or the polycomb group (Boyer 
et al., 2005; Boyer et al., 2006; Lee et al., 2006). Despite these efforts and 
interest in understanding transcriptional regulation, our knowledge of this 
regulatory system in higher organisms is still very basic.
One of the main reasons for our lack of knowledge is that, seven years 
after the initial publication of the human genome, we still do not have a high-
quality, comprehensive list of transcription factors in the human genome. 
The original human genome papers estimated between 200 and 300 general 
transcription factors and between 2,000 and 3,000 sequence-speciﬁc DNA-
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binding transcription factors (Lander et al., 2001; Venter et al., 2001). Since 
then, only two studies have tried to characterise the repertoire of human 
transcription factors. In the ﬁrst, Messina et al. (2004) used the Transfac 
database and proteins annotated as transcription factors in GO to build a 
set of transcription factors that they subsequently used as a seed for hidden 
Markov models searches against the human transcriptome. The results from 
this study detected a human transcription factor repertoire of 1962 members. 
A superﬁcial examination of the list reveals that some proteins are mis-
annotated as transcription factors. The reason behind this observation is 
that whereas some DNA-binding domains are very strict and are only found 
and used by transcription factors, other DNA-binding domains are very 
promiscuous and occur in many other proteins with different functions.
A similar approach for ﬁnding transcription factors is followed by 
Kummerfeld and Teichmann in the DBD database (Kummerfeld and 
Teichmann, 2006). There, a set of manually curated DNA-binding domains 
from Pfam and SUPERFAMILY were used to predict transcription factors 
for different species. They ﬁltered out those promiscuous DNA-binding 
domains in order to lower the false positive rate of detection. Although this 
second approach is much more accurate than the one mentioned above, the 
stringent DNA-binding ﬁltering, necessary to keep a low number of false 
positives, decreases the level of coverage for higher organisms.
1.6 Aim of this thesis
The work I present in this thesis aims to increase our level of knowledge 
about transcriptional regulation in human through the analysis of genomic 
data using computational and bioinformatic approaches. This is achieved 
by a global-scale analysis of genomes, gene expression data and sequence 
variation within and among species.
First I present statistical methods and software tools I developed to 
analyse diverse genomics data. As new data types emerge, it is necessary to 
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develop new techniques to analyse them. It is equally important to promote 
the use of these methods via the publication of software tools that are readily 
accessible. Many of these tools have been integrated into the Gene Expression 
Pattern Analysis Suite (GEPAS; Herrero et al., 2003a; Vaquerizas et al., 2005), 
which is a web-based microarray data analysis platform.
Second I present the identiﬁcation and characterisation of the human 
repertoire of transcription factors. As described earlier, the lack of a high-
conﬁdence list of transcription factors impedes the analysis of human 
transcriptional regulation at a global scale. This work aims to ﬁll this gap by 
providing a gold standard set for future genomic analyses of transcriptional 
regulation. The functional characterisation of these transcription factors, 
although performed at a basic level, provides insights regarding their 
regulatory functions and the global organisation of transcriptional regulation 
in the human genome.
Third I integrate sequence variation data within humans to detect 
nucleotide changes that potentially affect transcriptional activity; these are 
typically SNPs that modify gene promoters or mechanisms associated with 
mRNA processing. Sequence variation plays an important role in determining 
the sensitivity of particular individuals in adapting to the environment and 
understanding the effect on normal cellular regulation is an initial step in 
this direction. These insights will advance our understanding of multigenic 
diseases and preventive medicine.
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2. Objectives
Genomics aims to examine entire organisms in order to extract general 
principles governing the function of different biological systems. Here I 
describe work that utilises genomic data to increase our understanding of 
transcriptional regulation in the human genome.
Genomic datasets, such as microarray expression data, describe aspects 
of the cellular regulatory process and they require robust statistical treatment 
in order to interpret them in a meaningful fashion. Currently much research 
focus is directed at the analysis of transcription factor binding sites in the 
human genome. However, we have little knowledge of the transcription 
factors involved, or the effects that mutations have on their functions.
The objectives of this PhD are:
1. To develop methods and software tools for analysing high-throughput 
genomic data to increase our understanding of transcriptional regulation in 
humans.
2. To identify and analyse the function of sequence-speciﬁc DNA-binding 
transcription factors in the human genome.




3. Materials and Methods
One of the major tasks in genomics and bioinformatics is the integration of 
disparate data describing a particular biological system. By incorporating 
information from different viewpoints, we can construct a global picture of 
systems in term of their components and functionality, thus allowing us to 
extract general principles governing their behaviour.
The work presented in this thesis is purely computational, and the data 
utilised have been collected from numerous public sources. These datasets 
are very large, complex and diverse, ranging from genome sequences and 
protein structure information to gene expression measurements.
It is important to use robust methods when integrating and analysing 
genomic datasets, so that conclusions drawn from them are correct and 
biological meaningful.
In this chapter I describe the data, methods, programming languages and 
computational resources used for this thesis.
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3.1 Databases and datasets
This section describes the databases and datasets used in this thesis, 
which are summarised in Table 3.1.
3.1.1 Genome sequence databases
3.1.1.1 Ensembl
Ensembl is an automatic pipeline for genomic annotation developed jointly 
at the Sanger Institute and the European Bioinformatics Institute (Hubbard 
et al., 2007). It contains the DNA sequences, annotations, sequence variation, 
Methods
Table 3.1 | Data types and resources.
URL Reference
Genome sequences
Ensembl http://www.ensembl.org Hubbard et al., 2007
Ensembl Compara                "                "
Ensembl Variation                "                "
Inparanoid http://inparanoid.sbc.su.se O'Brien et al., 2005
Protein sequences
InterPro http://www.ebi.ac.uk/interpro Mulder et al., 2007
IPI http://www.ebi.ac.uk/IPI Kersey et al., 2004
Gene expression
ArrayExpress http://www.ebi.ac.uk/arrayexpress Parkinson et al., 2005
GNF dataset http://symatlas.gnf.org/SymAtlas Su et al., 2004
Unigene http://www.ncbi.nlm.nih.gov/UniGene Wheeler et al., 2007
AML/ALL dataset http://www.broad.mit.edu/cancer/pub/all_aml Golub et al., 1999
Transcription factors
Transfac http://www.gene-regulation.com Wingender et al., 2000
DBD http://www.transcriptionfactor.org Kummerfeld and Teichmann, 2006
Messina et al. 2004 http://www.genome.org/cgi/content/vol14/issue10b Messina et al., 2004
Sequence motifs
ESEFinder http://rulai.cshl.edu/tools/ESE Cartegni et al., 2003
Gene functions and literature
Gene Ontology http://www.geneontology.org Ashburner et al., 2000
Pubmed http://www.ncbi.nlm.nih.gov/entrez Wheeler et al., 2007
Type of data
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and comparative genomic data for 31 different eukaryotic organisms (version 
43) including human, chimpanzee and mouse. I have extensively used 
Ensembl as the main source of genomic information, such as gene, transcript 
and protein sequences and identiﬁers, and as a system to visualise them. 
Currently Ensembl has a continuous data release cycle of two months. Thus 
I have used different versions of the database as new updates were released; 
version numbers are indicated where appropriate.
Ensembl is freely available via four online interfaces: (i) the Ensembl web 
site (http://www.ensembl.org); (ii) BioMart, a web-tool that allows users to 
query Ensembl; (iii) a public MySQL server; and (iv) speciﬁc Perl functions 
that perform automatic database queries. All interfaces provide access to the 
same data, and I have employed all four options depending on the task.
3.1.1.2 Ensembl Compara
Ensembl Compara is an extension of the main database that contains 
whole-genome sequence alignments among the 31 genomes using the 
Blastz-net (Schwartz et al., 2003) and Pecan algorithms. In addition, it 
provides homologous relationships between genes from different species: (i) 
orthologous genes that diverged after a speciation event; and (ii) paralogous 
genes, that duplicated before the speciation event. Homologues are obtained: 
(a) by identifying Blast reciprocal best-hits or multiple Blast reciprocal best-
hits, which allows for many to many relationships; and (b) derived from 
syntenic genomic regions. Since v41 homologous relationships are also 
obtained through gene trees (see below). I have used these data in §4.2.7 of 
the thesis.
Gene trees
Phylogenetic gene trees generated by maximum-likelihood aim to 
represent the evolutionary history of genes. They provide a better way of 
detecting evolutionary relationships between genes in different species than 
approaches based only on sequence similarity searches. Ensembl Compara 
constructs gene trees by: (i) performing intra- and inter-species all-versus-
all pair-wise sequence alignments; (ii) multiple alignments using MUSCLE 
Databases and datasets
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(Edgar, 2004); and (iii) reconciling resulting phylogenetic trees with the 
species tree (NJTREE - http://treesoft.sourceforge.net/njtree.shtml). As 
the gene duplication and speciation events are traceable, Ensembl Compara 
is able to differentiate between orthologues and paralogues. I have used this 
approach to assess the evolutionary conservation of human transcription 
factors in different species (§4.1.7).
3.1.1.3 Ensembl Variation
Ensembl Variation contains sequence variation information such as single 
nucleotide polymorphisms (SNPs), insertions, deletions, and genomic 
repeats. The database integrates data from dbSNP and Hapmap — the major 
sources for sequence variation data — and maps them onto other genomic 
features contained in Ensembl. I have used this database in §4.3.
3.1.1.4 Inparanoid
Inparanoid contains orthology assignments for 26 eukaryotic species (version 
5.1; O’Brien et al., 2005). The database is based on inter- and intra-species 
pair-wise gene sequence alignments. An out-group is used to calculate a 
similarity score that is employed as a threshold to determine homologous 
genes. These are then grouped by species to distinguish between orthologues 
and paralogues. Versions 4 and 5 of the database were used in the work 
presented in this thesis (§4.2.7).
3.1.2 Protein databases
3.1.2.1 International Protein Index
The International Protein Index (IPI) database is a database that integrates 
non-redundant data describing eukaryotic proteomes from primary protein 
databases (Kersey et al., 2004). Data are collected from: SwissProt, TrEMBL, 
RefSeq, Ensembl, H-InvDB and Vega. IPI also contains protein domain 
assignments for InterPro entries (see below). We used the IPI database to 




InterPro is a protein sequence annotation database (Mulder et al., 2007). 
It integrates information from external protein sequence and structure 
databases, such as PFAM (Finn et al., 2006) and SUPERFAMILY (Gough 
et al., 2001), to deﬁne protein domains and motifs. There is a hierarchical 
classiﬁcation of the InterPro entries into families, domains, repeats and sites 
depending on the relationship described; several domains can form part of a 
family, and domains can contain several types of repeats.
Protein domains — represented by sequence signatures — are often 
associated to speciﬁc molecular functions such as ligand-binding. InterPro 
provides description and literature citations of the functions of each entry. 
These are extensively used o predict gene functions through the presence or 
absence of these domains in the sequence and it is the primary automated 
functional annotation by the Gene Ontology Annotation project (GOA). 
InterPro combines motif signatures from multiple databases; the predictions 
provide greater coverage than the individual data sources alone.
I used InterPro as the source of domains and families to identify sequence-
speciﬁc DNA-binding proteins (§4.2.1).
3.1.3 Gene expression databases and datasets
3.1.3.1 ArrayExpress
ArrayExpress is a major repository for microarray data hosted at the 
European Bioinformatics Institute (Parkinson et al., 2005), which provides 
public access to more than 1,770 user submitted datasets (May 2007). As the 
database complies with the MIAME standard (Minimum Information About 
a Microarray Experiment; Brazma et al., 2001), experiments are described 
with enough detail to reproduce them. Most microarray studies performed 
before the MIAME standard do not include this information, making them 
less useful for follow-up studies. The processed microarray data described 
in this thesis have been submitted to ArrayExpress to make them accessible 
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to the scientiﬁc community.
3.1.3.2 Gene expression data from the SymAtlas Genome Novartis 
Foundation dataset (GNF dataset)
The SymAtlas dataset from the Genome Novartis Foundation provides 
gene expression measurements for human, mouse and rat tissues and cell 
lines, obtained using Affymetrix GeneChips (Su et al., 2004). I have used 
the human dataset, which contains data for 79 human healthy tissues, 
cell lines and tumour samples. Each hybridisation was performed using 
pooled samples from four or more individuals and repeated to provide two 
biological replicates for each tissue. Two microarray types were used: (i) 
the commercial HGU133a; and (ii) a custom array covering genes and EST 
sequences not present on the commercial array. Together they interrogate the 
expression of 44,775 different transcripts. A full list of tissues can be found at 
http://wombat.gnf.org/samples/GeneAtlasv2_sample_info.html. I use this 
dataset in §4.2.5 to characterise transcription factor expression.
3.1.3.3 Acute lymphoblastic leukaemia and acute myeloid leukaemia 
dataset from Golub et al. 
The Golub et al. dataset (1999) measures gene expression for 6,817 human 
genes in 38 samples  derived from patients with acute lymphoblastic 
leukaemia (ALL) or acute myeloid leukaemia (AML) using Affymetrix 
GeneChips. This was the ﬁrst study to use microarrays for tumour sample 
classiﬁcation. I have used this dataset as a test-set for the validation of 
analysis methods presented in §4.1.2 and §4.1.3.
3.1.3.4 MSL1, MSL3, MOF, H4K16, Nup153 and Mtor dataset from the 
Akhtar laboratory (EMBL)
This dataset contains unpublished data for ChIP-chip experiments for the 
following proteins related to the Drosophila melanogaster Dosage Compensation 
Complex (DCC): MSL1, MSL3, MOF, histone 4 lysine-16 acetylation (H4K16), 
Nup153 and Mtor. MSL1, MSL3 and MOF are components of the complex 
(Straub and Becker, 2007). MOF in particular is a histone acetyl-transferase, 
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whose activity can be assessed by measuring histone-4 lysine-16 acetylation. 
Nup153 and Mtor form part of the nuclear pore (Akhtar and Gasser, 2007). 
Chromatin immunoprecipitations were performed in three male and female 
biological replicates to measure DNA-binding of these proteins. In addition, 
an antibody against H4K16 was used to measure MOF activity. Chromatin 
immunoprecipitations were hybridised against the Affymetrix GeneChip 
Drosophila Tiling 2.0R Array. Genomic input DNA and immunoprecipitated 
histone-4 were also hybridised as a baseline for comparison. I have used this 
dataset with kind permission from Dr. Asifa Akhtar, to develop an analysis 
method for ChIP-chip data that allows us to detect unbiased binding signal 
for DNA-binding proteins with different protein-DNA afﬁnities (§4.1.7).
3.1.3.5 Unigene
Unigene contains information about expressed sequence tags (EST) in 
numerous tissues and cell lines (Wheeler et al., 2007). The sequence reads 
are integrated and collapsed into Unigene clusters based on the overlap 
between ESTs, and associated to particular genomic loci. The presence of 
a Unigene cluster is indicative of gene expression. I used Unigene in §4.1.6 
as an alternative source of expression data, in order to calibrate Affymetrix 
GeneChip results.
3.1.4 Transcription factor databases and datasets
3.1.4.1 Transfac
The Transfac database contains literature-extracted descriptions about 
transcription factors, target genes, binding sites and position weighted 
matrices for consensus binding sequences in multiple species (Wingender et 
al., 2000). I have used the position weight matrices (version 7.3 Professional) 





DBD is a database of predicted DNA-binding transcription factors for 265 
prokaryotic and eukaryotic genomes (Kummerfeld and Teichmann, 2006). 
Transcription factors are predicted using hidden Markov model searches of 
DNA-binding domains described in PFam and SUPERFAMILY in the coding 
sequences for each organism. I used DBD to compare the human repertoire 
of transcription factors obtained in §4.2.1.
3.1.4.3 Transcription factor dataset by Messina et al.
Messina et al. (2004) identiﬁed 1,962 human transcription factors by sequence 
similarity searches against protein domains that were annotated as DNA-
binding domains. The authors used Transfac and a set of GO annotated 
transcription factors to build a seed-set of hidden Markov models, which 
were then used to search against the human transcriptome. I used the Messina 
dataset to compare with the transcription factor dataset that I obtained in 
§4.2.1.
3.1.5 Sequence motifs datasets
3.1.5.1 Motif-scoring matrices for exonic splicing enhancers
The serine/arginine-rich (SR) family of proteins are involved in mRNA 
splicing by recruiting two small nuclear ribonucleoproteins (U1 and U2AF) 
that recognise exonic splicing enhancer (ESEs) sequences found in exons. 
Several binding sites have been identiﬁed and used to create motif-scoring 
matrices describing consensus binding sequences (Cartegni et al., 2003). I 





Gene Ontology (GO) provides a deﬁned and structured vocabulary to 
describe gene and gene products in terms of their molecular functionality, 
biological processes and cell localisation (Ashburner et al., 2000). The terms 
are organised in the form of a directed acyclic graph in which more speciﬁc 
terms derive from broader ones and where child terms can have several 
parents. Gene annotations for different species are manually curated from 
the literature, or electronically annotated using domain assignments. I used 
GO to assess the level of knowledge about transcription factors (§4.2.2).
3.1.6.2 PubMed/MEDLINE
MEDLINE (Medical Literature Analysis and Retrieval System Online) 
is an international database of life sciences literature including biology, 
biochemistry and medicine journals. PubMed is a web interface for MEDLINE 
that allows users to perform global searches of the available citation data 
(Wheeler et al., 2007). In addition to using PubMed as a general source for 
biological information throughout this thesis, I have employed it speciﬁcally 
to assess the level of knowledge for particular transcription factors in §4.2.2.
3.2 Data analysis methods
The large amount of data generated by high-throughput technologies in the 
last decade has necessitated the development of new analysis methods. Some 
of these have become standard procedures and are now used routinely. In 
this section I summarise the methods and approaches that I have employed 
throughout this thesis to integrate genomics data. In most cases I have used 






The t-test allows us to determine whether two sets of observations are different 
with a certain level of conﬁdence. The standard Student’s t-test compares 
the mean of two sets of observations under the assumption that data follow 
a normal distribution and the variance of the two populations are equal. I 
have used a non-parametric variant of the standard t-test, Welch’s t-test, that 
does not require these assumptions. The t statistic is calculated using the 
following formula:
where X is the average expression, s the estimated variance and N the 
sample size for each group. This test was implemented as a method for 
selecting differentially expressed genes between two classes of samples; eg, 
cancer versus control sample (§4.1.2).
3.2.1.4 Wilcoxon test
The Wilcoxon test is a non-parametric statistical test equivalent to the t-test, 
to detect differences among variables between two groups by ranking the 
measurements and using the order to detect signiﬁcant differences. This 
method was implemented in §4.1.3 to sort genes based on their differential 
gene expression between classes of samples.
3.2.1.2 Fisher’s exact test
The Fisher’s exact test compares the association between two variables in a 2 
x 2 contingency table (Table 3.2).
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The probability of obtaining any data distribution is given by the 
formula:
and the signiﬁcance of this probability is assessed by comparing it with 
all other probabilities that are calculated from the same contingency table. 
I used this test to assess statistical signiﬁcance for categorical data, such as 
transcription factor annotations between sets of genes (§4.1.4).
Data analysis methods
condition A condition A' total
condition B a b a+ b
condition B' c d c + d
total a + c b + d n
Table 3.2 | 2x2 contingency table.
3.2.1.3 F-ratio
The F-ratio is the ratio of the between group variances against the within 
group variances  (Dudoit et al., 2002). It measures the degree of overlap 
between two distributions.
The method was implemented in §4.1.3 to sort genes based on their 
differential expression between classes of samples.
3.2.1.5 Permutation test
The permutation test determines the likelihood of an observation given a 
random sampling of the original distribution. The statistical signiﬁcance is 
p � a � b� �! c � d� �! a � c� �! b � d� �!
n!a!b!c!d!
Fratio �
I yi � k� �ki xkj x. j� �
2
I yi � k� � xij xkj� �2ki
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calculated by counting the number of times that random samples have a 
more extreme value than the observed data:
I have used the permutation test to obtain signiﬁcance values for different 
observations, such as the occurrence of transcription factor clusters in certain 
genomic regions (§4.2.4).
3.2.1.6 Multiple testing correction procedures
Multiple testing correction procedures involves the recalculation of p-values 
for experiments where a particular test has been repeated multiple times. 
The statistical signiﬁcance of each test cannot be used to detect signiﬁcant 
observations for the entire dataset as the probability of ﬁnding signiﬁcant 
observations increases with the number of preformed tests. This phenomenon 
is particularly important in genomics as often the number of observations is 
in the order of thousands (eg, microarray experiments).
Several mathematical techniques have been developed to deal with 
this problem. Here I have used the false discovery rate approach (FDR) 
(Benjamini and Hochberg, 1995). The method adjusts the expected proportion 
of incorrectly rejected null hypothesis from the rejected hypothesis and it 
returns a q-value, which is the minimal FDR of a particular observation at 
which the test is signiﬁcant. FDR is less conservative than other multiple 
testing adjustment approaches, such as the Bonferroni approach that requires 
a very strong evidence to reject the null hypothesis. I have used FDR instead 
of other approaches because changes in genomics and gene expression can 
be subtle and therefore not strong enough to resist other multiple testing 
corrections. In particular I have used FDR correction for: (i) adjusting p-
values in differential expression assignments (§4.1.2); (ii) adjusting p-values 
in the detection of signiﬁcant transcription factor clusters (§4.2.4); and (iii) 
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adjusting p-values for over- or under-representation of transcription factor 
binding sites in sets of genes (§4.1.4).
3.2.1.7 Hierarchical clustering
Classical hierarchical clustering is a mathematical grouping algorithm that 
partitions a dataset into sub-groups of similar members. The similarity 
between entries is calculated using a distance measurement. I have performed 
hierarchical clustering to represent: (i) groups of genes or tissues that share 
common expression patterns (§4.2.6); and (ii) to group different species based 
on the presence or absence of orthologues of human transcription factors 
(§4.2.7). In both cases I used Euclidean distance as the similarity measure.
3.2.1.8 ROC curves
Receiver operating characteristic (ROC) curves are graphical plots that 
represent the sensitivity — the proportion of true positives among all true 
samples — versus the speciﬁcity — the proportion of true negatives among 
all negatives — for a particular analytical approach. When multiple models or 
methods are available, ROC curves can be used to identify the best approach 
for analysis. I have used ROC curves to set the best gene expression threshold 
for Affymetrix data (§4.1.5).
3.2.1.9 Propensity
Propensity values were originally used to detect over- or under-representations 
of amino acids in particular positions of protein secondary structures, eg, in 
alpha-helices, using the following equation:







3.2.2 DNA and protein sequence analysis methods
3.2.2.1 BLAST
The Basic Local Alignment Search Tool (BLAST) is a sequence alignment 
software that allows the pair-wise comparison of protein and nucleotide 
sequences (Altschul et al., 1990). A typical BLAST search involves the 
matching of a query sequence in a database containing billions of sequences. 
In order to maximise the computational speed, the algorithm ﬁrst ﬁnds exact 
matches of small segments of the query sequence and then extends them 
using a particular penalty for mismatches. When a high-scoring, ungapped 
sequence is found BLAST then produces a gapped alignment using a variant 
of the Smith-Waterman algorithm. In this thesis I have used BLAST to identify 
human speciﬁc transcription factors (§4.2.7).
3.2.2.2 Match
Match is a program accompanying the Transfac database to detect potential 
transcription factor binding sites (Kel et al., 2003). The program uses position 
weight matrices derived from experimentally determined binding sites to 
identify motif in a given stretch of DNA sequence. The user can choose 
among three predeﬁned thresholds that quantify the signiﬁcance of a motif: 
(i) minimising false positives by using similarity values that do not hit in a 
pool of six million base pair sequences from third exons; (ii) minimising the 
false negative rate by ensuring detection of 90% of all possible motifs given 
a position weight matrix; (iii) balancing the two extremes by optimising the 
number of false positives and negatives. Here, I used option (i) to minimise 
the false positive rate in predicting transcription factor binding sites in §4.1.4 
and §4.3.
3.2.2.3 Triplex forming sequences detection
DNA triplexes are formed between a polypurine or polypyrimidine rich 
double-stranded nucleic acid and a purine rich single-stranded DNA (for 
details on the base pairing see Knauert and Glazer, 2001). Goni et al. (2004) 
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demonstrated that triplex-forming sequences are enriched in gene promoters, 
suggesting a role in regulating transcription. I predicted a potential triplex-
forming region if there are 10 or more consecutive guanines or cytosines in a 
sequence segment. I used these predictions to map functional SNPs (§4.3).
3.2.2.4 InterProScan
InterProScan identiﬁes InterPro domains in amino acid sequences by 
combining all the individual domain-ﬁnding algorithms from the member 
databases (Quevillon et al., 2005). These include ProDom (Servant et al., 
2002), PRINTS (Attwood et al., 2003), PIR Protein Sequence Database (Wu et 
al., 2003), Pfam (Finn et al., 2006), SMART (Letunic et al., 2006), TIGRFAMs 
(Haft et al., 2001), PROSITE (Hulo et al., 2006) and SUPERFAMILY (Gough et 
al., 2001). I utilised InterProScan to search for DNA-binding domains in the 
eukaryotic orthologues of human transcription factors (§4.2.7).
3.2.3 Microarray analysis methods
3.2.3.1 Loess print-tip normalisation
Locally weighted scatter-plot smoothing (loess) print-tip normalisation is a 
popular and effective method for processing two-colour cDNA arrays (Yang 
et al., 2002). It aims to correct for two major sources of bias in microarray 
data: (i) dye-dependent ﬂuorescence; and (ii) spatial effects. The ﬁrst is 
caused by differences in the ﬂuorescent properties of the two dyes, which 
causes a non-linear increase in ﬂuorescence intensities. The second is caused 
by spatial differences in hybridisation in a print-tip group, or because of 
handling procedures. The method normalises each print-tip group on the 
array separately by plotting a regression curve for the MA-scatter-plot using 
loess ﬁtting. It then scales the log-ratio of each probe with the formula:
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This normalisation method can be used only if: (i) the number of 
data points to normalize is large enough to cover the intensity range; (ii) 
no more than 40% of genes are differentially expressed; and (iii) there is, 
approximately, an equal number of up- and down-regulated genes. This 
method was implemented as the preferred normalising algorithm in §4.1.1.
3.2.3.2 Inter-array scale normalisation
Due to differences in experimental procedure (such as total RNA 
concentration) arrays can display large variations in their range of probe 
intensity ratios. Differences in scale result in weighting arrays differently 
to each other during subsequent analyses. Inter-array scale normalisation 
corrects for severe differences in scale between multiple two-colour cDNA 
arrays (Yang et al., 2002). The median absolute deviation is used to estimate 
the scale factor required to correct for inter-array differences:
The factor for each array is subtracted from the log-ratio values of each 
probe on the array. This method was implemented as the default between 
arrays normalisation in §4.1.1.
3.2.3.3 GC robust multi-array analysis
GC-Robust Multi-Array analysis (GC-RMA) is an analysis package 
distributed in Bioconductor for pre-processing Affymetrix GeneChip (Wu 
et al., 2004). Affymetrix GeneChips® measure expression levels using 10 to 
20 pairs of 25-mer probes distributed along each gene. Each pair of probes 
contains one that matches the nucleotide sequence exactly and another 
with one mismatch in the central base position. The method is based on 
three steps: (i) background subtraction; (ii) data normalisation; and (iii) 
summarization. Background subtraction aims to correct for the effects of 
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non-speciﬁc hybridisation. GC-RMA ﬁts a linear model to the intensity 
values assuming that the background follows a normal distribution. The 
background is then subtracted from the intensity values. Data normalisation 
is performed using quantile normalisation at the probe level. The method 
ranks the probes according to their intensity values and substitutes them by 
their mean expression. Summarization of all probes for a gene in a probeset 
is performed using median polish across all microarrays analysed. This 
allows us to account both for probe and array effect. I have used GC-RMA 
in sections §4.1.5 and §4.1.6 to produce high-quality pre-processed data from 
Affymetrix arrays.
3.2.3.4 AﬀyPLM
AffyPLM is a package to perform probe-level analyses of Affymetrix 
GeneChips (Bolstad et al., 2005). The package enables users to assess relative 
microarray quality and to determine whether different sets of arrays are of 
comparable among themselves. In particular, it allows calculations of spatial 
artefacts, relative log expression values and normalised unscaled standard 
errors. I have used these measures to assess the quality of the Genome 
Novartis Foundation dataset (§4.1.5).
3.2.3.5 MAS 5.0
MAS5.0 is a pre-processing method proposed by Affymetrix. It uses the mis-
match probes as a control for non-speciﬁc binding and compares the signal 
of these probes against the signal from perfect matches for each probeset to 
derive present and absent calls based on the signiﬁcance of these differences. 
However it has been demonstrated that mis-matches have more signal than 
perfect-matches in more than 30% of cases, suggesting that this approach 
might not be appropriate to produce such calls (Naef et al., 2002).
3.2.3.5 PANP
PANP is a method to calculate present and absent calls for Affymetrix 
arrays. About 300 probesets on the Affymetrix HGU133a GeneChip were 
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accidentally designed to match the antisense strand of annotated gene loci. 
As these probes should not hybridise any transcripts, they represent an 
ideal set of negative controls for the microarray that measures non-speciﬁc 
hybridisation. PANP uses the distribution of signal from these probesets to 
calculate thresholds with a known false positive rate to assign present/absent 
calls in each experiment. I used PANP to determine these calls in §4.1.5.
3.2.3.6 Linear models for microarray analysis
Linear models for microarray analysis (limma) is a Bioconductor package 
for the analysis of microarray data (Smyth and Speed, 2003). It contains 
normalisation and pre-processing functions for two colour cDNA arrays, 
and analysis methods based on linear models to perform platform-
independent differential expression studies. It implements methods such 
as loess normalisation, moderated t-statistics, and several multiple testing 
procedures including FDR. I used limma as the backbone for normalisation 
procedures implemented in the DNMAD tool (§4.1.1).
3.2.3.7 Classiﬁcation algorithms
Several classiﬁcation algorithms were implemented to build two-class 
predictors for microarray data (§4.1.3): (i) Diagonal Linear Discriminant 
Analysis (DLDA; Dudoit et al., 2002) is a machine learning method able 
to ﬁnd a linear combination of variables that best separate two classes; 
(ii) k-nearest neighbours (kNN; Dudoit et al., 2002) is a non-parametric 
classiﬁcation algorithm that predicts class membership based on the most 
similar k-samples measured using Euclidean distance; (iii) Random Forest 
(Breiman, 2001) is a classiﬁcation and regression tool based on an ensemble 
of single classiﬁcation trees; (iv) nearest shrunken centroids (Tibshirani et 
al., 2002) is a classiﬁcation algorithm that assigns samples to the class with 
a nearest centroid; and (v) Support Vector Machines (SVM; Vapnik, 1998; 
Noble, 2006) are an artiﬁcial intelligence technique that allows us to ﬁnd the 
optimal separating hyperplane between classes.
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All algorithms accept as input a gene expression matrix where rows 
represent genes and columns represent classes. The algorithm uses the class 
membership information to train itself. Once the classes have been learnt, 
a new sample will be assigned according to its similarity with the closest 
class. In order to maximise the data usage the prediction process is usually 
accompanied by cross-validation techniques.
3.2.3.8 Cross-validation
Cross-validation is a process by which the predictive accuracy of a model can 
be assessed based on learning and test datasets, both derived from an initial 
set of samples. In §4.1.3 a ten-fold cross-validation model was implemented. 
This method randomly divides a dataset into ten groups maintaining the 
class proportions, ie, same number of samples per class, whenever this is 
possible. One of the groups is left out and the prediction algorithm is trained 
using the other nine groups. The accuracy of the classiﬁcation algorithm is 
calculated using the left-out sample. The process is repeated until all groups 
have been evaluated and the ﬁnal cross-validated error rates are calculated as 
the mean error rate of all cross-validation rounds. Different cross-validation 
techniques are discussed in Ambroise and McLachlan (2002) and Braga-Neto 
and Dougherty (2004).
3.2.3.9 symp
symp is a Bioconductor package for the analysis of ChIP-chip data. It 
implements several pre-processing approaches for high-density tiling 
microarrays such as background subtraction and quantile normalisation 
provided by GC-RMA. The package also includes functions to obtain 
signiﬁcantly enriched regions in ChIP-chip experiments by using data points 
enriched in the non-immunoprecipitated sample to calculate a symmetric null 
distribution. This distribution is then used to calculate statistical signiﬁcance 
for probes enriched in the immunoprecipitated sample. In §4.1.7 I show the 




FatiGO is a web-tool for the comparison of Gene Ontology annotations 
between two sets of genes (Al-Shahrour et al., 2004). It calculates p-values for 
the enrichment of particular GO functions in one gene set over the other. This 
is done using a Fisher’s exact test to compare the proportion of genes with 
a certain GO annotation. p-values are corrected for multiple testing using 
FDR. I have used FatiGO in §4.1.6 to validate the usage of the propensity as 
a tissue-speciﬁcity marker.
3.3 Programming languages
The majority of programs developed in this thesis have been written in Perl, 
R (R Core, 2004, http://www.Rproject.org) and MySQL. In addition I have 
used Bioconductor extensively as a source of data analysis and visualisation 
software packages (Gentleman et al., 2004).
I have also used the Ensembl APIs (Core, Compara and Variation) and 
BioPerl to access and analyse genomic data.
3. 4 Computational facilities
The majority of the computational work presented in this dissertation was 
run in the research farm of the EMBL - European Bioinformatics Institute in 
64-bit architecture machines running CentOS operating system.
The web-tools presented in this thesis included in the GEPAS and 
Asterias packages run on pound web-balanced apache servers with Debian 
GNU/Linux operating systems at the Spanish National Cancer Centre and 
Centro de Investigación Príncipe Felipe (http://www.gepas.org; Herrero et 
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al., 2003a; Vaquerizas et al., 2005; http://asterias.bioinfo.cnio.es Diaz-





This chapter describes the main results obtained during my PhD research. 
It is divided into three main sections covering: (i) development of tools and 
methods for high-throughput data analysis; (ii) functional characterisation of 
the human transcription factor repertoire; and (iii) identiﬁcation of potential 
functional SNPs.
4.1 Development of microarray data analysis 
methods and tools
This ﬁrst section of the results presents web-tools and methods I have 
developed for the analysis of high-throughput gene expression data. These 
include: (i) two-colour cDNA microarray normalisation; (ii) differential 
gene expression analysis; (iii) class prediction for microarray data; (iv) 
functional annotation of transcription-factor regulated genes; (v) sensitivity 
and speciﬁcity measurement for Affymetrix GeneChips; (vi) determination 
of tissue-speciﬁc expression for microarray data; and (vii) analysis of tiling 
array experiments.
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4.1.1 DNMAD: Diagnosis and normalisation for two-colour 
cDNA arrays
DNMAD is a web-tool for the Diagnosis and Normalisation of MicroArray 
Data (http://dnmad.bioinfo.cnio.es). It allows users to normalise two-
colour cDNA microarrays using robust statistical methods and to perform 
quality assessments of the data (Vaquerizas et al., 2004). The application uses 
R and Bioconductor for all calculations and provides a web-based Perl CGI 
interface that communicates with R using the CGIwithR package. By default, 
it processes the data using print-tip loess normalisation; however, global 
loess and MAD inter-array normalisation are also provided as user-speciﬁed 
options. In addition to the processed data, the program outputs diagnostic 
graphs for data quality assessment such as box-plots, MA-plots and slide-
location plots.
DNMAD input
Figure 4.1 displays the web interface. Here, the user can select the 
microarray data ﬁles for upload. The server accepts compressed or plain 
text GenePix ﬁles that must be accompanied with a description of the slide 
layout. Custom ﬁles with appropriate headers are also allowed: these must 
contain a minimal amount of numerical information about each probe (Block, 
Column, Row, Name, ID, F635 Mean, B635 Median, F532 Mean, B532 Median 
and Flags).
Once data ﬁles have been uploaded, DNMAD offers several user-deﬁned 
options. At the experimental level, users may select the automated analysis of 
dye-swaps experiments by indicating the appropriate Cy5/Cy3 comparison 
for each microarray. At the microarray level, users can decide whether to 
include ﬂagged spots (ie, low quality spots identiﬁed by the user or scanning 
software). In addition they can choose whether to subtract the background 
intensity for each spot (which can lead to “negative” intensity values 
that must be discarded) or to substitute negative values with an arbitrary 
intensity value of 0.5. Finally, there is an option for performing global loess 
normalisation, which allows users to normalise the entire microarray in cases 
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where the criteria for print-tip loess are not met.
DNMAD output
The web-tool outputs normalised gene expression values for each 
microarray, described by Cy5/Cy3 log2 ratios (M-value) and average 
intensities (A-value). The data ﬁles can be downloaded from the output 
page or can be automatically transferred to other modules in the GEPAS 
microarray analysis suite for further analysis (Herrero et al., 2003b).
The output also records information about the normalisation procedure 
employed, errors, warnings, and plots to interpret the results and perform 
Microarray analysis tools
Figure 4.1 | Screenshot of DNMAD web interface. The data upload box and user-
deﬁned options are shown.
46
quality assessments (Figure 4.2, 4.3). These include: (i) box-plots for all 
microarrays and print-tip groups; (ii) MA-plots with regression curves for 
each print-tip group; and (iii) diagnostic plots.
Box-plots (Figure 4.2 A, B) represent the overall distribution of the log-
ratios. The box at each column indicates the inter-quantile range (IQR), 
within at which 25% and 75% of the distribution is located. The median is also 
indicated by a black line inside the box. Extreme intensity values that deviate 
from the IQR by more than 1.5 times are represented as single dots. Box-plots 
are computed for pre- and post-normalised data for all the microarrays in the 
experiment as well as for individual print-tip groups within each microarray. 
These allow the user to compare log-ratios across all samples and print-tip 
groups. In a typical experiment raw microarrays may have variable log ratio 
values between print-tips, which is corrected after normalisation. Extreme 
differences in raw print-tip behaviour within the same slide might indicate 
issues with the manufacturing, handling or hybridisation procedures.
The MA-plots in Figure 4.2 C-D show the relationship between the log2 
Cy5/Cy3 ratios (M-values) and average Cy5 and Cy3 intensities (A-values) 
for a single microarray. The plots are computed for raw and normalised data. 
In each case, differently coloured regression curves are shown for every 
print-tip group. Assuming that most genes in the experiment have roughly 
equal expression levels, signiﬁcant deviations from zero in the regression 
curve indicate differences in the detection of dyes across the intensity range. 
This effect can also be seen if the regression curve is non-linear. These effects 
should be corrected via the normalisation procedure, resulting in regression 
curves close to an M-value of zero.
The diagnostic plots (Figure 4.3) allow users to detect hybridisation artefacts 
on the microarrays (Smyth and Speed, 2003). Plots include: (i) histograms of 
the Cy5 and Cy3 foreground probe intensities; (ii) probability density plots of 
the same intensities for individual slides and the entire experiment; and (iii) 
schematic microarray diagrams of Cy5 and Cy3 foreground and background 
intensities, and log2 ratios before and after normalisation. These plots enable 
users to identify extreme ﬂuorescence intensities or spatial biases that arise 
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from problems during hybridisation and scanning.
Example of DNMAD usage
Figure 4.2 show pre- and post-normalisation box-plots and MA-plots for 
a single microarray from Bullinger et al. (2007), in which cDNA microarrays 
are used to differentiate subclasses of acute myeloid leukaemia. Here we 
observe how differences between the Cy5 and Cy3 intensity levels are 
corrected. Regression curves for each print-tip group in the pre-normalised 
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Figure 4.2 | Boxplots and MA-plots for a single cDNA microarray (Bullinger et al., 
2007) before and after normalisation. (A, B) Boxplots display the range of log2 Cy5/
Cy3 ratios for each print-tip group (labelled 1-48). (C, D) MA-plots show the breath 

































Figure 4.3 | Diagnostic plots for two-colour cDNA microarrays. The diagnostic 
plots allow users to detect quality problems due to the experimental procedure or 
the manufacturing process. (A, B) Histograms and probability distributions of Cy5 
and Cy3 log2 intensity values. Comparisons between plots allow users to detect 
extreme differences between slides. (C-E) Schematic representations of microarrays 
displaying Cy5 and Cy3 background and foreground intensities, and log2 ratios 
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MA-plots show how the Cy5 and Cy3 intensities vary non-uniformly across 
the intensity range. This effect is corrected via the normalisation procedure 
as shown in the post-normalised MA-plots. The diagnostic plots for this 
microarray allow us to determine that the slide does not suffer from spatial 
artefacts (Figure 4.3)
4.1.2 Pomelo: Diﬀerential expression for microarray experi-
ments
Pomelo is a web-tool for the detection of differentially expressed genes in 
microarray experiments. It combines several detection methods including the 
t-test, ANOVA and Fisher’s exact test. The expression of each gene is tested 
using the selected procedure. The tool then performs a random permutation 
test to calculate the statistical signiﬁcance for differential expression. This 
removes the necessity of assuming normality in the data. p-values obtained 
are then corrected for multiple-testing using the FDR procedure (see § 
3.2.1.6).
Pomelo input
The web-tool is a Perl CGI form that communicates with the main C++ 
program that runs the statistical tests (Figure 4.4). The server accepts a 
numerical matrix of expression values as input. Also, users have to provide a 
text ﬁle deﬁning the class membership of the biological samples. By default, 
the t-test is selected for measuring differential expression, allowing users 
to compare non-categorical variables between two classes of observations. 
Analysis of the variance (ANOVA) is also provided for cases when more 
than two classes are to be compared. The Fisher’s exact test allows analysis 
if non-numerical or categorical variables, such as the presence or absence 
of a gene. The number of permutations is set by default to 10,000 although 
this number can be modiﬁed depending on particular experiments. Finally, 
the interface includes several parameters that allow the user to modify the 




The output page returns a list of differentially expressed genes, along 
with the statistical test values, unadjusted and FDR adjusted p-values. 
The user can use the output as a guide for setting a signiﬁcance threshold 
for differential expression. A graphical output for the most differentially 
expressed genes is also provided (Figure 4.5), which allows users to evaluate 
visually the results. The output page is connected to other modules of the 
GEPAS microarray analysis suite so that differentially expressed genes can 
be analysed for functional annotation.
Results
Figure 4.4 | Screenshot of Pomelo web interface. The capture displays the data 
upload section as well as the user-deﬁned options. The tool is available at http://
pomelo.bioinfo.cnio.es.
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Example of Pomelo usage
We analysed the data from Golub et al. (1999) as a case study to illustrate 
the usage of Pomelo. The dataset contains gene expression measurements for 
6,817 genes in 38 samples of acute myeloid leukaemia and acute lymphoid 
leukaemia. The original study demonstrated the use of microarrays as 
a method for classifying cancer samples. Using the t-test on Pomelo we 
identiﬁed 656 differentially expressed genes at an FDR adjusted p-value 
threshold of 0.05. Figure 4.5 shows a graphical display of the top 50 most 
differentially expressed genes.
4.1.3 TNASAS: Class prediction for microarray data
TNASAS is a web-tool for class membership prediction using microarray 
data. The tool implements simple statistical techniques to output class 
predictors. These are lists of genes that allow us to distinguish between two 
different biological samples given their expression proﬁles.
Building class membership predictors
The procedure involves two steps: (i) selecting the genes to include in the 
class predictor; and (ii) evaluating the error rates of predictions.
For the ﬁrst, TNASAS ranks all genes in the dataset by their level of 
differential expression between classes, which will have the best predicting 
power. Although any of the approaches described in §4.1.2 could be used 
for this purpose, the permutation tests for calculating the p-values are 
computationally expensive. Therefore TNSAS implements gene ranking 
based on the statistic values themselves. Users can select from the following 
statistics: (i) the F-ratio, which is the ratio between the variances of the classes; 
(ii) the Wilcoxon statistic, which is a non-parametric version of the standard 
t-test; and (iii) variable importance derived from random forests. TNASAS 
then automatically selects the N best genes based on the ranking procedure, 





Figure 4.5 | Graphical output from the Pomelo tool. Here, the 50 most differentially 

















































































For the second, the tool uses one of the user-selected classiﬁcation 
algorithms to identify the best set of class predictors. TNASAS implements 
several simple classiﬁcation algorithms that have been shown to perform 
well in microarray data analysis (Diaz-Uriarte and Alvarez de Andres, 2006; 
Romualdi et al., 2003): (i) diagonal linear discriminant analysis (Barrier et 
al., 2007); (ii) k-nearest neighbours (Pomeroy et al., 2002); (iii) support vector 
machines (Vapnik, 1998); (iv) random forests (Svetnik et al., 2003); and (v) 
shrunken centroids (Tibshirani et al., 2002) (see §3.2.3.7 for details).
The algorithms are trained using a 10-fold cross-validation scheme, 
and prediction error rates are computed from the left-out sample during 
training.
Accounting for selection bias
When building class predictors, different biases can severely affect the 
estimates of the predicted error rates (Ambroise and McLachlan, 2002; Simon 
et al., 2003).
The ﬁrst source of bias arises during the ﬁltering procedure, in which 
genes are ranked by their expression levels. When all samples in the dataset 
are used for ranking purposes, the classiﬁcation procedure is biased towards 
the particular set of genes selected for those samples. This results in more 
optimistic predicted error rates during the cross-validation procedure as the 
left-out sample contributed already to the gene selection. TNASAS resolves 
this by drawing an extra 10-fold cross-validation procedure at the start of the 
gene ranking process, by which some samples from each class are left out 
from the ranking procedure and are only used to compute the error rates.
The second source of bias arises as we select the best number of genes 
to build the predictor ‘a posteriori’, ie, when we know the error rates of all 
predictors. To account for this bias, an extra layer of cross-validation is used 
to determine the error rate of building multiple predictors and then choosing 
the one that produces the smallest error rates of prediction.
Microarray analysis tools
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Figure 4.6 | Screenshot of TNASAS web interface. The image shows the data 
upload boxes and the user-selected algorithms. The tool is available at http://
tnasas.bioinfo.cnio.es.
TNASAS input
The tool was implemented using R and Bioconductor and the web-
interface is a Perl CGI form that communicates with R using the CGIwithR 
package (Figure 4.6; Firth, 2005). The server accepts as input a numerical 
matrix containing log
2
 gene expression values of all genes in the experiment 
and a plain text ﬁle indicating the class membership of the samples. The 





TNASAS outputs text and graphical representations of the best class 
predictors and the prediction error rates (Figure 4.7). The output also includes 
the results for the different cross-validation runs, allowing users to evaluate 
the robustness of predictions.
Example of TNASAS usage
We demonstrated the use of TNASAS by analysing the data from Golub 
et al. (1999). We selected the F-ratio ranking and SVM classiﬁcation algorithm 
to identify the best class predictors to distinguish between acute myeloid 
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Figure 4.7 | TNASAS cross-validated prediction error rates obtained for the Golub 
et al. (1999) dataset using Fisher’s statistic ranking and Support Vector Machines 
as classifying algorithm. The plot shows the error rate that would be obtained 
predicting the most common class (blue dotted line), the cross-validated error rate 
of the entire process (red dotted line), the error rate for the original sample (solid 
black line), and the error rates of all the cross-validation sets (grey lines).
56
leukaemia and acute lymphoid leukaemia and associated error rates.
The best predictor comprises a set of N=35 genes producing a cross-
validated error rate of 5.3%. This means that there is a good separation 
between the two classes for this dataset. 20 of the 35 genes present in the 
predictor were selected as predictors in the original study, including the 
cancer-related retinoblastoma, cyclin D2 and E2A genes. The classiﬁcation 
matrix showed that only one of the samples was misclassiﬁed and that the 
different cross-validation rounds were consistent (data not shown). We 
re-analysed the dataset using different combinations of gene ranking and 
classiﬁcation algorithms and observed that the predicted error rates were 
similar for all combinations (data not shown).
4.1.4 TransFAT: Transcription factor regulation for sets of 
genes
TransFAT (Transcription Factor Association Test) is a web-tool for identifying 
transcription factors that potentially regulate sets of human and mouse genes 
with similar expression proﬁles. The tool searches for over-represented 
transcription factor binding sites in the promoter of co-expressed genes. We 
scanned a 10kb region upstream of all human and mouse genes annotated in 
Ensembl (v25) using the Match program (Kel et al., 2003) with the following 
options: (i) vertebrate-speciﬁc position weight matrices; and (ii) minimisation 
of false positives (see §3.2.2.2 for details). This approach resulted in more 
than 2.5 million putative transcription factor binding sites for 270 different 
transcription factors in 51,817 human and mouse promoters. We then assigned 
genes to transcription factors based on the binding site predictions. Using 
these associations, TransFAT identiﬁes over- and under-representations of 
transcription factors in sets of genes via Fisher’s exact tests. A correction for 
multiple testing is provided which accounts for testing all human or mouse 
transcription factors in a given dataset at the same time.
TransFAT input
TransFAT was programmed as a Perl CGI script that communicates with 
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a MySQL relational database, which stores the transcription factor binding 
site predictions. The user inputs two lists of genes (eg, co-expressed genes 
and a reference set) that are used to compare the binding site occurrence in 
promoter regions (Figure 4.8).
TransFAT output
TransFAT outputs the Fisher’s exact test results for all evaluated 
transcription factors, showing the number of genes associated in each group, 
percentages, test statistic, p-value and FDR adjusted p-value.
Microarray analysis tools
Figure 4.8 | Screenshot of TransFAT web interface. The tool is available at http://
babelomics.bionfo.cipf.es.
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Example of TransFAT usage
We tested TransFAT on the set of differentially expressed genes from Golub 
et al. (1999). Unfortunately there were no signiﬁcantly over-represented 
transcription factor binding sites.
4.1.5 Assessing selectivity and speciﬁcity in Aﬀymetrix Gene-
Chips
Single-channel oligonucleotide microarrays, such as the Affymetrix 
GeneChips, allow us to obtain global measurements of mRNA expression 
levels. However, due to non-speciﬁc hybridisation and normalisation 
procedures, it is difﬁcult to determine whether a gene is expressed or not. 
Here, I present a method to detect the presence or absence of genes in 
Affymetrix GeneChips. The method is based on the combined usage of the 
PANP algorithm and EST sequences to assess the selectivity and speciﬁcity 
of the experiment. We performed the analysis for the GNF dataset and it 
forms the basis for the analysis of transcription factor expression presented 
in §4.2.
 Quality check and pre-processing of the GNF dataset
We ﬁrst performed a quality check of the GNF dataset to ensure its 
quality. We used the Bioconductor package AffyPLM to ﬁt a linear model to 
the expression measurements across all probes. By analyzing the computed 
weights and standard errors of the model, we can detect any systematic 
variance within the data and identify individual arrays that are of poor 
quality.
The Relative Log Expression (RLE) computes the median expression value 
across all microarrays, and subtracts value from each probe. The box plots 
in Figure 4.9A displays the distribution of RLE values for each microarray 
in the dataset. We expect a large fraction of genes to behave similarly across 
most cellular conditions, which should result in box plots that are centred on 




















































Figure 4.9 | Quality assessment plots for the GNF SymAtlas dataset. (A) Boxplots of 
the Relative Log Expression (RLE) values show the spread of gene expression levels 
for each microarray relative to the entire dataset. RLE values are centred about 0 and 
have small spreads, indicating that all the microarrarys behave similarly. (B) Boxplots 
of the Normalised Unscaled Standard Error (NUSE) show the standard errors for 
each microarray. NUSE values are fairly uniform across the dataset indicating that 
there are no large experimental artefacts affecting a subset of microarrays.
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The Normalised Unscaled Standard Error (NUSE) allows us to compare 
the standard errors across microarrays; similar standard errors within a 
dataset indicate that it is sensible to compare data between the arrays. The 
boxplots in Figure 4.9B show that the GNF dataset has similar NUSE values 
throughout. 
The linear model also allows us to draw schematic images of the arrays 
to identify any spatial artefacts (Figure 4.10). These can show: (i) the raw 
expression values; (ii) the weights of the model (ie, how much outliers have 
been down-weighted); (iii) and residual values (ie, the deviation from the 
expected expression value given the model).
After conﬁrming that the GNF dataset is of high quality and does not 
suffer from major errors, we then pre-processed the data using the GCRMA 
algorithm (§3.2.3.3).
 Speciﬁcity and sensitivity
As described in §3.2.3, PANP uses a set of negative strand-matching 
probesets to calculate false positive rates at different expression thresholds. 
The percentage of hits from these probesets gives an accurate estimate of 
speciﬁcity for the list of expressed genes.
To calculate the true positive rate, we compared the microarray data to 
EST measurements for equivalent tissue types. The Unigene database collects 
EST reads for different tissues and cell types, and clusters them to particular 
genomic loci. As an mRNA must be present in a sample to be sequenced, 
an EST provides proof of gene expression against which we can gauge 
microarray data. We selected 31 Unigene libraries covering 13 normal adult 
tissues (Table 4.1). We compare the distribution of microarray expression 
values for genes that are present or absent as ESTs in the Unigene libraries 
(Figure 4.11). It is clear that probesets associated with an EST have higher 
expression values than those that lack an EST. However, it is also notable 
that there are genes in the EST libraries displaying very low microarray 
expression values. This shows that although microarrays are able to detect 
Results
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accurately highly expressed genes, there is a limit to their detection capacity 
for genes expressed at lower levels.
A major difﬁculty in the analysis of microarray data is picking a threshold 
for deciding whether a gene is expressed or not. We plotted ROC curves to 
compare the performance of several methods for determining thresholds: 
Figure 4.10 | Schematic images of microarrays for the GNF SymAtlas medulla 
oblongata sample (3AJZ02081479a). The schematics display different values for each 
probe on the microarray, allowing users to identify visually any spatial artefacts. (A) 
Raw intensities (colour scale from black for low values to white for high values), (B) 
linear model weights (white to green), (C) residual values between the raw intensity 
and the linear model (blue to red), (D) negative residuals (blue to white), (E) positive 







arbitrary expression value cut-offs that are commonly used (log2(100), 
log2(150), log2(200)); MAS5.0; and PANP. We use the negative strand-matching 
probesets to calculate the speciﬁcity, and the presence or absence of ESTs as 
a measure of sensitivity.
Figure 4.12 displays the ROC curve for the lymph node. The solid black 
line represents sensitivity-speciﬁcity values for expression value thresholds 
between log2(1) and log2(200). There is a dramatic increase in sensitivity at 
lower expression values, followed by a shoulder in the curve and a slower 
Results
Unigene library ID Tissue Mean detected Mean undetected
6759 heart 5.109054 3.941986
6833 kidney 4.750552 3.893576
252 liver 5.582172 3.840463
6989 liver 4.760076 3.86308
249 lung 5.033341 3.890131
6834 lung 4.728005 3.898488
2709 lymph node 5.49709 4.015194
2710 lymph node 5.887549 4.045426
2711 lymph node 5.049647 4.097363
3718 lymph node 4.541702 4.046978
3719 lymph node 4.716034 4.111302
3720 lymph node 4.704832 4.109337
45 muscle 5.093514 3.881305
530 muscle 5.361126 3.871097
6761 muscle 4.515907 3.856882
14414 muscle 4.861265 3.916233
253 ovary 5.391216 3.960875
10196 ovary 4.276806 3.99185
5551 pancreas 5.126557 3.932393
6760 pancreas 5.576891 4.0339
13019 pituitary gland 5.164571 3.847367
250 placenta 6.342932 4.047371
2587 placenta 4.971826 3.903643
6835 placenta 5.278797 3.922187
13000 placenta 4.980353 3.996216
13001 placenta 5.313617 3.976539
6763 prostate 5.14798 3.928227
14129 prostate 5.082174 3.945071
14131 prostate 6.042568 4.099017
14590 spinal cord 5.831633 4.00117
13710 testis 4.959629 3.899426
Table 4.1 | Unigene libraries for the analysis of speciﬁcity of the 
Affymetrix GeneChip expression data. Mean detected and mean 
undetected columns correspond to mean expression values for 
probesets with and without corresponding EST.
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rise in sensitivity. A good threshold should maximise the sensitivity of 
detection and minimise the speciﬁcity. We clearly see that the commonly 
used arbitrary thresholds lie at the very left of the curve (orange data points): 
they produce few false positives, but also miss many expressed genes. The 
Affymetrix MAS5.0 algorithm gives reasonable false positive control, but 
returns a fairly low sensitivity (red data point lies right of the curve). At a 
1% false positive rate, the PANP algorithm appears to be too stringent (blue 
low data point). However at a 5% error rate the cut-off lies on the shoulder of 
the ROC curve, thus maximising sensitivity without compromising much on 
speciﬁcity. Application of the algorithm to all tissues with this cut-off results 
in detection rates from 45% to 65%. 
Microarray analysis tools
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Figure 4.11 | Probability density distributions of microarray expression values 
of ESTs. Microarray expression values are higher for transcripts that are detected 
as EST reads (solid red line), compared with those that are undetected (solid blue 
line). The vertical dotted lines represent the PANP thresholds at 1% (blue) and 5% 
error rates (red), and commonly used arbitrary thresholds at log2(100), log2(150), and 
log2(200) expression values (orange).
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4.1.6 Detection of tissue-speciﬁc gene expression
Statistical techniques such as those presented in §4.1.2 allow detection of 
differentially expressed genes among biological samples. However, these 
approaches become limited – both computationally and conceptually – with 
increasing numbers of samples, as in the GNF dataset. For example, it is not 
clear which tissue should be used as a common reference, and even with a list 
of differentially expressed genes from pairwise comparisons, it is non-trivial 
to deﬁne whether they are speciﬁcally expressed in particular samples.
Here we show how a simple statistic, the propensity (§3.2.1), can be used 
Results















Figure 4.12 | Receiver Operator Characteristic (ROC) curves measuring the 
sensitivity and speciﬁcity of microarray data for the lymph node. The solid black 
curve represents the quality of gene expression data at different thresholds at 
expression values between log2(1) and log2(200). Coloured dots represent different 
cut-offs: PANP at 1% and 5% error rates (blue), MAS5.0 (red) and commonly used 
arbitrary thresholds at log2(100), log2(150) and log2(200) (orange). The best balance 
between sensitivity and speciﬁcity is achieved using the PANP 5% cut-off, which 





Figure 4.13 | Heatmap of gene expression in 33 major human organs and tissues. 
Genes (rows) and tissues (columns) are aligned by hierarchical clustering of 
expression values. Intersecting cells in the heatmaps display (A) expression values 
(colours range from red to blue respectively for low to high expression) and (B) 
propensity values (same colour scale).
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to select class or tissue-speciﬁc expressed genes based on their expression 
values. The propensity measures how a gene’s expression level compares 
with the expression of genes in the tissue, and also the gene’s expression 
across all other tissues. A high propensity value indicates that the gene is 
relatively speciﬁc in a given tissue, whereas low propensity suggests that the 
gene is non-speciﬁc. Note that a given gene will have individual propensity 
values for each tissue that it is expressed in.
We calculated propensities for the GNF dataset, using the mean expression 
level for biological replicates (Figure 4.13). The distribution of propensity 
values is centred about 1, indicating that most genes are non-speciﬁc in most 
tissues. There is a long tail of higher propensities, and we select the top 5% of 
values to represent tissue-speciﬁc gene expression (Figure 4.14).
To validate the biological signiﬁcance of this threshold we analysed the 
GO functional annotations of expressed genes using the FatiGO web-tool. 
Though non-speciﬁc genes are not enriched in any functional categories, 

















Figure 4.14 | Histogram and probability density distribution for gene propensity 
values in 33 major human organs and tissues. The dotted line represents the 95th 





Figure 4.15 | Enriched Gene Ontology functions for tissue-speciﬁc genes. (A) 
Comparison of genes between whole blood (red bars) and whole brain (green) show 
that immune-related functions are enriched in the former, and neural development 
in the latter samples. (B) Comparison of genes between testis (red) and whole brain 
(green). The screenshot is taken from the FatiGO web-tool that was used for the 
analysis.
68
are relevant to the tissue in question. For example, a comparison of blood 
and brain shows that the former expresses many immune response genes, 
whereas the latter transcribes genes involved in neural processes (Figure 4.15 
A). In another comparison, we ﬁnd that reproductive genes are enriched in 
the testis compared with the brain (Figure 4.15 B). We observe similar trends 
for most other tissue-speciﬁc genes.
4.1.7 Analysis methods for tiling-array experiments 
Tilling microarrays allow us to detect genome-wide gene expression 
and transcription factor binding in an unbiased manner. In contrast to 
conventional microarrays that are designed with probes in only the coding 
or promoter regions, tiling arrays cover the entire genome including non-
coding sequences. This means that experiments using tiling arrays output 
different types of data, which require alternative methods for statistical 
analysis.
 Here I present the analysis of chromatin immunoprecipitation array 
(ChIP-chip) experiments that were performed in collaboration with Dr 
Asifa Akhtar’s laboratory at EMBL. The study examined the DNA-binding 
properties of members of the D. melanogaster dosage compensation complex 
(MSL1, MSL3, and MOF) and subunits in the nucleopore complex (Nup153 
and Mtor) in male and female cell lines. Precipitates were hybridised to the 
Affymetrix GeneChip Drosophila Tiling 2.0R Array in triplicate. Genomic 
DNA was used as the control. In addition, we assessed the effect of histone 
H4 acetylation on lysine 16 (H4K16Ac) by MOF, using an antibody that 
recognises the modiﬁcation.
 We pre-processed the raw array output using the GCRMA background 
correction and quantile normalisation. Genomic regions with enriched 
hybridisation, representing binding events, were then identiﬁed using the 
Bioconductor package symp (Figure 4.16). For each protein, we calculated the 
mean intensity of each probe across the three replicates. We then calculated 
the ratio of mean intensities between the ChIP and control samples. The 




















































































































































































































Figure 4.16 | Sample of ChIP-chip signals for MSL1-binding to the X chromosome. 
(A) GCRMA normalised intensity values for individual probes across three biological 
replicates (light orange). (B) Mean intensity values of the three biological replicates 
of MSL1-binding (orange). (C) GCRMA normalised intensity and mean values for 
the genomic DNA control (light and dark grey). (D) Ratios of MSL-binding and 
control mean intensity signals (light blue). (E) Smoothed ratios using a 500-bp sliding 
window (dark blue). (F) Top 1% ratio signal (dark blue).
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using a 500bp-sliding window. Finally, we identiﬁed genomic regions that 
are enriched for binding by comparing the ratios on the left side of the 
distribution (where the signal from the control – ie noise - is larger than 
the ChIP sample), with the ratios on the right side (where signals from the 
ChIP sample – ie binding events - is larger). We assumed a symmetrical null 
distribution based on the ratios on the left side, and deﬁned a binding event 
as any ratios extending beyond this distribution (FDR adjusted p-value 
<0.05). The results of these comparisons are presented in Table 4.2.
 The binding proﬁles for MSL1 are consistent with previous reports 
(Gilﬁllan et al., 2006). However, our results show substantial differences 
between in the numbers of binding sites of MSL1, MSL3 and MOF, which 
contradicts previous ﬁndings showing colocalisation by these proteins 
(Morales at el., 2004). Further, we fail to identify any binding by Nup153 and 
Mtor, which are known to interact with the DNA, and moreover, associate 
with the dosage compensation complex (Mendjan et al., 2006).
 These anomalies probably occur because the protocols or antibodies 
were optimised for MSL1. The experiments do not account for differences 
in DNA-binding afﬁnities or antibody speciﬁcities, leading to insufﬁcient 
binding enrichment of precipitated DNA fragments. This impacts on the 
analysis in several ways as: (i) all comparisons are made against the same 
control sample; (ii) equal thresholds are applied for identifying binding sites; 
and (iii) Nup153 and Mtor, which are structural proteins in the nuclear pore, 
are more difﬁcult to precipitate. These lead to artefacts in which proteins 
appear to bind to different genomic locations, with different speciﬁcities.
 We removed such biases from the analysis by ranking probe intensity 
ratios. By using the top 1% signal as the cut-off for signiﬁcant binding, we are 
able to compare the binding patterns across all proteins (Table 4.3).
 We used this approach to assess whether the proteins display chromosomal 
bias in their binding. As shown in Figure 4.17, binding is overwhelmingly 
favoured on the X chromosomes compared with the autosomes in male cell 
lines. However, this difference is abolished for MOF and H4K16 in female 




Table 4.2 | Signiﬁcant binding sites for DCC and associated proteins using symp 
symmetric null distribution (FDR adjusted p-value < 0.05).
Table 4.3 | Signiﬁcant top 1% probes for DCC and associated proteins.
Figure 4.17 | Number 
of top 1% binding sites 
on the autosomes and X 
chromosome. Counts are 
normalised by the total 
number of tiles from each 
class of chromosomes.




















Sample # tiles # autosome # chr. X
Male
MSL1 29872 265 (0.9%) 29607 (99.1%)
MSL3 " 734 (2.5%) 29138 (97.5%)
MOF " 10696 (35.8%) 19176 (64.2%)
H4K16 " 4316 (14.5%) 25556 (85.5%)
Nup153 " 16837 (56.4%) 13035 (43.6%)
Mtor " 15639 (52.4%) 14233 (47.6%)
Female
Kc MOF 29872 24051 (80.5%) 5821 (19.5%)
Kc H4K16 " 24355 (81.5%) 5517 (18.5%)
Kc Nup153 " 20201 (67.6%) 9671 (32.4%)
Kc Mtor " 20553 (68.8%) 9319 (31.2%)
Chromosome MSL1 MSL3 MOF H4K16 Nup153 Mtor Fem. MOF Fem. H4K16
2L 0 0 120 3371 1 0 0 2048
2R 4 0 124 3512 1 0 4 2552
3L 2 0 135 3578 1 0 0 2492
3R 1 2 196 4446 4 2 3 2693
4 0 0 6 268 0 0 0 249
X 700 92 707 4313 3 4 2 2254
Male Female
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we relax the threshold to the top 2, 5, 7, 10 and 15% signal suggests that the 
observations are robust and are independent of the cut-off (Figure 18).
Results
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Figure 4.18 | Number of binding sites on autosomes and X chromosome. (A) 
MSL1, (B) MSL3, (C) MOF, (D) MOF (female cell line),  (E) H4K16 acetylation, (F) 
H4K16 acetylation (female), (G) Nup153, and (H) Mtor. Numbers are shown for the 
top 1, 2, 5, 7, 10 and 15% of sites (light to dark blue).
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 As many of the proteins function as part of a complex, many of the 
binding sites are expected to overlap. Here, we restrict the binding sites to 
those occurring within a gene locus (Ensembl v41), and we deﬁne an overlap 
if two or more proteins bind to the same gene. Venn diagrams in Figure 4.19 
illustrate the high degree of overlap between the MSL proteins, MOF and 
nuclear pore complex on the X chromosome in male cell lines. This overlap 
is not apparent for autosomal genes (Figure 4.19C). This conﬁrms that the 
MSL and MOF proteins function together. Furthermore, it suggests that the 
nuclear pore complex not only associates with the DNA, but also may be 
involved in dosage compensation.
 We also analysed the location of binding by classifying them by their 
occurrence in: intergenic, upstream (10kb of the 5’-exon), 5’- and 3’-UTR, 
intronic and exonic regions (Figure 4.20). Deﬁnitions for genomic regions 
were extracted from Ensembl (v41) and binding sites were mapped using 
genomic coordinates supplied by Affymetrix. The majority of binding is 
found in coding sequences and the UTRs. Of particular importance is the 
difference in the location of MOF binding on autosomal and X-chromosomal 
genes, when comparing male and female cell lines: MOF binds at both the 5’- 
and 3’-UTRs in the male X chromosome, but is restricted to just the 5’-UTR in 
male autosomes, and female cell lines.
These results suggest a mechanism of dosage compensation in which 
MSL1 and MSL3 on the male X chromosome actively relocate MOF to the 





























































Figure 4.19 | Overlap of bound genes. Number of overlapping genes for: (A) MSL1, 
MSL3, MOF, H4K14 on the X chromosome; (B) MSL1, MSL3, Nup153, Mtor on the X 
chromosome; (C) MSL1, MSL3, MOF, H4K16 on the autosomes.
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Figure 4.20 | Location of binding sites relative to gene loci. Binding sites are 






























































































































































































































































































































































4.2 Identiﬁcation and functional characterisa-
tion of human transcription factors
The second section of this chapter describes the identiﬁcation and functional 
analysis of sequence-speciﬁc DNA-binding transcription factors in the human 
genome. The analysis includes assessment of: (i) GO functional annotation; 
(ii) structural features; (iii) tissue-speciﬁc expression; (iv) evolutionary 
conservation; and (v) chromosomal location.
4.2.1 Identiﬁcation of the human transcription factor reper-
toire
We compiled a high-quality dataset of human transcription factors. First we 
extracted 256 protein domains and families representing sequence-speciﬁc 
DNA-binding domains from the InterPro database. We manually inspected 
each InterPro entry using its description and associated literature citations in 
order to ﬁlter out non-DNA-binding domains (Table 4.4).
Next we performed a sequence similarity search using the hidden 
Markov model for each InterPro domain, and identiﬁed all human genes 
containing DNA-binding domains. This resulted in the selection of 3,848 
transcripts associated with 1,932 loci. We also included 525 genes from the 
DBD (Kummerfeld and Teichmann, 2006) and Messina et al. (2004) datasets 
that were not detected in our search. This resulted in a list of 2,457 gene loci 
encoding for potential transcription factors.
Finally, we removed false positives by manually curating every potential 
transcription factor by examining information available from GeneCards 
(Safran et al., 2003), Entrez (Maglott et al., 2007) and UniProt (Apweiler et 
al., 2004). We also assessed the promiscuity of InterPro domains in terms of 
giving false positive matches and the combination of domains in the genes. 
We grouped genes into three classes: (i) probable transcription factors, which 
contain a non-promiscuous DNA-binding domain and have experimental 
evidence for transcriptional regulatory activity; (ii) potential transcription 
Results
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Human Repertoire of Trancription factors
Table 4.4 | InterPro entries describing DNA-binding domains found in the human 
genome. 72 different InterPro domains are found in the human genome. We have 
have grouped similar domains together according to the parent-child relationships 
deﬁned in InterPro.
Interpro entry Family
























































factors, which contain a promiscuous DNA-binding domain and do not 
have any associated experimental evidence; and (ii) unlikely transcription 
factors, which have experimental evidence for molecular functions that are 
not compatible with transcription factor regulatory activity.
Out ﬁnal dataset comprises 1,369 probable, 239 potential, and 849 unlikely 
transcription factor loci (Table 4.5). The remainder of the analysis uses only 
the probable transcription factors (Appendix B).
4.2.2 Transcription factor functional annotations in GO and 
PubMed
We investigated the current level of knowledge of the regulatory functions 
for our dataset of human transcription factors by examining: (i) abstract 
citations in PubMed; and (ii) annotation of biological processes in the Gene 
Ontology database.
First we queried PubMed to count the number of articles that cite each 
transcription factor in the title or abstract (Figure 4.21). We separated entries 
Results
Table 4.4 | Continued.






















that focus on the human gene and orthologues in other species. Clearly, a small 
number on transcription factors dominate, such as the tumour suppressor 
P53 and the immune response regulator NFkB. However, the vast majority 
of transcription factors remain uncited.
Second we evaluated the GO “biological process” annotations of each 
transcription factor. Only 71 (5%) transcription factors have a GO annotation 
that is supported by experimental evidence (Figure 4.22 A). The percentage 
increases to 35% (468 genes) when we relaxed the criteria for supporting 
evidence to include “TAS” (traceable author statement; Figure 4.22 B). 
However, even when a transcription factor is annotated, very little detail is 









































































































Figure 4.21 | PubMed entries for the top 20 most cited transcription factors. Blue 
bars represent the number of citations for studies in human and grey bars show the 
number of citations for all other organisms.
Human Repertoire of Trancription factors
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These results demonstrate that most human transcription factors are 
completely uncharacterised and our dataset provides a unique opportunity 
for discovery by researchers interested in mammalian transcriptional 
regulation. In the remainder of this section I will describe computational 
analyses we performed to characterise the regulatory function of these 
transcription factors.
4.2.3 Structural classiﬁcation
The most common classiﬁcation for transcription factors is based on the 
structure of the DNA-binding domain. In ﬁgure 4.23 we show that three types 
of transcription factors dominate, comprising over 80% of the repertoire: 
Figure 4.22 | Gene Ontology annotations of biological processes for the human 
transcription factor dataset. Different sources of evidence are used for annotations: 
(A) experimental evidence, and (B) traceable author statements (ie, statements in 
publications that cannot be attributed to a source). (C) The most common Gene 
Ontology annotations for the transcription factor dataset (number of annotated 















C2H2 Zn-ﬁnger, homeodomain and helix-loop-helix. As observed previously, 
these transcription factor families bind the DNA by inserting an alpha-helix 
into the DNA major groove, providing speciﬁcity though interactions with 
nucleotide base edges and stability via interactions with the sugar-phosphate 
backbone (Luscombe et al., 2000).
4.2.4 Tissue-speciﬁc expression of transcription factors
One good indicator of gene function is its expression proﬁle. We examined the 
distribution of transcription factor expression in the human body by using 
the Genome Novartis Foundation SymAtlas dataset presented in §4.1.5.
We ﬁrst examined whether levels of transcription factor expression are 
different to that of other genes. Figure 4.24 displays mean expression levels 
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Figure 4.23 | Classiﬁcation of the human transcription dataset according to the 
DNA-binding domain. (A) Distribution of DNA-binding domains sorted according 
to the number of transcription factors. Schematic illustrations of the structures of the 
most common DNA-binding domains complexed with DNA: (B) C2H2-zinc ﬁnger 
(PDB code: 1aay), (C) homeodomain (1fjl), and (D) helix-loop-helix (1am9) (adapted 
from Luscombe et al., 2000).
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tend to be expressed at lower levels than non-transcription factor genes (p < 
10-16).
Next we investigated the tissue-speciﬁc usage of transcription factors 
across 33 major tissues and organs. A transcription factor was deﬁned as 
“present” if its expression value exceeded the PANP threshold for each 
array as described in §4.1.5. The histogram in Figure 4.25 (A) shows a large 
difference in the numbers of transcription factors expressed in each tissue, 
ranging from 331 in fetal-lung to 155 in the appendix. These differences can 
in part be explained by the fact that more complex tissues (in terms of cell 
type content, metabolic and secretory activity) require more transcription 
factors.
Figure 4.24 | Mean expression levels for transcription factors (blue) and non-
transcription factor genes (red) across 79 human organs, tissues and cell lines. 



















































































































































We then assessed how widely transcription factors are expressed. 
Figure 4.25 B shows the number of tissues in which transcription factors are 
expressed. The distribution is bimodal, indicating that transcription factors 
are generally either expressed ubiquitously across all tissues or speciﬁcally 
Figure 4.25 | Distributions of transcription factor expression in 33 major human 
organs and tissues. Histograms display the: (A) number of transcription factors 
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in a small number of tissues.
Figure 4.26 displays a heatmap of 508 transcription factors that are 
expressed in at least one of the 33 tissues examined. We calculated propensity 
values (§4.1.6) to deﬁne formally whether a transcription factor is tissue-
speciﬁc or general (ie, non-tissue-speciﬁc) in its expression.
We classiﬁed 165 transcription factors as having non-speciﬁc expression. 
Most of these are ubiquitously expressed although they are sometimes 
missing from certain tissues. Examples of non-speciﬁc transcription factors 
include well-known regulators such as C/EBP or JUND.
There are also 343 tissue-speciﬁc transcription factors, which are expected 
to play an important role in dictating the cell’s identity. Most are expressed 
uniquely in only one tissue, although some are speciﬁcally expressed in 
several tissues (eg, transcription factors that are speciﬁcally expressed in fetal 
brain, adult brain and spinal cord). Finally, a few transcription factors are 
expressed ubiquitously but are nonetheless speciﬁc as they display higher 
expression levels in a particular tissue. Different tissues express diverse 
numbers of speciﬁc transcription factors. For example, whole blood, testis or 
brain contain a larger proportion of speciﬁc regulators compared with other 
tissues such as tongue, heart or appendix.
127 transcription factors are regulators speciﬁc to one tissue. Among these 
are well-known tissue-speciﬁc regulators such as the hepatocyte nuclear 
factor 4 (HNF-4) in liver and the Zn-ﬁnger protein ZBTB32 in testis.
Other transcription factors are shared speciﬁcally between sets of tissues. 
In general this is either because the tissues are related, or because there is a 
contamination between assayed samples. There is often a strong correlation 
in transcription factor expression between fetal and adult tissues. For 
example fetal and adult brain, lung and thyroid, share 21, 13 and 8 tissue-
speciﬁc transcription factors respectively. We also observed similar patterns 
in the central nervous system (brain, spinal cord and fetal brain), in which 
transcription factors such as the calmodulin-binding transcription activator 
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Figure 4.26 | Heatmap of transcription factor expression in 33 major human 
organs and tissues. Transcription factors (rows) and tissues (columns) are aligned 
by hierarchical clustering of expression values. Intersecting cells in the heatmaps 
display (A) expression values (dark red for low expression and dark blue for high 
expression), and (B) propensity values (same colour scale). 
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factors such as the proto-oncogene MYCN in fetal brain or the homeobox 
protein PKNOX2 in brain.
Speciﬁc transcription factors in whole blood must be treated with caution 
as they are likely to display shared expression owing to cross-contamination 
of tissue samples. Among the 60 speciﬁc transcription factors, only 22 are 
unique to blood and the remaining 38 are shared with 27 other tissues, such 
as lymph node, thymus, lung, tonsil, bone marrow or thyroid.
Entire classes of transcription factors families sometimes show similar 
expression proﬁles. The LIM-homeodomains are expressed in the brain, 
which agrees with previous studies from the C. elegans nervous system 
(Vermeirssen et al., 2007). Transcription factors containing myelin-like 
DNA-binding domains are expressed at high levels in fetal and adult brain, 
and spinal cord. Other families, such as the C2H2 Zn-ﬁngers do not have 
such patterns and are both ubiquitous and speciﬁc (Figure 4.27). Notably, 
a signiﬁcant proportion of transcription factors are not expressed in any 
sample, but might become tissue-speciﬁc under particular conditions such 
as development or different stresses.
In summary our results demonstrate a two-tier system of regulation 
based on global and tissue-speciﬁc transcription factors. Most transcription 
factors lack information regarding their regulatory function. However, our 
results deﬁne the conditions in which transcription factors might act and 
therefore suggest their function.
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Figure 4.27 | Heatmap of expression for C2H2 Zn-ﬁnger transcription factor family. 
Transcription factors (rows) and tissues (columns) are aligned using hierarchical 
clustering of expression values (dark red for low expression and dark blue for high 
expression).
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4.2.5 Evolutionary conservation of human transcription fac-
tors
We examined the evolutionary conservation of human transcription factors 
across other eukaryotes. We performed this by analysing the gene trees 
provided by Ensembl Compara (v41) for 1,369 transcription factors. Figure 
4.28 shows a heat map depicting the presence or absence of transcription 
factor orthologues in 25 eukaryotic organisms ranging from yeast to 
chimpanzee. There are four clear clusters representing major expansions 
in the transcription factor repertoire, which occurred at important stages 
of evolution in the human lineage (appearance of animals, vertebrates, 





























































Figure 4.28 | Heatmap of transcription factor orthologues in 25 eukaryotic 
genomes. Transcription factors (rows) and organisms (columns) are hierarchically 
clustered according to the presence (blue) or absence (white) of a transcription factor 
orthologue. Orthologues are identiﬁed using automatically generated gene trees 
from Ensembl Compara. Transcription factors with human paralogues are shown 
next to the H. sapiens column.
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predicting orthologues such as BLAST bi-directional best-hits, and orthology 
assignments by Ensembl Compara (v37) or Inparanoid (v5) (Figure 4.29). 
50% of our dataset have paralogues within the human genome. Most of these 
are also conserved in other vertebrates, which agrees with the hypothesis 
of a whole genome duplication in early chordates (McLysaght et al., 2002). 
Other paralogues are conserved in mammals and primates suggesting more 
recent duplication events (Figure 4.28).
There are 69 (5%) human transcription factor orthologues in S. cerevisiae. 
These transcription factors have functions such as cell cycle control, signalling 
or stress response in both yeast and human suggesting roles in regulating 














































































































Figure 4.29 | Heatmap of transcription factor orthologues in 19 eukaryotic genomes. 
Orthogloues are the union of entries from Ensembl Compara and Inparanoid.
Human Repertoire of Trancription factors
90
no predicted orthologues in chimpanzee or macaque; however, rather than 
being human-speciﬁc regulators, we ﬁnd that these are artefacts caused by 
the poor gene annotation of non-human primate genomes.
We next focused on different transcription factor families. Several 
appeared at different evolutionary points; for example the STAT family is 
present in all animals, and the myelin-like transcription factors are only 
found in vertebrates. Of the three most abundant families, homeodomains 
and helix-loop-helix are well conserved in all animal genomes. Zn-ﬁngers 
on the other hand show four stages of expansion in animals, vertebrates, 
mammals and primates (Figure 4.30).
Previous studies have hypothesised that there is a relationship between 
conservation and expression proﬁle (Freilich et al., 2005); these propose that 
more evolutionary conserved genes should perform more general cellular 
functions (such as metabolism) and therefore have a broader expression 
proﬁle. We compared the tissue speciﬁcity of transcription factor expression 
and the level of conservation by extracting orthology assignments from 
Ensembl Compara (v37) and Inparanoid (v5). To minimise false positives 
in the ortholog assignments, we analysed only the union from the two 
databases. As shown in Figure 4.31, there is no clear relationship between 
the degree of conservation and expression proﬁle for transcription factors.
We also repeated the analysis by grouping transcription factors into 
phyletic classes (ie, primate-speciﬁc, mammal-speciﬁc, vertebrate-speciﬁc, 
animal-speciﬁc, and unicellular). Figure 4.32 shows there is no apparent 
relationship here either. 
It is unclear whether this lack of relationship is because of the data quality, 
or the fact that transcription factors and their functions evolve rapidly and 
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Figure 4.30 | Heatmap of orthologues for transcription factor families. (A) C2H2 
Zn-ﬁnger, (B) homeodomain and (C) helix-loop-helix. 














































































































































































































Figure 4.31 | Relationship between transcription factor expression and evolutionary 
conservation. (A) Scatter plot of the number of tissues in which transcription factors 
are expressed, and the number of organisms in which orthologues are found. 





Chromosomal location is an important characteristic of genes as it can have 
strong effects on gene regulation and mutation rates (Boutanaev et al., 2002; 
Chuang and Li, 2004; Pirrotta, 1997). 
We ﬁrst examined whether transcription factor genes are distributed 
evenly throughout the human genome. We counted the number of 
transcription factor genes in each chromosome and calculated whether they 
are over-represented compared with non-transcription factor genes in the 
same chromosome. Using a random permutation test, we ﬁnd that only 
chromosome 19 is enriched with transcription factors (p < 0.0001; Table 4.6). 
In contrast, chromosomes 1-5, 13, 22 and X are depleted (p < 0.05; Table 4.6).
Figure 4.32 | Relationship between transcription factor expression and 
evolutionary conservation. Plot shows the distribution of the number of tissues in 
which a transcription factor is expressed, and the most distant evolutionary organism 
in which there is an ortholog.
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There are certain sets of transcription factors that are known to be co-
localised in clusters; for example, the Hox A-D developmental genes on 
chromosomes 2, 7, 10 and 17, and the Zn-ﬁnger clusters on chromosome 
19 (Eichler et al., 1998). Through clustering, it has been proposed that these 
transcription factors coordinate their evolution and regulatory activity 
(Klymenko et al., 2006).
We searched for further transcription factor clusters by sliding a 1Mb 
window along each chromosome. We counted the number of transcription 
factors within the window and compared this number against the expected 
numbers of transcription factors given the chromosomes’ gene content 
(using 10,000 permutations). We applied a threshold of p < 0.05 (adjusted 
for multiple testing using FDR) to identify such clusters. The results were 
consistent with different window sizes (data not shown).
We detected all the previously reported Hox A-D and Zn-ﬁnger clusters. 
We also identify 40 new clusters, even on chromosomes that are depleted for 
transcription factors (Figure 4.33).
Overall, 521 (38%) transcription factors are co-localised in clusters. 23 of 





1 3134 113 (3.61%) 0.016
2 2149 77 (3.58%) 0.042
3 1670 57 (3.41%) 0.031
4 1287 31 (2.41%) 0.0002
5 1399 41 (2.93%) 0.004
11 1856 51 (2.75%) 0.0002
13 592 16 (2.70%) 0.024
22 733 19 (2.59%) 0.0096
X 1360 44 (3.24%) 0.022
Enriched
19 1767 262 (14.83%) 0.0001
Table 4.6 | Transcription factor enriched and depleted 
chromosomes in the human genome. The p-values were calculated 
via random permutation tests for each chromosome.
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only Zn-ﬁngers), which is the expected frequency given the abundance of this 
family in the genome. Eight clusters are over-represented by homeodomains, 
fork-head, or hormone receptor regulators, whereas 21 clusters contained a 
mixture of multiple transcription factor families.
17 clusters are located in peri-centromeric or sub-telomeric regions. This 
suggests two possibilities. First, transcription factor clusters may allow for 
coordinated transcriptional control. Second, these chromosomal regions 
have been reported as hot-spots for gene duplication, and transcription 
factor clusters may have formed following recent duplication event.
Figure 4.33 | Clusters of transcription factors in the human genome. Previously 
known clusters of Hox genes (blue boxes) and Zn-ﬁngers (green) are found as well 
as 40 new clusters (red).
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To elucidate whether clusters enable co-expression we checked their 
cluster-dependent expression. Although we did not detect signiﬁcant 
correlation between transcription factors in the same cluster, we found 
tentative evidence suggesting coordinated repression of entire clusters, 
perhaps resulting from chromatin condensation (data not shown).
We then evaluated whether clusters consist of duplicated genes that 
inserted close to the original sequence. In 5 out the 52 clusters (10%), all 
members of the cluster are paralogues. In the majority of cases however, 
most paralogous genes are located in a different region of the genome.
We then assessed when clusters were formed by examining the proportion 
of transcription factors with ancestors only above the catarrhini and eutheria 
clades. We ﬁnd that the clusters in sub-telomeric and peri-centromeric regions 
have slightly higher proportions of newer transcription factors, although the 
signiﬁcance was marginal (p = 0.0541).
4.3 Identiﬁcation and characterisation of func-
tional SNPs
Single nucleotide polymorphisms (SNPs) are the most common type of DNA 
sequence variation in the human genome. This section examines the potential 
effects of SNPs on gene expression.
SNPs are formally deﬁned as polymorphisms occurring in at least 1% of 
a given population, and therefore should not produce a disease phenotype 
on their own. The effect of SNPs on phenotypes and disease susceptibility is 
of great interest. Although their effect is likely to be most marked when they 
occur in protein-coding sequences, they may also be important in introducing 
changes in the mechanisms for gene expression control. Here, we identify 
potential functional SNPs located in: (i) transcription factor binding sites; (ii) 




4.3.1 SNPs aﬀecting transcription factor binding sites
Many transcription factors bind and regulate at the promoter of speciﬁc 
genes by recognising certain DNA sequence motifs. Therefore, changes in 
the sequence of binding site motifs by mutations or SNPs could alter the 
binding speciﬁcity of transcription factors and so affect the expression of the 
downstream target genes.
First we predicted the binding sites of 270 transcription factors in the 
promoter regions of the human genome. We limited the search to a 10kb 
region upstream of genes, as they are the most likely area for transcription 
factor binding and regulation. Using 330 high-quality position weight 
matrices from TRANSFAC, we scanned the promoter regions of 24,037 
Figure 4.34 | Cartoon representation of possible mechanisms by which SNPs could 
affect the regulation of gene expression. (A) Representation of a normal regulatory 
process where the allele of a particular SNP is functional. (B) If the allele disrupts 
any element of the gene promoter, such as transcription factor (green) binding sites 
or triplex forming regions, the overall transcriptional activity of the downstream 
gene can be modiﬁed. (C) SNPs located in regions related to splicing, such as ESEs 
or splicing donor/acceptor sites can alter pre-mRNA processing and therefore the 












annotated Ensembl genes (v18.34) using the Match program. We applied 
settings that minimised the false positive rate for binding site predictions. 
This resulted in 2,587,478 potential binding sites.
Next we identiﬁed all Ensembl annotated SNPs located in those binding 
sites. 57,412 SNPs overlap with 71,444 binding sites. 19,010 genes contain at 
least one affected binding site in the promoter.
4.3.2 SNPs aﬀecting splicing boundaries
Splicing is a key mechanism for removing introns from newly transcribed pre-
mRNA molecules. The splicesome, which is responsible for this, recognises 
speciﬁc sequences at the start and end of each intron, and uses them to drive 
the chemical reactions that eventually result in intron excision. Dinucleotide 
sequences at the 5’-start (GU) and 3’-end (AG) are present in more than 99% of 
all introns, and are crucial to ensure correct splicing. Thus, SNPs that disrupt 
those sequences are likely to impact on the correct processing of mRNAs, 
and may even result in the expression of non-functional proteins.
We identiﬁed all SNPs situated in one of the four base position of all gene 
transcripts annotated in Ensembl (v18.34). This resulted in 884 SNPs located 
in the intron-exon boundaries of 598 genes.
4.3.3 SNPs aﬀecting exonic splicing enhancers
The serine- and arginine-rich (SR-rich) family of proteins recognise speciﬁc 
exonic sequences to recruit the U1 and U2AF small nuclear ribonucleoproteins 
that mediate splicing. The sequences bound by SR-rich proteins are termed 
exonic splicing enhancers and were originally determined by SELEX 
experiments (Cartegni et al., 2002). SNPs located in these sequences could 
therefore affect pre-mRNA-processing.
We scanned all human exons using the score matrices of exonic splicing 
enhancers for the SR-rich proteins SF2/ASF, SC35, SRp40 and Rp55 (Cartegni 
et el., 2003). We then mapped the predicted enhancers to the human genome 
and identiﬁed SNPs that overlapped with these predictions. This resulted in 
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138,746 SNPs affecting 17,312 genes.
4.3.4 Triplex target sequences disrupting SNPs
A DNA triplex is a speciﬁc nucleic acid conformation produced when a 
duplex containing a poly-purine sequence is recognised by a triplex-forming 
oligonucleotide. Genomic surveys have shown that triplex target sequences 
are signiﬁcantly over-represented in gene promoters (Goñi et al., 2004). 
Although their functionality is not clear, they have been proposed to act as 
stabilisers of promoter conformation. DNA triplexes are formed in regions 
with continuous tracks of poly-purines and therefore SNPs in these regions 
can modify the ability of a sequence to form this structure.
We predicted triplex-forming regions by searching for sequences 
containing at least 10 consecutive purines in the 10kb upstream and the 
3’UTRs of all annotated human genes (Ensembl v18.34). We then identiﬁed 
364,314 SNPs located within the predicted triplex-forming sequences.
4.3.5 PupaSNP
All predicted functional SNPs are stored in a MySQL relational database and 
the information is distributed through a web-based tool called PupaSNP 
(http://www.pupasnp.org; Conde et al., 2004). The web-tool also highlights 
SNPs that produce non-synonymous changes (ie, altering the amino acid 
sequence of the encoded protein), and population frequencies from the 
HapMap project that can be used in association studies (The International 






5.1 Development of methods and tools for high-
throughput data analysis
In order to allow researchers to interpret genome-scale data in a meaningful 
manner, the development of new experimental techniques often has to be 
accompanied by the development of associated analysis techniques. Here 
I have presented methods and approaches for analysing data from three 
major genome-scale expression and binding measurement techniques: two-
colour cDNA microarrays, Affymetrix Gene Chips, and ChIP-chip coupled 
with tiling arrays.
5.1.1 Normalisation for two-colour cDNA microarray
Normalisation is the most important step in the microarray data analysis 
workﬂow, as one needs to ensure that the data are of high quality before 
making any inference from them. For two-colour cDNA arrays the main 
sources of bias arise from the non-linear differences in response between the 
different dyes, and manufacturing and hybridisation mistakes. The print-tip 
loess algorithm (Yang et al., 2002) allows us to correct for both errors and is 
therefore highly recommended.
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These techniques are specialised and generally inaccessible to most 
laboratories without statistical expertise. Therefore I developed DNMAD, 
a web-tool that allows users to perform a quality check of their microarray 
data and then normalise them using the print-tip loess method. No previous 
statistical training is needed to use the tool, making it accessible to anyone 
who wishes to analyse their own data.
There are two major limitations of most web-based tools: (i) they are 
often implemented as isolated applications that do not feed into any other 
software; and (ii) they usually limit the amount of data that can be uploaded. 
DNMAD takes advantage of its integration with the GEPAS software package 
(Herrero et al., 2003a; Vaquerizas et al., 2005), which allows users to perform 
the entire microarray analysis within the same program. It is also designed 
to cope with a large number of microrrays thus overcoming the data capacity 
limitation.
5.1.2 Diﬀerential gene expression
Identifying differentially expressed genes between distinct cellular conditions 
has been one of the mayor areas where microarrays have been employed. 
Many approaches have been used to rank genes according to the amount 
of expression change between sets of biological samples. These range from 
direct comparisons using the ratio of expression from two-colours cDNA 
microarrays (van de Peppel et al., 2003), to more robust methods such as the 
use of statistical tests (Golub et al., 1999). We developed Pomelo, a tool that 
implements multiple statistical tests to quantify differential gene expression. 
We employed simple procedures such as the t-test, and Fisher’s exact test 
for continuous and discrete data respectively. A novel aspect of this tool was 
the implementation of strategies to deal with the multiple-testing problem, 
which arises from assessing the expression of many genes at once.
However, the simple statistics implemented in this tool have difﬁculty 
in estimating the population variances when dealing with small numbers of 
replicate microarrays. To solve this, methods have been implemented that 
estimate the variance from the expression of all probes on the array rather 
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than individually; for example, different versions of the moderated t-test, and 
the empirical Bayes estimations (Baldi and Long, 2001; Lonnstedt and Speed, 
2002; Smyth, 2004; Tusher et al 2001). These approaches have increased the 
sensitivity for detecting differentially expressed genes and are now favoured 
for studies containing only a small number of microarrays.
5.1.3 Building class predictors from microarray data
A major aim of microarray studies is to identify marker genes that are indicative 
of the cellular states of different samples. Genes grouped in a predictor could 
be used to predict the class membership of new uncharacterised sample 
based on its expression proﬁle. Intuitively, one expects the best predictors 
to be those genes that display greatest differential expression. However, if 
two genes are signiﬁcantly differentially expressed but behave similarly, 
having both as markers would not improve the predictive power. Similarly, 
including a very large number of genes in the predictor will increase the 
noise compromising the quality of the predictions. Therefore we require a 
method that balances these needs to build reliable predictors.
Another aspect to be considered when building predictors is the 
reported error rate. Several studies have reported predictors for different 
conditions; for example, van ‘t Veer and collaborators (2000) published a 
gene set to determine whether post-surgery breast tumour patients require 
chemotherapy. The results of this seminal paper were used to produce a 
commercial microarray — the Mammaprint — which is now used in clinical 
settings. Unfortunately, this, and other similar studies, have been criticised 
because the prediction rates reported in the original publications were 
overestimated, so resulting in not so accurate clinical predictions (Ambroise 
and McLachlan, 2002; Ransohoff, 2005a; Ransohoff, 2005b).
I have presented a method called TNASAS for building class predictors that 
combines a gene selection procedure with supervised training classiﬁcation. 
The tool computes error rates in an unbiased manner, as it implements a 
full cross-validation procedure and does not predetermine the number of 
predictor genes to be outputted.
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5.1.4 Functional annotation of co-regulated genes
By integrating functional descriptions of individual genes, we can interpret 
the expression data from a biologically meaningful standpoint. The most 
common approach is the use of Gene Ontology information (Al-Shahrour 
et al., 2004; Beissbarth and Speed, 2004; Dennis et al., 2003), but there are 
also other sources of information that may be of interest, including InterPro 
(Mulder et al., 2007), to detect enrichment of particular protein domain 
classes; and the Kyoto Encyclopaedia of Genes and Genomes (Kanehisa et al., 
2006), to identify pathways which contain differentially expressed genes.
In §4.1.4 I presented Transfat, a tool that searches for over- and under-
represented transcription factor-target gene relationships. Although this 
potentially allows us to predict the regulators of genes, it is important to note 
that most transcription factor binding site predictions return a large number 
of false positives.
5.1.5 Assessing sensitivity and speciﬁcity for Aﬀymetrix data
It is sometimes important to determine the presence or absence of genes 
in the cell rather than their relative expression. Affymetrix GeneChips 
are hybridised using only one biological sample, and since there is no 
competition for probes, the resulting ﬂuorescence can be used a measure for 
absolute levels of expression. One of the major sources of experimental noise 
is non-speciﬁc cross-hybridisation with probes, which must be considered to 
determine absolute gene expression measurements.
In §4.1.5 I presented an approach that estimates the true and false positive 
rates of detection using a set of negative strand matching probe sets and 
EST measurements from Unigene. By balancing the two, we are able to set 
objective and reliable thresholds for gene expression levels.
The use of sensible present and absent calls will also beneﬁt differential 
gene expression measurements. We can ﬁlter genes that are absent from all 
conditions, thereby reducing noise and increasing the sensitivity of multiple-
testing procedures (as the number of distinct tests, and thus the degree of 




In addition to measuring differential expression, it is often of interest to 
identify genes that are uniquely expressed in a single condition. However 
this is not trivial when there are more than two biological samples.
In §4.1.6 I demonstrated the use of the propensity value as a measurement 
for tissue speciﬁcity. Propensity calculations were extensively used in 
structural biology to determine the amino acid composition of alpha-helices 
(Pace and Scholtz, 1998). Here we adapted the calculation to highlight genes 
that are speciﬁcally expressed in a single tissue. We validated the results by 
examining the functions of speciﬁc and non-speciﬁc genes which showed that 
propensity values allow us to identify automatically genes that contribute to 
the specialised functions of particular tissues.
5.1.7 Tiling arrays
Tiling arrays allow us to interrogate genomes in an unbiased manner since 
the entire genome is represented (Bertone et al., 2004). In §4.1.7 we developed 
an approach to detect DNA-binding from ChIP-chip experiments for which 
the binding strengths vary widely between the different proteins under 
consideration. We selected the top 1-15% of binding signals in each ChIP 
sample. Although this method does not allow us to estimate the absolute 
number of binding events, it enables us to detect biases in the binding site 
location between samples.
We detect preferential binding to the X-chromosome for subunits in 
the Drosophila melanogaster dosage compensation complex and structural 
proteins in the nuclear pore. We also demonstrated that these proteins tend 
to bind coding sequences rather than introns or intergenic regions, and 
that the binding occurs preferentially at the 3’-end of genes. By varying the 
thresholds for the binding signal we showed that the results were robust.
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5.1.8 Development of high-throughput data analysis meth-
ods
With the continued ﬂood of data from high-throughput experiments, there is 
a need to develop tools and methods to analyse and infer sensible conclusions 
from these data. Without appropriate statistical and mathematical treatment 
of the data, it is difﬁcult to obtain accurate and reproducible results that can 
be validated in follow-up experiments.
A crucial aspect of methods development is making them available 
publicly, so they can be rigorously tested by the scientiﬁc community and can 
be developed further (Dudoit et al., 2003). A major success of this model is 
the Bioconductor (Gentleman et al., 2004) open-source initiative for genomic 
analysis software using the R statistical package. Bioconductor freely offers 
a multitude of software tools for analyses ranging from image processing 
to classiﬁcation algorithms. As opposed to commercial software such as 
GeneSpring, the open source model allows everyone to contribute updates 
and challenge existing methods, leading to a product that is developed more 
quickly and accurately.
It is also important to take into account the interaction between wet-labs, 
that perform the experiments, and bioinformaticians, who interpret the results. 
Although biological research employs more and more genomic approaches, it 
is clear that most laboratories do not have the necessary expertise to perform 
all the analyses. These interactions will become increasingly important. 
Fostering a ﬂuent and bidirectional communication between laboratories 
will enhance the outcome of projects. In many circumstances, as protocols 
and experimental techniques become standardised some of the analysis will 
also become routine. In such cases we should aim to automate the analysis in 
the form of web tools. These methods can then be used with the appropriate 
training by non-bioinformaticians (Fox et al., 2006).
This will not always be possible when there are very new techniques or 
unusual data sets involved, and novel methods will have to be developed 
on a case-by-case basis by experts. An example of this is described in §4.1.7, 
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where a speciﬁc approach was necessary. It is important that these new 
methods are tested using suitable benchmarks to demonstrate their validity.
5.2 Human repertoire of transcription factors
A major challenge in the post-genomic era is to understand the functions and 
usage of genes under different cellular conditions. Transcriptional regulation 
plays a central role in this as it controls the amount of mRNA produced by cells. 
Consequently there is a great research interest in deciphering the regulatory 
interactions between transcription factors and their targets. Most genomic 
research to date has been directed towards the prediction of transcription 
factor binding sites using phylogenetic footprinting and integrating the results 
with gene expression data (Tompa et al., 2005). Although these approaches 
have been used extensively, the predictions are still very unreliable and we 
are still at the beginning of understanding how gene regulatory networks are 
organised. A reliable dataset of human transcription factors that can be used 
in these studies is something which has been conspicuously lacking.
In §4.2 I presented a high-conﬁdence dataset of human transcription 
factors identiﬁed by the presence of DNA-binding domains. The list has 
been manually curated to ensure a low number of false positives and a high 
level of coverage. The results outperform previous attempts to identify 
mammalian transcription factors.
The regulatory functions of the vast majority of these factors are unknown. 
Therefore a major aim of the thesis was to functionally characterise the 
repertoire of human transcription factors by integrating genomic data. We 
ﬁrst showed that three families — C2H2-zinc ﬁnger, homeodomain and helix-
loop-helix — dominate, comprising more than 80% of the dataset. Spatially, 
a large proportion of transcription factors are located in dense clusters on 
the chromosomes. Some of these have already been reported (Eichler et al., 
1998; Lemons and McGinnis, 2006) and are known to be regulated together 
by chromatin remodelling (Klymenko et al., 2006), suggesting an important 
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form of control for coordinating transcription factor activity. Surprisingly 
many clusters reside in sub-telomeric and centromeric regions. These have 
been recently reported as regions for creating new genes, owing to the large 
numbers of segmental duplications (Linardopoulou et al., 2005). The presence 
of clusters in these areas might have contributed to the rapid expansion of 
C2H2-Zn-ﬁngers in the primate lineage.
Gene expression data for 33 human tissues showed that different numbers 
of transcription factors are expressed depending on tissue complexity: more 
transcription factors are expressed in tissues that contain diverse cell types, are 
developing, or are highly active in metabolism and signal transduction. The 
expression data also revealed a two-tier organisation: about 80 transcription 
factors are constitutively expressed across all tissues, whereas around 450 
factors are only expressed in one or two. These tissue-speciﬁc regulators, 
combined with the ubiquitous ones, specify the exact expression programme 
required by different cell types.
An analysis of the evolutionary conservation of human transcription 
factors across eukaryotic species revealed a step-wise introduction of protein 
families at key stages of evolution. The biggest increase in transcription 
factors occurred during the emergence of mammals and primates.
Several studies have reported a direct relationship between the level 
of evolutionary conservation of genes and their range of expression. They 
suggest that genes arising earlier in evolution should be involved in basic 
cellular functions and therefore be expressed more broadly (Freilich et al., 
2005). This has been disputed in other studies however, where no correlation 
between tissue origin and expression levels has been reported, suggesting a 
high rate of evolution for tissues with common ancestral tissue and therefore 
no conservation of the original expression patterns (Cannon et al., 2004; 
Yanai et al., 2006). For our transcription factor dataset we were unable to 
detect any relationship between evolutionary conservation and breadth of 
expression, and we have yet to determine whether or not this is because the 
effect is masked by the rapid expansion of the Zn-ﬁngers.
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Our dataset is of very high quality and will be invaluable to any researcher 
interested in human transcriptional regulation. However, the analysis we 
performed is still basic and much more work is required to complete our 
understanding of regulatory systems in mammalian organisms.
Follow-up studies include integrating further sources of information 
such as transcription factor binding sites identiﬁed using ChIP-chip and 
phylogenetic footprinting. This will provide the basis for generating a 
regulatory network for humans. Medically it will be of interest to assess the 
usage of these transcription factors in diseased cells, such as tumours.
In the long-term it will be important to examine the transcriptional 
regulatory system in conjunction with other processes. One possible avenue 
for exploration is the control of transcription factors themselves, as this 
impacts all the downstream targets. Transcription factors are controlled 
by many means, such as chromatin condensation, multiple transcription 
initiation sites or microRNAs. By integrating the combined effects of these 
mechanisms we will understand more fully the general mechanism of gene 
expression control.
5.2.1 Implications of the evolutionary conservation of tran-
scription factors
Due to their major importance in controlling cellular behaviour, the 
evolutionary conservation of transcription factors plays a fundamental role 
in understanding the differences between species. For example, the human 
and chimpanzee genomes have 99% sequence similarity (The Chimpanzee 
Sequencing and Analysis Consortium, 2005), but gene expression patterns 
vary considerably between the two organisms, in particular in tissues such 
as the brain, testis, and immune system (Heissig et al., 2005; Khaitovich et 
al., 2006a; Khaitovich et al., 2004; Khaitovich et al., 2006b). We have so far 
not identiﬁed any human-speciﬁc transcription factor, but it is clear that the 
regulatory system plays an important role in differentiating the two species.
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5.2.2 Collaborations with experimental groups
The impact of the data presented here is highlighted by the fact that they 
have already been used by experimentalists.
One of the most important characteristics of transcription factors is their 
binding speciﬁcity to particular DNA sequences. Currently, we know very 
little about DNA sequences recognised by different transcription factors, 
and consensus binding sequences are available for only 123 transcription 
factors (Sandelin et al., 2004). Further, as these consensus sequences are 
obtained from a limited number of experimentally veriﬁed sites, they may 
be biased towards particular types of promoters. Hallikas and collaborators 
recently developed a method to measure transcription factor-binding 
afﬁnities in an unbiased screen (Hallikas et al., 2006; Hallikas and Taipale, 
2006). The method clones the entire transcription factor or its DNA-binding 
domain fused to a renilla luciferase protein. This is followed by competitive 
hybridisation in streptavidin plates of biotin-labelled consensus sequences 
against all possible unlabelled variants. By comparing the level of binding 
between the sequences, it is possible to measure the relative binding afﬁnity 
of a given transcription factor. In collaboration with Prof. Jussi Taipale’s 
group in Helsinki, this method has been extended to our transcription factor 
dataset. The afﬁnities will provide a fundamental resource for identifying 
cis-regulatory binding sites, among many other applications.
An alternative approach for identifying binding sites is to perform ChIP-
chip experiments. The CRG in Barcelona is currently generating antibodies 
for 300 transcription factors in our dataset, in preparation for the chromatin 
immunoprecipitation experiments.
Eukaryotic cells beneﬁt from the extra combinatorial possibilities 
offered by different heterodimeric associations of transcription factors. 
This constitutes an extra level of regulation, since the transcription of each 
associated monomer can be modulated accordingly. Another study being 
considered is a two-hybrid screen of transcription factors to determine their 




Together, the data from these studies will allow us to begin building a 
network of the human regulatory system.
5.3 SNPs Analysis
One major task after the genome sequencing is to determine what makes 
individuals unique. Although the majority of the genome is shared 
between individuals, there are always variations in the exact nucleotide 
sequences, except in the case of identical twins. There are several sources 
of sequence variation including repeats, translocations, transpositions, and 
single nucleotide polymorphisms. The biggest effects of these changes are 
observed when they occur in coding regions as they can affect the function 
of the proteins. In addition, variations in regulatory motifs can impact the 
regulatory system by affecting gene expression levels or post-transcriptional 
processing. Most such changes are phenotypically neutral but they can also 
sometime cause diseases (Walker, 2007).
In §4.3 I presented an analysis of SNPs that might have phenotypic 
consequences due to changes in: (i) transcription factor binding sites; (ii) 
triplex forming regions in gene promoters; (iii) splicing donor and acceptor 
sites; and (iv) spliceosomal SR-rich protein recognition sites.
The degree to which SNPs affect the transcriptional and pre-mRNA 
processing mechanisms will depend greatly on the location of the 
polymorphism. For SNPs affecting splicing sites, an alternative transcript 
of the gene will be produced, although the effect may be attenuated in 
heterozygotes. The importance of the splicing sites is highlighted by their high 
level of conservation as well as the low number of SNPs. For the other classes 
of functional SNPs considered here the effect is less well understood.
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5.3.1 Human variation aﬀects gene activity at diﬀerent lev-
els
The analysis of human variation presented in this thesis is one of the ﬁrst 
studies assessing how single nucleotide polymorphisms can affect regulatory 
mechanisms controlling gene expression. Several of the predictions I made 
have been already experimentally validated. These include association 
studies in which putative functional SNPs have been linked to cell-cycle 
control (Belanger et al., 2005), breast cancer (Barroso et al., 2006; Fernández 
et al., 2006; Pooley et al., 2006), hypertension (Gong et al., 2007), depression 
and suicide (Lim et al., 2007) and Alzheimer’s disease (Bullido et al., 2007).
Belanger and collaborators (2005) selected 127 SNPs in the promoter 
region of 16 genes involved in the G1/S transition of the cell cycle, 90 of 
which where predicted to impact on transcription factor binding sites. They 
used electrophoresis mobility shift assays to associate eleven of these SNPs 
with a gain or loss of binding afﬁnity in transcription factor binding sites. 
Ultimately four promoter haplotypes were conﬁrmed via gene reporter 
assays.
In another study, Lim et al. (2007) measured allele-speciﬁc transcription 
of the tryptophan hydroxylase isoform 2 (TPH2) in sections of human pons, 
and detected a functional SNP, predicted to disrupt an exonic splicing 
enhancer, that occurs with high frequency in normal human subjects. The 
non-functional version of the SNP is thought to create a truncated protein 
resulting in a decrease of the global expression level of TPH2. Other 
laboratories (Barroso et al., 2006; Bullido et al., 2007; Fernández et al., 2006; 
Gong et al., 2007; Pooley et al., 2006), have used our predictions to explain 
the signiﬁcance of SNPs detected in case-control studies.
As I have mentioned previously, predictions for transcription factor 
binding sites, triplex forming regions or exonic splicing enhancers, suffer from 
a high false positive rate and this makes it difﬁcult to ﬁnd truly functional 
SNPs. The inclusion of evolutionary information, for example through 
phylogenetic footprinting, may improve predictions. In a similar fashion, the 
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inclusion of population frequencies in the algorithm would permit selection 
of polymorphisms under linkage disequilibrium, which would highlight 
the association of functional SNPs with particular phenotypes. These 
modiﬁcations have been included in later versions of the SNP selection tool 
(Conde et al., 2005; Conde et al., 2006).
5.4 Future work
The work presented in this thesis aims to further our knowledge of how 
regulatory systems control gene expression. However the work is limited by 
its focus on transcription factors. Nevertheless, it is a starting point from which 
we can progress to broader studies of cellular regulation. In particular, my 
mid-term goals are to integrate the transcription factor binding afﬁnities with 
expression data to characterise tissue-speciﬁc development in mammalian 
organisms. The integration of other genomic data, such as polycomb binding, 
will be vital, as it will introduce other regulatory mechanisms achieved by 
chromatin condensation or relaxation.
Further, new data types will emerge in the next few years. One of these 
will be the information generated by the new sequencing technologies, 
such as 454 or Solexa. In particular, transcriptome-sequencing and ChIP-seq 
experiments are emerging as serious competitors to microarrays.
Genome-scale RNAi knockout experiments (Ashraﬁ et al., 2003; Baeg 
et al., 2005; Boutros et al., 2004) and large-scale imaging data (Neumann et 
al., 2006) will also contribute to a much more complex view of biological 
systems. These data will require the development of new analysis methods. In 
addition, we will face the challenge of integrating these new data types with 
existing ones, as only by combining measurements of different aspects of the 
regulatory system will we be able to decipher its full biological function.
Finally I stress that the importance of collaborations between wet and 
dry laboratories will continue to grow. Early genomic collaborations tended 
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to involve a one-way interaction in which bioinformaticians analysed the 
data generated by experimentalists. We are now entering an era where these 
analyses are generating new hypotheses, which are in turn tested by the 
original experimental groups, so completing a collaborative cycle.
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6. Conclusions
Despite the importance of the transcriptional regulatory system to human 
viability, its complexity means that we are still yet to understand the system 
fully. Indeed we continue to make discoveries that were unexpected just a 
few years ago.
In this thesis, I have presented computational work investigating the 
nature of transcriptional regulation in the human genome. Although the 
study falls far short of a full description of the system, my hope is that the 
ﬁndings provide a useful basis for future work.
From the work presented in this PhD dissertation “Computational 
Approaches to Study Transcriptional Regulation in the Human Genome”, 
we can conclude that:
1. I have identiﬁed and analysed the repertoire of DNA-binding 
transcription factors in the human genome. This is the ﬁrst thorough study 
of its kind, and the dataset as well as the analyses, provide invaluable results 
for further genomic investigations.
We reveal that:
i) three protein families — the C2H2-zinc ﬁngers, homeodomain and helix-
loop-helix — dominate the repertoire of human transcription factors.
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ii) 40% of transcription factors are located in clusters in the genome, 
which may be indicative of their coordinated activity.
iii) transcription factors are expressed either ubiquitously or speciﬁcally 
giving rise to a two-tier system of global and local regulators.
iv) speciﬁc families of transcription factors have expanded in the human 
lineage at key points during evolution, possibly contributing to our identity 
as a species.
2. I have predicted SNPs  that disrupt the normal function of 
transcriptional regulation and post-transcriptional processes. In doing so, I 
have shown that there are thousands of natural variations in the sequence of 
the human genome which can potentially impact greatly on the regulatory 
system. The predictions will contribute to our understanding of multigenic 
diseases by directing experimental studies to the most promising SNPs.
3. I have developed statistical methods and software tools for the analysis 
of genomic data. Such resources are essential for the robust interpretation 
of these datasets, and our need for more tools will continue to rise with 
the increase in complexity and diversity of data types. Further, as more 
experimentalists employ genomic methods in their work, there will be a 
greater need to make these methods easily accessible.
Conclusions
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Appendix A - Resumen
A.1 Introducción
La información genética que cualquier organismo utiliza para crear el 
conjunto de proteínas que le caracteriza está contenida en su genoma. Estos 
están formados por largas moléculas de ADN que forman una doble hélice 
donde la información está codiﬁcada mediante secuencias de nucleótidos 
(Watson and Crick, 1953). En estas moléculas de ADN, podemos encontrar 
determinados fragmentos, los genes, que contienen la secuencia necesaria 
de nucleótidos para producir una proteína. Dependiendo de los niveles de 
expresión de diferentes proteínas cada célula del organismo adquiere una 
identidad propia.
Las proteínas se producen mediante una serie de procesos que están muy 
regulados. El primero, denominado trascripción, consiste en la utilización 
de un segmento determinado de ADN como molde para la creación de una 
molécula de ARN mensajero, que será procesada y posteriormente traducida 
por los ribosomas para crear una proteína (revisado en Alberts et al., 2002).
El segundo paso se denomina traducción y es el mecanismo mediante el 
cual un ARN mensajero es utilizado como molde para concatenar la secuencia 
de nucleótidos que conforma una proteína. Este proceso es posible gracias a 
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la correspondencia entre tripletes de nucleótidos y aminoácidos y señales de 
parada de la traducción (revisado en Lodish et al., 2003).
Esta cadena polipeptídica se pliega en una estructura tridimensional 
que puede continuar siendo procesada mediante modiﬁcaciones post-
transduccionales. Estas modiﬁcaciones pueden tener un efecto en la actividad 
de la proteína, si esta ha sido producida en forma de precursor, o en su 
localización celular (revisado en Lodish et al., 2003).
Los niveles de proteína producidos son controlados mediante diferentes 
mecanismos en cada una de estas de etapas. De esta manera, el nivel de 
compactación de la cromatina, la regulación del nivel de expresión, o el 
procesamiento del ARN afectan a la fase transcripcional. Otros mecanismos, 
como por ejemplo la exportación del ARN del núcleo al citoplasma, el 
nivel de degradación del ARN o la eﬁciencia de la traducción, controlan 
la etapa transduccional (Darnell, 1982). Aunque todos estos mecanismos 
tienen importancia respecto al nivel ﬁnal de proteína activa producida, el 
control de la trascripción, en la base del proceso, es crucial para el correcto 
funcionamiento de la célula, ya que de el dependen el resto de fases.
La enzima responsable de transcribir los genes es la ARN polimerasa, 
de la cual hay varias isoenzimas entre procariotas y eucariotas. Esta enzima 
no es capaz de reconocer secuencias especiﬁcas en el ADN, y por tanto si no 
hubiese un mecanismo que guiase a partir de donde tiene que transcribir, los 
ARN producidos serian aleatorios. Sin embargo, los genes son transcritos 
normalmente a partir de una región situada inmediatamente anterior al 
gen, el promotor, lo que demuestra que hay mecanismos que permiten a 
la polimerasa reconocer donde están los genes. Las proteínas que permiten 
este reconocimiento se denominan factores de trascripción, que se pueden 
clasiﬁcar en: (i) factores de trascripción generales; y (ii) factores de trascripción 
especíﬁcos de secuencia.
Los factores de trascripción generales, aunque alguno puede reconocer 
secuencias en el DNA, como por ejemplo TBP (de TATA binding protein), 
son los encargados de reclutar a la polimerasa y a otros factores asociados 
y formar el complejo de pre-iniciación. Posteriormente están implicados en 
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la iniciación, elongación y terminación de la trascripción. Estos factores son 
capaces de producir niveles basales de expresión génica (Hampsey, 1998; 
Thomas and Chiang, 2006).
Los factores de trascripción especíﬁcos de secuencia, por el contrario, son 
los encargados de promover la transcripción o reprimirla en función de las 
condiciones particulares de cada célula. Estos factores se unen especíﬁcamente 
a determinadas secuencias, lo que les proporciona la posibilidad de reconocer 
regiones especíﬁcas del genoma (Kadonaga, 2004). La interacción entre los 
factores de trascripción especíﬁcos de secuencia y la molécula de ADN ha 
sido estudiada en detalle. Esto ha permitido determinar una de las maneras 
mas frecuentes de interacción entre factores de transcripción y el ADN, 
que consiste en el intercalado de una alfa-hélice proteica en el surco mayor 
del ADN. De esta manera, los factores de trascripción pueden reconocer 
secuencias especíﬁcas de nucleótidos (revisado en Luscombe et al., 2000). 
Existen muchas otras proteínas que se unen especíﬁcamente al ADN, 
como por ejemplo co-factores y enzimas modiﬁcadoras de histonas. A pesar 
de que muchas estudios agrupan estas proteínas en el conjunto de factores de 
trascripción de un organismo, has sido excluidas del trabajo presentado en 
esta tesis, ya que el mecanismo por el que ejercen regulación transcripcional 
es muy diferente.
La importancia de la regulación transcripcional se pone de maniﬁesto en 
el gran numero de enfermedades asociadas a fallos en estos mecanismos de 
control como por ejemplo el cáncer (Darnell, 2000) o enfermedades durante 
el desarrollo embrionario (Boyadjiev and Jabs, 2000). Por lo tanto, es crucial 
caracterizar y entender los mecanismos que las células emplean para regular 
la trascripción.
La genómica
Los avances en biología molecular se han basado tradicionalmente en 
aproximaciones reduccionistas en las que sistemas biológicos complejos son 
separados en sus componentes mas simples para ser estudiados en el mayor 
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detalle posible. Una vez que estos componentes has sido caracterizados, sus 
características y funciones se intentan integrar para explicar el funcionamiento 
del sistema. Este método ha sido muy efectivo para determinar la 
función molecular de muchos genes y las causas de enfermedades como 
la fenilcetonuria (revisado en Eisensmith and Woo, 1992) y la hemoﬁlia 
(revisado en Bowen, 2002). No obstante, este método se basa en que los 
diferentes componentes se comporten de la misma manera cuando actúan 
en solitario o con el resto de componentes. Se ha demostrado que esto no es 
cierto en numerosos casos y que las interacciones entre los componentes de 
un sistema suelen estar acompañadas de nuevas funcionalidades (Kitano, 
2002). Este es quizá uno de los motivos por los que las técnicas tradicionales 
de biología molecular has tenido un éxito limitado a la hora de entender 
sistemas complejos como el cáncer o las enfermedades neurodegenerativas, 
que conllevan la actividad combinada de muchos genes.
Una aproximación complementaria es estudiar sistemas biológicos desde 
un punto de vista global empleando técnicas de genómica. La genómica se 
puede deﬁnir como el análisis de genomas completos de organismos y la 
integración de la funcionalidad de cada uno de los componentes para crear 
una visión global del sistema. Debido a la enorme cantidad de datos a integrar 
en análisis genómicos, es completamente necesario el uso de técnicas de 
bioinformática y biología computacional. Estas técnicas nos permiten tratar 
de manera matemática, y, automáticamente, la información disponible para 
obtener resultados relevantes desde un punto de vista biológico.
La genómica ha revolucionado en los últimos años la manera en 
la que afrontamos preguntas biológicas ya que nos permite evaluar el 
comportamiento de sistemas biológicos al completo. Un ejemplo reciente 
de como aproximaciones genómicas han cambiado radicalmente nuestro 
conocimiento sobre sistemas biológicos es el estudio de promotores de genes 
en mamíferos (Carninci et al., 2006). La visión clásica de estos promotores se 
derivó a partir de estudios en procariotas, cuyos genes presentan normalmente 
una región rica en AT, llamada caja TATA, que se sitúa alrededor de 30 pares 
de bases delante del sitio de inicio de trascripción. Carninci y colaboradores 
demostraron que la mayor parte de genes de eucariotas superiores carecen 
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de una caja TATA en su promotor. Adicionalmente también demostraron que 
los genes sin caja TATA poseen múltiples sitios de inicio de la trascripción en 
vez de un único sitio.
Técnicas de alto rendimiento
Las aproximaciones a escala genómica han sido posibles gracias al 
desarrollo de diferentes tecnologías de alto rendimiento que nos permiten 
escalar los experimentos clásicos de biología molecular, como por ejemplo los 
northern blots, o experimentos de knock-out condicional, de un solo gen por 
experimento a varias decenas de miles por experimento. La secuenciación 
de diversos genomas, como por ejemplo el de humano, ratón o chimpancé, 
ha contribuido enormemente a la consecución de este objetivo, ya que una 
vez que conocemos la secuencia de ADN para una especie determinada es 
posible determinar sus genes y diseñar experimentos para investigar su 
comportamiento bajo determinadas condiciones (Lander et al., 2001; The 
Chimpanzee Sequencing and Analysis Consortium, 2005; Venter et al., 2001; 
Waterston et al., 2002).
Matrices de ADN
Una de las primeras tecnologías desarrolladas fueron las matrices de ADN 
(generalmente conocidos como microarrays), que permiten la monitorización 
de los niveles de expresión de decenas de miles de genes al mismo tiempo. 
Esto se consigue mediante el diseño de sondas de ADN de cadena simple 
con secuencias especiﬁcas para interrogar determinados genes (Schena et al., 
1995). Estas sondas se ﬁjan físicamente a un soporte que nos permite evaluar 
la presencia de cada gen en determinadas condiciones celulares. Este tipo 
de tecnología se ha empleado para detectar genes involucrados en el ciclo 
celular (Spellman et al., 1998), genes que permiten pronosticar el desarrollo 
de enfermedades (van’t Veer et al., 2002), o para determinar los niveles 




Recientemente, y gracias a avances en el proceso de fabricación de los 
microarrays, la técnica ha sido escalada y es capaz de interrogar no solo 
regiones codiﬁcantes del genoma sino también regiones intergénicas, 
como por ejemplo los promotores de los genes. A su vez, los microarrays se 
han acopado a diferentes procesos, tales como inmunoprecipitación de la 
cromatina, lo que permite detectar interacciones especíﬁcas entre factores 
de trascripción y el ADN (Boyer et al., 2005; Cawley et al., 2004; Horak et al., 
2002a,b; Iyer et al., 2001; Martone et al., 2003; Ren et al., 2000).
Técnicas de secuenciación
La capacidad para secuenciar ácidos nucleicos ha mejorado sustancialmente 
en los últimos 30 años. Esto ha permitido poder secuenciar diferentes 
individuos de una determinada especie así como diversos organismos modelo. 
La disponibilidad de estas secuencias nos permite estudiar la variación entre 
miembros de la misma especie, así como entre distintas especies. El primer 
tipo de variación, entre miembros de una misma especie, permite a la especie 
adaptarse fácilmente a los cambios en el entorno en forma de población. 
Existen diferentes mecanismos causantes de la variación del ADN intra-
especie tales como la recombinación, duplicaciones, inserciones, delecciones 
y mutaciones. El tipo mas frecuente de variación entre individuos de una 
misma especie son las mutaciones puntuales, que se propagan en la población 
si no son fatales y si ocurren en la línea germinal. Cuando estas mutaciones 
aparecen en mas un 1% de una población se les denomina polimorﬁsmos 
de cambio único de base (single nucleotide polymorphism, SNP; Chakravarti, 
2001). Los individuos de una especie pueden tener más predisposición a 
sufrir una enfermedad o a tolerar de manera diferente distintas condiciones 
dependiendo de la combinación de alelos de diferentes SNPs.
Appendix A
151
Genómica y regulación transcripcional
En los últimos años, los mecanismos de regulación transcripcional han 
sido estudiados extensivamente desde un punto de vista genómico. La mayor 
parte de estudios experimentales se han realizado en levadura, ya que es un 
organismo que tiene altos niveles de conservación respecto a otros eucariotas 
y con el cual es fácil experimentar. Estos estudios han consistido en estudiar 
la expresión de los genes en diferentes condiciones como por ejemplo las 
diferentes fases del ciclo celular o daño al ADN (Chu et al., 1998, DeRisi 
et al., 1997). Estas aproximaciones se han complementado con métodos 
experimentales para determinar sitios de unión de factores de trascripción in 
vivo mediante inmunoprecipitación de la cromatina acoplada a microarrays 
de ADN. La combinación de estos datos junto con diferentes técnicas 
computacionales ha permitido recrear la red de regulación transcripcional 
de levadura y determinar que partes están activas en diferentes condiciones 
(Luscombe et al., 2004).
En humano sin embargo, la mayor parte de estudios que han empleados 
técnicas de genómica se han centrado en comparar el transcriptoma de 
muestras de determinadas enfermedades y tejidos sanos. No obstante, 
según las técnicas experimentales han ido mejorando, ha aumentado el 
interés en descifrar el entramado que controla los procesos de regulación 
transcripcional. La mayor parte de los esfuerzos actuales se centran en 
entender como combinaciones de diferentes factores de trascripción regulan 
diferentes procesos (Lemon and Tjian, 2000), para lo cual se han empleado 
técnicas computacionales de análisis de secuencias (Tompa et al., 2005) que a 
su vez han sido complementadas mediante aproximaciones experimentales 
para determinar estos sitios (Boyer et al., 2005; Boyer et al., 2006; Lee et al., 
2006). Pese a estos esfuerzos y al interés general en entender los mecanismos 
que regulan el control de la trascripción, nuestro conocimiento de estos 
sistemas en organismos superiores, y en particular en humano, es muy 
escaso.
Una de las razones detrás de esta falta de conocimiento es que siete años 
después de la publicación del genoma humano todavía no disponemos de una 
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lista de calidad de factores de trascripción en humano. Los primeros estudios 
estimaron un total de entre 200 y 300 factores de trascripción generales y 
entre 2,000 y 3,000 especíﬁcos de secuencia (Lander et al., 2001, Venter et al., 
2001). Desde entonces, solo dos estudios se han centrado en determinar este 
conjunto de genes. El primero, realizado por Messina y colaboradores (2004), 
se basa en una lista de factores de transcripción anotados en Transfac y GO 
para predecir, utilizando dominios proteicos de unión a ADN presentes en 
estos genes, el repertorio completo de factores de trascripción en el genoma. 
Utilizando esta aproximación, los autores detectaron 1,962 factores de 
trascripción. Examinado superﬁcialmente la lista de factores propuestos 
podemos se pone de maniﬁesto que esta contiene muchos genes anotados 
erróneamente, posiblemente debido a la deﬁciente deﬁnición de muchos de 
los dominios de unión a ADN utilizados.
En la segunda aproximación, Kummerfeld y Teichmann (2006) utilizaron 
una selección de dominios de unión a ADN ﬁltrando aquellos con una baja 
deﬁnición. Esta aproximación resultó en una mejora en la tasa de falsos 
positivos respecto a Messina et al. (2004), a costa de una perdida en cuanto a 
la sensibilidad de la detección.
El trabajo que presento en esta tesis esta dirigido a aumentar nuestro 
nivel de conocimiento sobre regulación transcripcional en humano mediante 
el análisis de datos a escala genómica utilizando técnicas bioinformáticas. 
En particular el trabajo se centra en el análisis a escala global de genomas, 
expresión génica y variación de secuencias de ADN entre miembros de una 
especie y diferentes especies.
En primer lugar presento métodos estadísticos y herramientas 
bioinformáticas que he desarrollado y que nos permiten analizar datos a escala 
genómica. En segundo lugar presento la identiﬁcación y caracterización del 
repertorio de factores de trascripción especíﬁcos de secuencia en el genoma 
humano. Por ultimo presento los resultados del impacto de la variación 





En concreto, los objetivos de la tesis doctoral son:
1. Desarrollar los métodos y herramientas necesarias para poder analizar 
e integrar los datos procedentes de experimentos de alto rendimiento a 
estudios sobre el control de la regulación transcripcional.
2. Identiﬁcar y caracterizar funcionalmente los factores de trascripción 
humanos.
3. Identiﬁcar y evaluar como los SNPs pueden afectar al proceso de 
control transcripcional.
A.3 Métodos
Una de las tareas más importantes en genómica y bioinformática consiste en 
la integración de diferentes tipos de datos que describen un sistema biológico 
en particular. Incorporando fuentes de información respecto a diferentes 
aspectos del sistema podemos construir una visión global del mismo que 
nos permita deﬁnir los principios básicos de su funcionamiento.
El trabajo que se presenta en esta tesis es puramente computacional. Los 
datos analizados se obtuvieron de las principales bases de datos publicas de 
genomas, proteínas y expresión génica. Estas incluyen:
(i) Bases de datos de genomas. Ensembl y las bases de datos satélite 
Ensembl Compara y Ensembl Variation se utilizaron como fuente de anotación 
genómica, conservación evolutiva y datos de SNPs, respectivamente. También 
se utilizaron otras bases de datos que contienen información evolutiva como 
por ejemplo Inparanoid.
(ii) Bases de datos de proteínas. Además de la anotación proteica que 
proporciona Ensembl, se utilizó la base de datos InterPro como fuente de 
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información sobre dominios proteicos de unión a ADN.
(iii) Bases de datos de expresión génica. Se utilizo ArrayExpress y 
sobretodo los datos de expresión del Genome Novartis Foundation SymAtlas 
(Su et al., 2004) como fuente de expresión génica en tejidos sanos en humano. 
Además se utilizaron otros conjuntos de datos describiendo diferentes 
condiciones, como por ejemplo el conjunto de datos de leucemia linfoblástica 
aguda y leucemia mielocítica aguda publicado por Golub et al. (1999), o el 
conjunto de datos sobre el complejo de compensación de la dosis génica en 
D. melanogaster procedente del laboratorio de Dr. Asifa Akhtar.
(iv) Otras bases de datos y conjuntos de datos. Estos incluyen diversas 
bases de datos como por ejemplo TRANSFAC o los repertorios de factores de 
transcripción obtenidos por Messina et al. (2004), o Kummerfeld y Teichmann 
(2006). También se incluyen aquí bases de datos de anotación génica como 
Gene Ontology o literatura cientíﬁca como PubMed. 
Estos datos fueron analizados mediante diferentes métodos estadísticos. 
Estos se pueden clasiﬁcar en: (i) métodos de estadística general; (ii) métodos 
de análisis de secuencias de ADN y proteína; y (iii) métodos de análisis de 
microarrays.
(i) Métodos de estadística general. Estos incluyen diferentes métodos 
estadísticos que han sido empleados a lo largo de la tesis tales como el test 
de la t, test exacto de Fisher, ajuste de p-valores por comparaciones múltiples 
o agrupamiento jerárquico.
(ii) Análisis de secuencias de ADN y proteína. aquí se han empleado 
métodos generales para analizar secuencias biológicas tales como BLAST 
(Altschul et al., 1990), Match (Kel et al., 2003) o InterProScan (Quevillon et 
al., 2005).
(iii) Métodos de análisis de microarrays. Estos métodos incluyen técnicas 
de normalización de microarrays de ADN, selección de genes diferencialmente 




Desarrollo de métodos y herramientas para el análisis de 
datos de microarrays
La primera sección de los resultados presenta diferentes herramientas de 
Internet y métodos que he desarrollado para analizar datos procedentes de 
experimentos de microarrays. Estos incluyen: (i) normalización de microarrays 
de ADNc; (ii) análisis de expresión diferencial de genes; (iii) predicción de 
clase para datos de microarrays; (iv) regulación mediada por factores de 
trascripción de grupos de genes co-expresados; (v) determinación de la 
especiﬁcidad y sensitividad para Affymetrix GeneChips; (vi) detección de 
expresión especíﬁca de tejido para datos de microarrays; y (vii) análisis de 
tiling microarrays.
DNMAD: Normalización de microarrays de ADNc
En esta sección describo DNMAD, una herramienta web diseñada para 
normalizar datos de expresión procedentes de experimentos de microarrays 
de ADNc. La normalización es un proceso por el cual se elimina variación 
sistemática en la señal procedente de los microarrays. DNMAD usa R y 
Bioconductor para realizar los cálculos correspondientes y una interfaz 
programada en Perl CGI desde la que el usuario puede seleccionar los datos 
a normalizar así como diferentes opciones. DNMAD implementa por defecto 
el método de normalización denominado print-tip loess (locally weighted 
scatter-plot smoothing), mediante el cual se ajustan las intensidades de los dos 
ﬂuoróforos teniendo en cuenta la posición de las sondas en el microarray. 
DNMAD también implementa otros tipos de normalización tales como loess 
global y normalización inter-arrays. DNMAD proporciona como resultado los 
valores de expresión normalizados. Además se incluyen diferentes gráﬁcos 
que proporcionan al usuario una guía para valorar los resultados del proceso 
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de normalización así como la calidad de los microarrays analizados.
Pomelo: expresión diferencial de genes en experimentos de microarrays
Pomelo es una herramienta web para la detección de genes 
diferencialmente expresados en experimentos de microarrays. Le herramienta 
implementa diversos métodos de análisis que incluyen el test de la t, análisis 
de la varianza y el test exacto de Fisher. El procedimiento consiste en testar 
estadísticamente los valores de expresión para cada gen incluido en el 
microarray entre dos o más grupos de muestras. La herramienta proporciona 
los p-valores asociados a cada gen ajustándolos para corregir el fenómeno de 
test múltiple.
TNASAS: Predicción de clases en experimentos de microarrays
TNASAS es una herramienta web que permite obtener predictores de 
clase basados en datos de expresión génica. La herramienta es un programa 
en Perl que se comunica con R para realizar las tareas computacionales. 
TNASAS implementa diferentes métodos para seleccionar genes basándose 
en su expresión diferencial entre clases, que posteriormente son usados por 
un algoritmo de predicción de clase. TNASAS devuelve como resultado la 
lista de genes que forma el mejor predictor probado así como tasas de error 
de predicción insesgadas basadas en un sistema de validación cruzada.
TransFAT: regulación mediada por factores de trascripción de grupos de gene 
co-expresados
TransFAT es una herramienta web que permite identiﬁcar co-regulación 
por factores de trascripción en grupos de genes co-expresados. La herramienta 
es un interfaz web programado en Perl que se comunica con R para realizar 
tareas de calculo. El programa se basa en predicciones de sitios de unión para 
270 factores de trascripción presentes en la base de datos TRANSFAC, que 
son obtenidas para 10kb en la región 5’ anterior al inicio de trascripción de 
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todos los genes de humano y ratón mediante el programa Match. TransFAT 
utiliza el test de Fisher con ajuste para test múltiple para encontrar factores 
de trascripción con sobre-representaciones de sitios de unión en grupos de 
genes co-expresados.
Determinación de la especiﬁcidad y sensitividad para Affymetrix GeneChips
Los microarrays de Affymetrix, al hibridar una sola muestra por microarray 
permiten evaluar los niveles de expresión de manera global. Sin embargo, 
debido a fenómenos de hibridación no competitiva así como por efecto de 
las técnicas de normalización, determinar cuando un gen se expresa o no 
es complicado. En esta sección describo un método que permite detectar 
la presencia o no de genes en estos experimentos. El método se basa en el 
uso combinado del algoritmo PANP (§3.2.3) junto a librerías de secuencias 
expresadas (ESTs) que permite valorar la especiﬁcidad y sensitividad del 
experimento. En §4.1.5 describo el uso de este método con el conjunto de 
datos SymAtlas de la fundación Genome Novartis. Para ello seleccionamos 
de la base de datos Unigene 31 librerías de secuencias que son expresadas 
en diferentes tejidos humanos sanos, y posteriormente evaluamos la 
diferencia de expresión reportada por los experimentos de microarrays para 
genes detectados como EST frente a genes no detectados. Los resultados 
de esta comparación muestran que pese a que hay un enriquecimiento de 
genes expresados con altos niveles de expresión, una parte signiﬁcativa de 
los genes se expresan a un nivel que no permite diferenciarlos de genes no 
expresados.
Posteriormente, utilizando los ESTs como grupo de verdaderos positivos 
y el grupo de sondas diseñadas contra la cadena negativa que emplea PANP 
como verdaderos negativos, pudimos determinar mediante curvas ROC 
los niveles de especiﬁcidad y sensitividad para los diferentes microarrays, 
situándose estos entre el 45% y el 65% dependiendo de la muestra.
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Expresión especiﬁca de tejido para datos de microarrays
En §4.1.6 describo el uso de un estadístico simple, la propensión, para 
determinar expresión especíﬁca de tejido. La propensión mide la relación 
entre el nivel de expresión de un gen respecto al nivel de expresión de 
ese gen en todas las muestras y el nivel de expresión global para el tejido 
examinado. Altos valores del estadístico indican que el gen esta expresado en 
el tejido examinado por encima del resto, lo cual indica expresión especíﬁca 
de tejido.
Evaluamos la validez del método analizando los niveles de propensión para 
el conjunto de datos SymAtlas. Para ello calculamos a partir de los niveles de 
expresión los valores de propensión para cada gen, y seleccionamos aquellos 
genes con valores de propensión entre los 5% mas altos como especíﬁcos 
de tejido. Posteriormente validamos esta aproximación mediante el análisis 
funcional de los genes especíﬁcos, que presentaban términos GO relacionados 
con la función de cada tejido signiﬁcativamente sobrerrepresentados.
Métodos de análisis para tiling microarrays
Los tiling microarrays nos permiten evaluar de manera sistemática la 
expresión génica o la unión de factores de trascripción al ADN a escala 
genómica ya que estos microarrays contienen sondas para interrogar regiones 
continuas del genoma. En §4.1.7 presentamos un método para el análisis de 
tiling arrays basado en una selección insesgada del ranking de las sondas mas 
signiﬁcativas en diferentes muestras. El método fue testado realizando un 
análisis del complejo de compensación de la dosis génica en D. melanogaster 
en colaboración con el laboratorio de la Dr. Asifa Akhtar en EMBL. El análisis 
incluye la determinación de los sitios de unión para cinco proteínas que 
forman parte o están relacionadas con este complejo: MSL1, MSL3, MOF, 
Mtor y Nup153. Estas proteínas tienen diferentes aﬁnidades de unión al ADN 
lo que diﬁculta el análisis combinado de los sitios de unión de los diferentes 
miembros del complejo. Este efecto se ve acentuado por la diferente eﬁciencia 
de los anticuerpos utilizados para realizar la inmunoprecipitación de la 
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cromatina para cada una de las proteínas.
Utilizando nuestro método basado en el ranking de las sondas fuimos 
capaces de determinar la existencia de una preferencia en cuanto a unión 
al cromosoma X por parte de las proteínas evaluadas, así como un posible 
mecanismo de acción del complejo basado en una diferente localización en 
el cuerpo del gen de la proteína MOF.
Identiﬁcación y caracterización funcional del repertorio 
de factores de trascripción especíﬁcos de secuencia en hu-
mano
En la segunda parte de los resultados se muestra como se identiﬁcaron y 
caracterizaron funcionalmente el grupo de genes que constituye el repertorio 
de factores de transcripción en humano.
La identiﬁcación de los factores de trascripción se llevo a cabo utilizando 
las secuencias que deﬁnen los dominios proteicos de unión a ADN disponible 
en la base de datos InterPro. Debido a la promiscuidad de alguno de estos 
dominios se llevo a cabo una comprobación manual de cada uno de los 
factores para eliminar falsos positivos. Esto resulto en la identiﬁcación de 
1,369 genes como el repertorio de factores de trascripción de humano.
Posteriormente realizamos la caracterización funcional del mismo. Para 
ello primero evaluamos el nivel de conocimiento sobre estos genes analizando 
su anotación en Gene Ontology y el numero de citas por factor de trascripción 
en PubMed. Los resultados mostraron una muy pobre caracterización para 
la mayor parte de los factores.
Seguidamente, y utilizando datos genómicos, procedimos a caracterizar 
diversos aspectos del conjunto de factores de trascripción especíﬁcos de 
secuencia de humano tales como su: (i) clasiﬁcación estructural; (ii) expresión 
y uso en tejidos sanos; (iii) conservación evolutiva; y (iv) localización 
cromosómica.
Los principales resultados que se pueden extraer del análisis son que: (i) 
tres familias de factores de trascripción (los dedos de zinc, los homeodominios 
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y los hélice-bucle-hélice) dominan sobre el resto de familias constituyendo 
un 80% del total de factores de transcripción en humano; (ii) diferentes 
tejidos del cuerpo humano utilizan un numero muy diferente de factores de 
trascripción, existiendo al menos en parte una correlación entre el numero de 
tipos celulares y actividad metabólica y secretora, con el numero de factores 
de trascripción activos por tejido. Además, estos factores de trascripción se 
organizan en dos capas de funcionamiento. Una capa global, con factores de 
trascripción expresados ubicuamente en todos los tejidos, y una local con 
factores de trascripción especíﬁcos de tejido; (iii) diferentes familias de factores 
de trascripción han aparecido en diferentes momentos durante la evolución, 
como por ejemplo la aparición de organismos multicelulares, vertebrados, 
mamíferos o primates; y (iv) una gran parte de factores de trascripción están 
localizados en grupos en el genoma, lo que podría concederles algún tipo 
especial de regulación.
Identiﬁcación y caracterización de SNPs funcionales
La tercera parte del trabajo presentado consiste en la detección de aquellos 
SNPs localizados en regiones del genoma en las que la existencia de un cambio 
de secuencia pueda tener un efecto en cuanto a la regulación transcripcional 
o el preprocesado del ARN mensajero.
Para ello se determinaron regiones del genoma con función reguladora, 
como por ejemplo: (i) sitios de unión de factores de trascripción; (ii) sitios 
de formación de ADN-triplex; (iii) potenciadores exónicos del proceso de 
splicing; y (iv) sitios aceptores y donantes de splicing.
Posteriormente se detectaron todos aquellos SNPs localizados en 
cualquiera de estas zonas. Los resultados de este análisis se hicieron públicos 
a través de la herramienta PupaSNP (Conde et al., 2004), cuyo contenido es 




El desarrollo de técnicas de alto rendimiento a partir de la secuenciación 
de múltiples genomas ha producido, y continua produciendo, un ﬂujo de 
información que requiere el desarrollo de métodos y herramientas para 
analizarlos. Sin los métodos estadísticos y el tratamiento matemático de los 
datos es muy difícil obtener resultados ﬁables y reproducibles que puedan 
ser posteriormente validados en subsiguientes experimentos. En este 
disertación he presentado métodos y herramientas para analizar resultados 
de mediciones de expresión génica o unión de factores de trascripción a 
escala genómica.
Uno de los mayores retos de la era post-genómica es entender las 
funciones y el uso de los genes en diferentes condiciones celulares. La 
regulación transcripcional juega un papel fundamental ya que determina 
que genes son expresados y en que medida bajo diferentes circunstancias. 
A pesar del gran interés que suscita esta línea de investigación, la mayor 
parte de los esfuerzos se han centrado en detectar sitios de unión de factores 
de trascripción en promotores de genes. Por el contrario, la caracterización 
del conjunto de factores de trascripción en humano no es suﬁcientemente 
completa.
En §4.2.1 presentamos un conjunto de factores de trascripción humanos 
especíﬁcos de secuencia de alta calidad que posteriormente caracterizamos 
funcionalmente. Esta lista ha sido manualmente comprobada para asegurar 
un bajo numero de falsos positivos y un alto nivel de cobertura. Es importante 
resaltar la contribución de este conjunto de factores de trascripción al campo, 
ya que proporciona un conjunto de factores de trascripción que servirán 
como referencia para cualquier estudio sobre regulación transcripcional en 
mamíferos. Su importancia se destaca por el hecho de que varios laboratorios 
experimentales ya están usando los datos en este momento.
Por ultimo, cabe resaltar que otro de los mayores retos después de la 
secuenciación del genoma humano es determinar que hace a cada individuo 
único. Aunque la mayor parte del genoma es idéntico entre distintos 
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individuos de la misma especie, siempre hay variaciones en la secuencia 
nucleotídica causadas por translocaciones, transposiciones o mutaciones 
entre otros mecanismos. La mayor fuente de variación entre individuos de 
una misma especie la constituyen los SNPs.
En §4.3 detectamos aquellos SNPs que son susceptibles de producir un 
cambio en la correcta regulación de la trascripción o preprocesado de un gen. 
Algunos de estos SNPs han sido encontrados en regiones con desequilibrio 
de ligamiento que han asociados posteriormente con diversas enfermedades 
complejas, como por ejemplo Alzheimer o depresión.
A.6 Conclusiones
En esta tesis he presentado trabajo computacional dedicado a investigar la 
naturaleza de la regulación transcripcional en el genoma humano. Aunque el 
estudio no constituye una completa caracterización del sistema, si que forma 
unos sólidos cimientos que sirvan de base para trabajos posteriores.
Especíﬁcamente, del trabajo presentado en esta tesis doctoral titulada 
“Computational Approaches to Study Transcripcional Regulation in the Human 
Genome” podemos concluir que:
1. He identiﬁcado y analizado el repertorio de factores de trascripción 
especíﬁcos de secuencia de humano. Este es el primer estudio de este tipo, 
y el conjunto de datos, así como los análisis desarrollados son resultados 
importantes para próximas investigaciones genómicas.
Este estudio ha revelado que:
(i) tres familias de proteínas — dedos de Zn C2H2, homeodominos y hélice-
bucle-hélice — dominan el repertorio de factores de trascripción humano.
(ii) los factores de trascripción se expresan bien de manera ubicua o bien 
especíﬁcamente en un tejido, dando lugar a un sistema regulación formado 
por reguladores globales y locales.
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(iii) familias especíﬁcas de factores de trascripción se han expandido a lo 
largo del linaje humano coincidiendo con puntos claves en la evolución.
(iv) alrededor de un 40% de los factores de trascripción se localizan 
en clusters en el genoma, pudiendo esto ser indicativo de su actividad 
coordinada.
2. He predicho SNPs que modiﬁcan el funcionamiento normal de los 
procesos de regulación transcripcional y post-transcripcional. De esta manera 
he demostrado que existen miles de variaciones en el ADN que potencialmente 
pueden tener un impacto en estos sistemas regulatorios. Estas predicciones 
contribuirán a mejorar nuestro entendimiento de enfermedades complejas, 
dirigiendo estudios experimentales hacia los SNPs mas prometedores.
3. He desarrollado métodos estadísticos y herramientas para el análisis 
de datos genómicos. Además he demostrado como estas son esenciales para 
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Ensembl ID DB-domain DB-family Class HGNC Symbol Tissue specific































- Ets ETV1 whole.brain, 
adrenal.cortex
ENSG00000006704 IPR011991 - Other GTF2IRD1







ENSG00000007866 IPR009057 IPR000818 Homeodomain_like TEAD3 placenta
ENSG00000007968 IPR011991 IPR003316 Other E2F2
ENSG00000008196 - IPR004979 
IPR008122
Other TFAP2B
ENSG00000008197 - IPR004979 Other TFAP2D












- Ets SAM_PNT ETV7
ENSG00000010244 IPR007087 - ZNF_C2H2 ZNF207
ENSG00000010539 IPR007086 
IPR007087
- ZNF_C2H2 ZNF200 whole.blood.JJV
ENSG00000010818 IPR007087 - ZNF_C2H2 HIVEP2 whole.brain, 
fetal.brain
ENSG00000011332 IPR007087 - ZNF_C2H2 DPF1
ENSG00000011451 IPR007087 - ZNF_C2H2 -
ENSG00000011590 IPR007087 - ZNF_C2H2 ZBTB32 testis
ENSG00000012504 IPR001628 IPR000324 
IPR001723











































ENSG00000025434 IPR001628 IPR000324 
IPR001723
IPR001728



















ENSG00000029363 - - TF_bZIP BCLAF1
ENSG00000030419 IPR007087 - ZNF_C2H2 ZNFN1A2














- Homeodomain_like HOXC8 skeletal.muscle.p
soas


















- TF_bZIP NFE2L3 placenta












- TF_Fork_head FOXC1 trachea, 
salivary.gland
ENSG00000056277 IPR007087 - ZNF_C2H2 SUHW3
ENSG00000057657 IPR007087 - ZNF_C2H2 PRDM1
ENSG00000059728 IPR011598 - HLH_DNA_bd MXD1
























ENSG00000064218 IPR001275 - DM_DNA_bd DMRT3
ENSG00000064489 IPR002100 - TF_MADSbox MEF2B















ENSG00000065978 IPR002059 - CSP_DNA_bd YBX1




- Ets SPI1 lung, 
whole.blood.JJV
ENSG00000066422 IPR007087 - ZNF_C2H2 ZBTB11
ENSG00000066827 IPR007087 - ZNF_C2H2 ZNF406
ENSG00000067082 IPR007087 - ZNF_C2H2 KLF6 lung
ENSG00000067646 IPR007087 IPR006794 ZNF_C2H2 ZFY
ENSG00000067955 - IPR003417 Other CBFB
ENSG00000068305 IPR002100 - TF_MADSbox MEF2A







- Homeodomain_like PITX1 tongue, pituitary
ENSG00000069667 IPR001628 IPR001723 
IPR003079
Hrmn_rcpt_DNA_bd RORA
ENSG00000069812 IPR011598 - HLH_DNA_bd HES2
ENSG00000070444 IPR011598 - HLH_DNA_bd MNT





















ENSG00000073861 IPR008967 IPR001699 P53_like_DNA_bd TBX21 whole.blood.JJV
ENSG00000074047 IPR007087 - ZNF_C2H2 GLI2
ENSG00000074219 IPR009057 IPR000818 Homeodomain_like TEAD2




































ENSG00000081059 IPR000910 - HMG_1/2_box TCF7








































ENSG00000084093 IPR007087 - ZNF_C2H2 REST
ENSG00000085274 IPR007087 - ZNF_C2H2 MYNN skeletal.muscle.p
soas




ENSG00000086102 IPR000967 - Znf_NFX1 NFX1
ENSG00000087510 - IPR004979 
IPR008123




- RFX_DNA_bd RFX2 testis, 
bone.marrow
ENSG00000088876 IPR007087 - ZNF_C2H2 ZNF343






ENSG00000089225 IPR008967 IPR001699 
IPR002070
P53_like_DNA_bd -
ENSG00000089335 IPR007087 - ZNF_C2H2 ZNF302 fetal.brain

























ENSG00000091831 IPR001628 IPR000324 
IPR001723
IPR012239









- IRF ISGF3G RNF31
ENSG00000092607 IPR008967 IPR001699 P53_like_DNA_bd TBX15





IPR001630 TF_bZIP CREM adrenal.gland, 
adrenal.cortex










- ZNF_C2H2 ZNF42 thymus, prostate,
fetal.thyroid






ENSG00000100146 IPR000910 - HMG_1/2_box SOX10 spinal.cord, 
trachea





- TF_bZIP XBP1 trachea, liver, 
prostate,
salivary.gland






ENSG00000100644 IPR011598 IPR001321 HLH_DNA_bd HIF1A smooth.muscle




















ENSG00000101076 IPR001628 IPR000003 
IPR001723
Hrmn_rcpt_DNA_bd HNF4A liver






















- SAND_like GMEB2 testis, thymus
ENSG00000101412 IPR011991 IPR003316 Other E2F1















- Ets ELF4 thymus, 
placenta,
bone.marrow, 
ENSG00000102145 IPR000679 - ZnF_GATA GATA1
ENSG00000102349 IPR007087 - ZNF_C2H2 -
ENSG00000102554 IPR007087 - ZNF_C2H2 KLF5 skin, pancreas, 
trachea, 
placenta, tonsil, 
ENSG00000102804 - IPR000580 Other TSC22D1













ENSG00000102935 IPR007087 - ZNF_C2H2 ZNF423 spinal.cord, 
whole.brain, 
uterus








ENSG00000103449 IPR007087 - ZNF_C2H2 SALL1 spinal.cord, 














ENSG00000104903 IPR011598 - HLH_DNA_bd LYL1 bone.marrow, 
fetal.liver
ENSG00000105066 IPR007087 - ZNF_C2H2 -


















- TF_bZIP DBP thyroid
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ENSG00000105856 IPR000910 - HMG_1/2_box HBP1 whole.blood.JJV





- Homeodomain_like DLX5 placenta
























































ENSG00000106459 IPR002100 - TF_MADSbox NRF1
ENSG00000106462 IPR001005 
IPR009057















ENSG00000106546 IPR011598 - HLH_DNA_bd AHR























- Homeodomain_like LHX3 pituitary
ENSG00000107249 IPR007087 - ZNF_C2H2 GLIS3








































- Homeodomain_like TCF2 kidney










- Homeodomain_like DLX4 placenta
ENSG00000108924 IPR004827 
IPR011700











































ENSG00000110693 IPR000910 - HMG_1/2_box SOX6
ENSG00000110851 IPR007087 - ZNF_C2H2 PRDM4
ENSG00000111046 IPR011598 - HLH_DNA_bd MYF6 skeletal.muscle.p
soas
ENSG00000111049 IPR011598 - HLH_DNA_bd MYF5





























- TF_bZIP CREBL2 adrenal.gland, 
pituitary

















- TF_bZIP BACH2 tonsil, fetal.brain
ENSG00000112200 IPR007087 - ZNF_C2H2 ZNF451
ENSG00000112238 IPR007087 - ZNF_C2H2 PRDM13
ENSG00000112242 IPR011991 IPR003316 Other E2F3 whole.blood.JJV
ENSG00000112246 IPR011598 IPR001067 HLH_DNA_bd SIM1









ENSG00000112561 IPR011598 - HLH_DNA_bd TFEB whole.blood.JJV
ENSG00000112658 IPR002100 - TF_MADSbox SRF
ENSG00000112837 IPR008967 IPR001699 
IPR002070
P53_like_DNA_bd TBX18





ENSG00000113580 IPR001628 IPR001409 
IPR001723














- ZNF_C2H2 BCL6 skeletal.muscle.p
soas,
whole.blood.JJV
ENSG00000114126 IPR011991 IPR003316 Other - testis, thymus














































ENSG00000115568 IPR007087 - ZNF_C2H2 ZNF142
ENSG00000115738 IPR011598 - HLH_DNA_bd ID2 liver











- TF_bZIP ZNF_C2H2 ATF2 fetal.brain, 
thyroid
ENSG00000116016 IPR011598 IPR001067 HLH_DNA_bd EPAS1 placenta, lung, 
fetal.lung






















ENSG00000116604 IPR002100 - TF_MADSbox MEF2D
ENSG00000116731 IPR007087 IPR009170 ZNF_C2H2 PRDM2 whole.brain, 
fetal.brain
ENSG00000116793 - - Other PHTF1
ENSG00000116809 IPR007087 - ZNF_C2H2 ZBTB17
ENSG00000116819 - IPR004979 Other TFAP2E
ENSG00000116833 IPR001628 IPR000324 
IPR001723
Hrmn_rcpt_DNA_bd NR5A2 pancreas
ENSG00000116990 IPR011598 IPR002418 HLH_DNA_bd MYCL1
















































- Homeodomain_like MYB thymus, 
bone.marrow








- TF_Fork_head FOXO3A bone.marrow, 
lung










ENSG00000119138 IPR007087 - ZNF_C2H2 KLF9 uterus



















ENSG00000119715 IPR001628 IPR000003 
IPR001723
Hrmn_rcpt_DNA_bd ESRRB
ENSG00000119725 IPR007087 - ZNF_C2H2 ZNF410 testis





























































ENSG00000120798 IPR001628 IPR000324 
IPR001723
Hrmn_rcpt_DNA_bd NR2C1
ENSG00000120837 IPR003958 IPR003956 
IPR003957
CBFA_NFYB_domain NFYB
ENSG00000120963 IPR007087 - ZNF_C2H2 ZNF706
ENSG00000121068 IPR008967 IPR001699 
IPR002070
P53_like_DNA_bd TBX2 placenta, lung, 
fetal.lung










ENSG00000121406 IPR007087 - ZNF_C2H2 ZNF549




















ENSG00000122145 IPR008967 IPR001699 P53_like_DNA_bd TBX22










ENSG00000122691 IPR011598 - HLH_DNA_bd TWIST1 skin, placenta, 
human.cultured.a
dipocyte, uterus
ENSG00000122859 IPR011598 - HLH_DNA_bd NEUROG3
ENSG00000122877 IPR007087 - ZNF_C2H2 EGR2 thyroid






IPR001630 TF_bZIP ATF1 whole.blood.JJV, 
thyroid
ENSG00000123307 IPR011598 - HLH_DNA_bd NEUROD4





































ENSG00000123870 IPR007087 - ZNF_C2H2 -
ENSG00000123933 IPR011598 - HLH_DNA_bd MXD4 thymus, lung
ENSG00000124092 IPR007087 - ZNF_C2H2 CTCFL






ENSG00000124232 IPR002909 - IPT_TIG_rcpt RBPSUHL
ENSG00000124440 IPR011598 IPR001067 HLH_DNA_bd HIF3A fetal.lung

















- Ets SAM_PNT SPDEF
ENSG00000124766 IPR000910 - HMG_1/2_box SOX4 thymus, 
smooth.muscle,
fetal.brain






ENSG00000124827 - IPR003902 Other GCM2
ENSG00000125285 IPR000910 - HMG_1/2_box SOX21
ENSG00000125347 IPR001346 
IPR011991


















ENSG00000125533 IPR011598 - HLH_DNA_bd BHLHB4
ENSG00000125618 IPR009057 
IPR011991










ENSG00000125812 IPR007087 - ZNF_C2H2 ZNF336
ENSG00000125813 IPR009057 
IPR011991








- Homeodomain_like NKX2-2 spinal.cord, 
whole.brain
ENSG00000125846 IPR007087 - ZNF_C2H2 ZNF133
ENSG00000125850 IPR007087 - ZNF_C2H2 OVOL2
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ENSG00000125952 IPR011598 IPR002418 HLH_DNA_bd MAX whole.blood.JJV




ENSG00000126003 IPR007087 - ZNF_C2H2 PLAGL2 testis
ENSG00000126351 IPR001628 IPR001723 
IPR001728
Hrmn_rcpt_DNA_bd THRA spinal.cord, 
whole.brain, 
fetal.brain



















ENSG00000126733 IPR009061 - Other DACH2















ENSG00000127124 IPR007087 - ZNF_C2H2 HIVEP3
ENSG00000127152 IPR007087 - ZNF_C2H2 BCL11B thymus























































ENSG00000129911 IPR007087 - ZNF_C2H2 KLF16
ENSG00000130182 IPR007087 - ZNF_C2H2 ZNF206













ENSG00000130684 IPR007087 - ZNF_C2H2 ZNF337 fetal.brain
ENSG00000130700 IPR000679 IPR008013 ZnF_GATA GATA5
ENSG00000130711 IPR007087 - ZNF_C2H2 PRDM12
















ENSG00000130940 IPR007087 - ZNF_C2H2 CASZ1


















ENSG00000131408 IPR001628 IPR000324 
IPR001723













































ENSG00000133250 IPR007087 - ZNF_C2H2 ZNF414
ENSG00000133740 - IPR003316 Other E2F5
ENSG00000133794 IPR011598 IPR001067 HLH_DNA_bd ARNTL







ENSG00000134025 IPR002909 IPR003523 IPT_TIG_rcpt EBF2




- Homeodomain_like MEIS2 prostate, uterus, 
salivary.gland, 
pituitary, 
ENSG00000134317 IPR007604 - CP2 GRHL1






ENSG00000134532 IPR000910 - HMG_1/2_box SOX5 testis
ENSG00000134595 IPR000910 - HMG_1/2_box SOX3











ENSG00000135111 IPR008967 IPR001699 
IPR002070



















- Ets SAM_PNT ELF5 trachea, 
salivary.gland
ENSG00000135457 IPR007604 - CP2 TFCP2
ENSG00000135547 IPR011598 - HLH_DNA_bd HEY2


































ENSG00000136451 IPR007087 - ZNF_C2H2 ZNF161 thymus, uterus, 
whole.blood.JJV
ENSG00000136535 IPR008967 IPR001699 P53_like_DNA_bd TBR1









- Homeodomain_like HLX1 bone.marrow, 
lung,
whole.blood.JJV

















ENSG00000136997 IPR011598 IPR002418 HLH_DNA_bd MYC

















- IRF IRF4 lymph.node, 
tonsil
ENSG00000137270 - IPR003902 Other GCM1 placenta
ENSG00000137273 IPR001766 
IPR011991
- TF_Fork_head FOXF2 lung, fetal.lung
ENSG00000137310 - - Other TCF19










ENSG00000137871 IPR007087 - ZNF_C2H2 - uterus

































- Ets SAM_PNT ETV6
ENSG00000139154 IPR007087 - ZNF_C2H2 AEBP2











ENSG00000139651 IPR007087 - ZNF_C2H2 ZNF740
ENSG00000139800 IPR007087 - ZNF_C2H2 ZIC5





































ENSG00000141040 IPR007087 - ZNF_C2H2 ZNF287


























ENSG00000141956 IPR007087 - ZNF_C2H2 PRDM15













- Ets SPIB lymph.node, 
heart, tonsil








ENSG00000142611 IPR007087 - ZNF_C2H2 PRDM16
ENSG00000142684 IPR007087 - ZNF_C2H2 ZNF593 liver
ENSG00000142700 IPR001275 - DM_DNA_bd -






ENSG00000143067 IPR007087 - ZNF_C2H2 ZNF697
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ENSG00000143171 IPR001628 IPR000003 
IPR001723
Hrmn_rcpt_DNA_bd RXRG
ENSG00000143178 IPR008967 IPR001699 
IPR002070






















ENSG00000143373 IPR007087 - ZNF_C2H2 ZNF687
ENSG00000143390 IPR003150 
IPR011991
- RFX_DNA_bd RFX5 lymph.node





ENSG00000143842 IPR000910 - HMG_1/2_box SOX13












ENSG00000144026 IPR007087 - ZNF_C2H2 ZNF514
ENSG00000144218 - - Other AFF3










ENSG00000144852 IPR001628 IPR000324 
IPR001723

































ENSG00000147488 IPR013681 IPR002515 Myelin_TF   ST18 spinal.cord
ENSG00000147596 IPR007087 - ZNF_C2H2 PRDM14
ENSG00000147789 IPR007086 
IPR007087
- ZNF_C2H2 ZNF7 skeletal.muscle.p
soas
ENSG00000147862 IPR003619 IPR000647 MAD_MH1 NFIB smooth.muscle
ENSG00000148143 IPR007087 - ZNF_C2H2 ZNF462
ENSG00000148200 IPR001628 IPR000324 
IPR001723
Hrmn_rcpt_DNA_bd NR6A1

























ENSG00000149054 IPR007087 - ZNF_C2H2 ZNF215






ENSG00000150347 - - Other -
ENSG00000150907 IPR001766 
IPR011991
- TF_Fork_head FOXO1A ovary
ENSG00000151090 IPR001628 IPR001723 
IPR001728
Hrmn_rcpt_DNA_bd THRB




















- Ets SAM_PNT FLI1 whole.blood.JJV















ENSG00000152284 IPR000910 - HMG_1/2_box TCF7L1
ENSG00000152433 IPR007086 
IPR007087




ENSG00000152467 IPR007087 - ZNF_C2H2 ZSCAN1
ENSG00000152518 IPR000571 - ZnF_CCCH ZFP36L2 whole.blood.JJV, 
thyroid












ENSG00000152977 IPR007087 - ZNF_C2H2 ZIC1 spinal.cord, 
whole.brain, 
fetal.brain
ENSG00000153234 IPR001628 IPR001723 
IPR003070
IPR003073
Hrmn_rcpt_DNA_bd NR4A2 trachea, ovary, 
adrenal.gland,
adrenal.cortex










- Homeodomain_like HOXA10 prostate, uterus














- Ets SAM_PNT GABPA
ENSG00000154832 - - Other CXXC1
ENSG00000154957 IPR007087 - ZNF_C2H2 -
































































ENSG00000158773 IPR011598 - HLH_DNA_bd USF1








IPR000040 P53_like_DNA_bd RUNX1 thymus










ENSG00000159882 IPR007087 - ZNF_C2H2 ZNF230













ENSG00000160007 - - Other GRLF1
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ENSG00000160062 IPR007087 - ZNF_C2H2 -
ENSG00000160113 IPR001628 IPR001723 
IPR003068



















ENSG00000160685 IPR007087 - ZNF_C2H2 ZBTB7B
ENSG00000160908 IPR007086 
IPR007087


























ENSG00000161642 IPR007087 - ZNF_C2H2 ZNF385
ENSG00000161853 IPR007087 - ZNF_C2H2 ZBTB12
ENSG00000161914 IPR007087 - ZNF_C2H2 ZNF653















ENSG00000162676 IPR007087 - ZNF_C2H2 GFI1 thymus, 
bone.marrow
ENSG00000162702 IPR007087 - ZNF_C2H2 ZNF281















































ENSG00000163508 IPR008967 IPR001699 P53_like_DNA_bd EOMES
















ENSG00000163795 IPR007087 - ZNF_C2H2 ZNF513
ENSG00000163848 IPR007087 - ZNF_C2H2 SLC12A8 
ZNF148
fetal.thyroid
ENSG00000163884 IPR007087 - ZNF_C2H2 KLF15










ENSG00000164107 IPR011598 - HLH_DNA_bd HAND2
ENSG00000164185 IPR007087 - ZNF_C2H2 ZNF474
ENSG00000164256 IPR007086 
IPR007087















ENSG00000164458 IPR008967 IPR001699 
IPR002070
P53_like_DNA_bd T
ENSG00000164532 IPR008967 IPR001699 P53_like_DNA_bd TBX20




- ZNF_C2H2 ZNF12 uterus, pituitary
ENSG00000164651 IPR007087 - ZNF_C2H2 SP8
ENSG00000164683 IPR011598 - HLH_DNA_bd - spinal.cord, 
whole.brain, 
lung, fetal.brain
ENSG00000164684 IPR007087 - ZNF_C2H2 ZNF704
ENSG00000164736 IPR000910 - HMG_1/2_box SOX17 uterus, lung


















































- Homeodomain_like PKNOX2 whole.brain
ENSG00000165512 IPR007086 
IPR007087

























ENSG00000165643 IPR011598 - HLH_DNA_bd SOHLH1
ENSG00000165655 IPR007087 - ZNF_C2H2 ZNF503








ENSG00000165804 IPR007087 - ZNF_C2H2 ZNF219
ENSG00000165821 IPR007087 - ZNF_C2H2 SALL2 spinal.cord, 
whole.brain, 
pituitary








ENSG00000166261 IPR007087 - ZNF_C2H2 ZNF202
ENSG00000166402 - - Other -











ENSG00000166716 IPR007087 - ZNF_C2H2 ZNF592



























































ENSG00000167395 IPR007087 - ZNF_C2H2 ZNF646














ENSG00000167685 IPR007087 - ZNF_C2H2 ZNF444
ENSG00000167766 IPR007086 
IPR007087


































ENSG00000168269 IPR001766 - TF_Fork_head -
ENSG00000168310 IPR001346 
IPR011991








































ENSG00000168795 IPR007087 - ZNF_C2H2 ZBTB5







ENSG00000168916 IPR007087 - ZNF_C2H2 -
ENSG00000169016 - IPR003316 Other E2F6



















ENSG00000169297 - IPR001723 Other NR0B1 testis









ENSG00000169594 IPR007087 - ZNF_C2H2 BNC1





















ENSG00000169926 IPR007087 - ZNF_C2H2 KLF13 thymus, 
human.cultured.a
dipocyte, lung























ENSG00000170260 IPR007087 - ZNF_C2H2 ZNF212
ENSG00000170265 IPR007087 - ZNF_C2H2 ZNF282
ENSG00000170322 - - Other NFRKB

















- Homeodomain_like EMX2 whole.brain, 
uterus, kidney
ENSG00000170374 IPR007087 - ZNF_C2H2 SP7




































- TF_bZIP ZNF_C2H2 ATF7






















- ZNF_C2H2 ZNF350 whole.blood.JJV













































- ZNF_C2H2 ZNF274 lymph.node, 
whole.blood.JJV













- CG-1 IPT_TIG_rcpt CAMTA1 spinal.cord, 
whole.brain, 
fetal.brain
ENSG00000171786 IPR011598 - HLH_DNA_bd NHLH1









ENSG00000171843 - IPR005033 Other MLLT3 fetal.brain
ENSG00000171872 IPR007087 - ZNF_C2H2 KLF17
ENSG00000171940 IPR007087 - ZNF_C2H2 ZNF217 lymph.node, 
thymus, 
placenta,














ENSG00000172059 IPR007087 - ZNF_C2H2 KLF11 testis, uterus, 




ENSG00000172238 IPR011598 - HLH_DNA_bd ATOH1
ENSG00000172262 IPR007087 - ZNF_C2H2 -
ENSG00000172273 IPR007087 - ZNF_C2H2 MIZF









- Heat shock factor 
(HSF)-type
HSFY1 HSFY2












ENSG00000172818 IPR007087 - ZNF_C2H2 OVOL1
ENSG00000172819 IPR001628 IPR001723 
IPR003078
Hrmn_rcpt_DNA_bd RARG













ENSG00000173068 IPR007087 - ZNF_C2H2 BNC2 uterus










ENSG00000173275 IPR007087 - ZNF_C2H2 ZNF449
ENSG00000173276 IPR007087 - ZNF_C2H2 ZNF295
201
Transcription Factor Repertoire


























































ENSG00000174738 IPR001628 IPR000324 
IPR001723
Hrmn_rcpt_DNA_bd NR1D2 uterus, pituitary, 
thyroid
ENSG00000174963 IPR007087 - ZNF_C2H2 ZIC4





































ENSG00000175727 IPR011598 - HLH_DNA_bd MLXIP
ENSG00000175745 IPR001628 IPR001723 
IPR003068




















































ENSG00000176399 IPR001275 - DM_DNA_bd DMRTA1
ENSG00000176407 IPR007087 - ZNF_C2H2 - testis














ENSG00000176887 IPR000910 - HMG_1/2_box SOX11 fetal.brain
ENSG00000177030 IPR000770 
IPR010919







ENSG00000177125 IPR007087 - ZNF_C2H2 ZBTB34
ENSG00000177311 IPR007087 - ZNF_C2H2 ZBTB38 smooth.muscle, 
uterus













ENSG00000177468 IPR011598 - HLH_DNA_bd OLIG3












IPR002112 TF_bZIP JUN uterus, lung, 
thyroid















ENSG00000178042 IPR007087 - ZNF_C2H2 -
ENSG00000178150 IPR007087 - ZNF_C2H2 ZNF114
































ENSG00000178860 IPR011598 - HLH_DNA_bd MSC
ENSG00000178919 IPR001766 
IPR011991








ENSG00000178951 IPR007087 - ZNF_C2H2 ZBTB7A
ENSG00000179059 IPR007087 - ZNF_C2H2 ZFP42




ENSG00000179348 IPR000679 - ZnF_GATA GATA2 placenta, 
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ENSG00000180357 IPR007087 - ZNF_C2H2 -
ENSG00000180479 IPR007087 - ZNF_C2H2 ZNF571
ENSG00000180532 IPR007087 - ZNF_C2H2 ZSCAN4




















- Homeodomain_like HOXC10 human.cultured.a
dipocyte, kidney







ENSG00000181007 IPR007087 - ZNF_C2H2 ZNF545
ENSG00000181135 IPR007087 - ZNF_C2H2 -
ENSG00000181220 IPR007087 - ZNF_C2H2 ZNF746
205
Transcription Factor Repertoire
ENSG00000181315 IPR007087 - ZNF_C2H2 ZNF322A
ENSG00000181444 IPR007086 
IPR007087
- ZNF_C2H2 ZNF467 whole.blood.JJV








ENSG00000181666 IPR007087 - ZNF_C2H2 HKR1
ENSG00000181690 IPR007087 - ZNF_C2H2 PLAG1






































































ENSG00000183434 IPR011991 IPR003316 Other TFDP3






ENSG00000183733 IPR011598 - HLH_DNA_bd -




ENSG00000183779 IPR007087 - ZNF_C2H2 ZNF703
ENSG00000183850 IPR007086 
IPR007087
- ZNF_C2H2 ZNF254 ZNF539
ENSG00000183900 NA NA Other FOXD1 testis, 
smooth.muscle
ENSG00000184058 IPR008967 IPR001699 P53_like_DNA_bd TBX1



















































ENSG00000184677 IPR007087 - ZNF_C2H2 ZBTB40
ENSG00000184828 IPR007087 - ZNF_C2H2 -
ENSG00000184895 IPR000910 - HMG_1/2_box SRY






















ENSG00000185219 IPR007087 - ZNF_C2H2 ZNF445
ENSG00000185252 IPR007087 - ZNF_C2H2 ZNF74










ENSG00000185551 IPR001628 IPR001723 
IPR003068
Hrmn_rcpt_DNA_bd NR2F2 uterus
































ENSG00000185811 IPR007087 - ZNF_C2H2 ZNFN1A1
ENSG00000185947 IPR007086 
IPR007087























ENSG00000186130 IPR007087 - ZNF_C2H2 ZBTB6




ENSG00000186300 IPR007087 - ZNF_C2H2 ZNF555
ENSG00000186350 IPR001628 IPR000003 
IPR001723





























ENSG00000186918 IPR007087 - ZNF_C2H2 FBXO16 ZNF395 placenta, 
prostate,




ENSG00000187079 IPR009057 IPR000818 Homeodomain_like TEAD1





























































ENSG00000188785 IPR007087 - ZNF_C2H2 -
ENSG00000188786 IPR007087 - ZNF_C2H2 MTF1
ENSG00000188801 IPR007087 - ZNF_C2H2 ZNF322B
ENSG00000188841 - IPR003316 Other -
ENSG00000188868 IPR007087 - ZNF_C2H2 ZNF563


























































- Homeodomain_like DUX2 DUX4







































































































































ENSG00000197162 IPR007087 - ZNF_C2H2 ZNF688
ENSG00000197279 IPR007087 - ZNF_C2H2 ZNF165
ENSG00000197283 IPR007087 - ZNF_C2H2 ZBTB9
ENSG00000197294 IPR007087 - ZNF_C2H2 ZNF72
ENSG00000197337 - IPR003316 Other - bone.marrow, 
fetal.liver








































































ENSG00000197905 IPR009057 IPR000818 Homeodomain_like TEAD4 thyroid














































ENSG00000198169 IPR007087 - ZNF_C2H2 ZNF251


















































































ENSG00000198740 IPR007087 - ZNF_C2H2 ZNF652 prostate
ENSG00000198767 IPR007087 - ZNF_C2H2 YY2
ENSG00000198783 IPR007087 - ZNF_C2H2 CCDC16










ENSG00000198839 IPR007087 - ZNF_C2H2 ZNF277 whole.blood.JJV














































ENSG00000203883 IPR000910 - HMG_1/2_box SOX18











ENSG00000204210 IPR007087 - ZNF_C2H2 ZBTB22








ENSG00000204335 IPR007087 - ZNF_C2H2 -




















- Homeodomain_like DPRX DPRXP4
ENSG00000204604 IPR007086 
IPR007087





































ENSG00000205927 IPR011598 - HLH_DNA_bd OLIG2 spinal.cord, 
whole.brain
ENSG00000206083 IPR007087 - ZNF_C2H2 ZNF409
ENSG00000206207 IPR007087 - ZNF_C2H2 -






- Homeodomain_like PBX2 whole.blood.JJV
ENSG00000206280 IPR007087 - ZNF_C2H2 -






- Homeodomain_like PBX2 whole.blood.JJV
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ABSTRACT
The Gene Expression Profile Analysis Suite, GEPAS,
has been running for more than three years. With
.76 000 experiments analysed during the last year
and a daily average of almost 300 analyses, GEPAS
can be considered a well-established and widely
used platform for gene expression microarray data
analysis. GEPAS is oriented to the analysis of whole
series of experiments. Its design and development
have been driven by the demands of the biomed-
ical community, probably the most active collective
in the field of microarray users. Although cluster-
ing methods have obviously been implemented in
GEPAS, our interest has focused more on methods
for finding genes differentially expressed among dis-
tinct classes of experiments or correlated to diverse
clinical outcomes, as well as on building predictors.
There is also a great interest in CGH-arrays which
fostered the development of the corresponding
tool in GEPAS: InSilicoCGH. Much effort has been
invested in GEPAS for developing and implement-
ing efficient methods for functional annotation of
experiments in the proper statistical framework.
Thus, the popular FatiGO has expanded to a suite
of programs for functional annotationof experiments,
including information on transcription factor binding
sites, chromosomal location and tissues. The web-
based pipeline for microarray gene expression data,
GEPAS, is available at http://www.gepas.org.
INTRODUCTION
GEPAS, which stands for Gene Expression Profile Analysis
Suite, is a web tool designed and oriented to the analysis of
DNA microarray gene expression experiments. The emphasis
in the development of new tools for GEPAS has been driven
by the requirements of data analysis in the most active fields
using microarray technologies, which are, without doubt,
biomedical applications [e.g. (1–4)]. As a consequence,
much stress has been put on the implementation of proper
methods for gene selection, predictors, CGH-arrays and
functional annotation of experiments. More classical data
analysis approaches, such as clustering, have also been incor-
porated into GEPAS, as well as different options for data
preprocessing.
GEPAS has been conceived as an integrated web-based
pipeline for the analysis of gene expression patterns where
different methods can be used within an integrated interface
that provides a user-friendly environment to end users. The
way in which the methods are connected has been designed to
guide the user by suggesting all the available possibilities to
continue with the analysis and to prevent possible inappropri-
ate uses of the tools.
GEPAS, which was originally the backbone of the pipeline
of microarray data analysis of the CNIO, was made public
three years ago and first published in 2003 (5,6). In the years
since, GEPAS has become a de facto standard for many
researchers and its use has undergone a spectacular growth.
In terms of the scope of analysis, GEPAS is the most complete
web-based resource that can be found nowadays.
Our aim is to keep GEPAS ‘living’ by the continuous
addition of new algorithms. Here we report the new modules,
some trends observed in its use and some novelties.
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SCOPE OF GEPAS
As previously mentioned, GEPAS is experiment oriented. This
means that facilities for data manipulation such as rows and
columns management are deliberately absent in its design.
With the exception of the module DNMAD, which can take
as input Genepix (Axon instruments) GPR files from a scanner
(see below), GEPAS accepts as input data already preselected
(usually coming from a database) in a very simple format: a
tab-delimited text file containing genes in rows and experi-
ments in columns (except the first column, which contains the
identifiers for the genes).
Several preprocessing facilities are provided. These are nor-
malization along with different kinds of data transformation
such as missing value imputation, filtering of ‘flat’ patterns
and extraction of genes based on functional properties.
GEPAS permits two main types of experimental designs:
those oriented towards class discovery, for which different
clustering methods are available, and those related to super-
vised questions, which include mainly gene selection and
building predictors. GEPAS includes two tools for dealing
with both of these problems.
In addition, there is a great interest now in tools that allow
CGH-arrays to be handled. GEPAS includes a module for
mapping either genomic or mRNA hybridizations over the
corresponding chromosomal locations, with different facilities
for data visualization.
Finally, GEPAS provides a module for functional annota-
tion of experiments that includes the popular FatiGO (8), as
well as a variety of new tools.
GEPAS AT A GLANCE
GEPAS includes a number of interconnected tools imple-
mented as individual modules that can be used either inde-
pendently or within the pipeline (Figure 1). Since the previous
version (6), GEPAS has undergone a number of technical
improvements which have not had much impact on its exter-
nal aspect but have notably changed its performance. Internal
links among modules have been improved and redesigned in
order to avoid wrong pathways in the pipeline. Some CPU-
intensive modules have been moved to dedicated computers
(in particular DNMAD, Pomelo and Tnasas). The structure of
GEPAS is as follows.
Preprocessing
DNMAD (9) is for normalization using print-tip loess (10,11)
(http://www.bioconductor.org), with different possibilities.
Some additional options have been included in this new ver-
sion: the possibility of using a spot’s flags, optional use of
background subtraction and the possibility of using global
loess (instead of print-tip). We have also included a better
management of flagged dots, new diagnostic plots (the density
plots for either raw or background-corrected red and green
channels) and automatic dye-swap. DNMAD can take as input
Genepix (Axon instruments) GPR files.
Preprocessor (12) performs some preprocessing of the data
(log-transformations, standardizations, imputation of missing
values, etc.). Data can also be filtered on the basis of their
functional labels [GO terms (13)] using the Knowledge
Filtering module (6).
Figure 1. TheGEPAS pipeline. The figure summarizes themost important features of the GEPAS pipeline. Black arrows show the flow of information from the raw
data to the threemain types of analysis: CGH-array, unsupervised clustering and supervised analysis (gene selection or predictors). Functional annotation is possible
from the latter two options. Grey arrows represent the possibility to re-analyse parts of the experiments.
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IDconverter, a new module, maps lists of accession
numbers and identifiers among different clone, gene or protein
standards. IDconverter includes distinct levels of information
such as gene level (gene HUGO name, Ensembl gene, Unigene
cluster, LocusLink, RefSeq, gene location, gene description),
clone level (Affymetrix, GenBank accession number, IMAGE
Clone ID) and protein level (SwissProt, TrEMBL, now UNI-
PROT). Chromosomal locations are obtained from Ensembl.
Analysis
Unsupervised clustering includes different methods such
as aggregative clustering (14), SOTA (15,16), SOM (17),
K-means (18) (which is a new addition in this version of
GEPAS) and SOM-Tree (19).
Supervised analysis includes
(i) Gene selection. Analysis of genes differentially expressed
between two or more classes, related to a continuous
experimental factor (e.g. the concentration of a metabolite)
or to survival is performed by the module Pomelo (6).
Different methods for multiple testing adjustment are
included (20–22).
(ii) Predictors. Themodule Tnasas (for ‘This is not a substitute
for a statistician’) implements a simple, although effective,
way of building class predictors from microarray data. The
error rate is computed taking into account the effect of gene
selection and is not biased downwards by the ‘selection
bias’ problem so common in many microarray studies
[e.g. (23,24)].
For the analysis of CGH-arrays, given the growing interest
in microarray-based CGH (array CGH) (25), we have expan-
ded the capabilities of the InSilicoCGH tool, which allows the
mapping of the results of microarray hybridizations onto chro-
mosome coordinates. The InSilicoCGH module has been
designed for the simultaneous analysis of genomic and
mRNA hybridizations on the same expression array. It can
also deal with BAC-arrays. We have added a new option: the
zoom. This magnifies the view of the desired chromosomal
location in order to facilitate detection of the precise position
of chromosomal gains and losses; in general, it allows hybrid-
ization values at gene level to be viewed in more detail.
Figure 2 is a screenshot of the zoom tool.
Functional analysis of experiments
Functional annotation of microarray experiments is an import-
ant aspect of analysis that very few packages incorporate.
Several modules for functional annotation of microarray
Figure 2. The zoom tool of InSilicoCGH in action. Clicking on the desired chromosomal region produces a pop-upwindowwith a zoom facility. The user can freely
move around the point chosen and can easily visualize in detail the hybridization values. Borders of deleted or amplified regions can be precisely defined in this way.
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experiments are available. These programs, along with
similar ones, are discussed in an accompanying paper by
our group (7)
(i) FatiGO (8) allows significant asymmetrical distributions
of GO terms between groups of genes to be found.
(ii) FatiWise (6) does the same with InterPro motifs (26),
KEGG (27) pathways and SwissProt keywords, when
available.
(iii) TransFAT performs the same operations for putative tran-
scription factor binding sites in the promoter regions of
genes as predicted by the program Match (28), from the
Transfac database (29).
(iv) TMT, the Tissues Mining Tool, is a web application to
extract significant information related to the differential
expression of two sets of genes in tissues.
(v) FatiScan allows the detection of modest but coordinate
changes in gene expression values by applying the FatiGO
algorithm to lists of genes ordered according to their
differences in expression.
All these tools, in addition of being connected to GEPAS
(because of its obvious usefulness for the analysis of
microarray data), are grouped as an independent resource
called Babelomics (7). Babelomics has, at its general
purpose, the facilitation of functional annotation in any type
of high-throughput experiments (proteomics, interactomics,
massive sequencing, etc.).
In terms of its internal architecture, GEPAS is a collection
of programs mainly written in C++, although some were writ-
ten in other programming languages such as R [DNMAD (9)]
or PERL [Preprocessor (12)]. These modules are interconnec-
ted by PERL wrappers.
A PIPELINE OF MICROARRAY DATA ANALYSIS
TOOLS
The efficiency of a modular package such as GEPAS lies
largely in its degree of integration of the different data analysis
tools. Users can move through a complete pipeline of data
analysis in a transparent way, without needing to perform any
reformatting operation. In addition, a properly designed work-
flow can help to prevent possible wrong operations in microar-
ray data analysis owing to misconceptions. Figure 1 illustrates
the structure of the GEPAS pipeline. Raw data can be loaded
and normalized. Several data transformation options are avail-
able through the Preprocessor tool. Depending on the particu-
lar problem addressed, data can be directed to any of the three
main types of analysis: CGH-array, unsupervised clustering
and supervised analysis (gene selection or predictors). A func-
tional annotation is possible from the last two options. GEPAS
has been designed in a way that prevents possible misuses of
the methods implemented in the package.
TRAINING PROGRAMME AND GEPAS
In addition to the tools, a collection of on-line tutorials that can
be used to learn the use of the tools or as a part of a course is
available on the GEPAS web page. The structure of the tutori-
als includes some theory, a guided example and several
examples based on publicly available datasets. There are
tutorials for (i) normalization using DNMAD, (ii) data pre-
processing using the Preprocessor tool, (iii) data clustering
using the different algorithms available (UPGMA, SOM,
SOTA), (iv) selection of differentially expressed genes using
the Pomelo tool and (v) functional annotation using FatiGO.
The tutorials are currently used on different courses, such as
a masters in bioinformatics (Spain) and the international
FCUL-IGC Post-Graduate Programme in Bioinformatics
(http://bioinformatics.fc.ul.pt/).
CONSOLIDATION OF GEPAS AS A WIDELY
USED PACKAGE
Our records indicate that, since March 2004, GEPAS has been
used to analyse >76 000 experiments, with a daily average of
almost 300 uses (statistics can be checked at http://bioinfo.
cnio.es/docus/webalizer/ on the different pages for GEPAS,
and the particular pages for Pomelo, Tnasas, DNMAD and
FatiGO, which are independently monitored). Compared with
last year’s records (35 000 experiments per year with a daily
average of 130) (6), there has been a clear increase in the use of
the tool. The distribution of users has also changed. Whereas
one year ago it was used more by Spanish researchers (25%),
followed by US (.edu and .net domains) (15%), French (10%),
UK (5%) and other users (Japanese, German, Dutch, etc.) (6)
the profile of users during this last year has changed to 23%US
(.edu and .net), 9% French, 6% Spanish, 5% UK and others.
These figures suggest that GEPAS seems to be becoming more
popular among US-based researchers. Obviously the usage in
all countries has increased, since the remainder of the percent-
ages appear to maintain the same level while the absolute
number of uses has increased 2-fold.
CONCLUSIONS
Despite the availability of many programs and packages for
microarray data analysis, there are still many aspects of the
analysis with poor or incomplete coverage. There are a number
of options for analysing DNA microarray data (see e.g. http://
www.dnamicroarrays.info/software.html). Most of the soft-
ware available for microarray data analysis focuses on unsu-
pervised cluster methods, which, in many cases, are used for
inadequate purposes (23). There are also different initiatives
such as BASE (30), Bioconductor (31) and BRB tools (http://
linus.nci.nih.gov/BRB-ArrayTools.html), but these are in
some cases dependent on a particular computer operating
system and usually require from the user previous training
in statistics. GEPAS can be considered the most complete
web-based resource that can be found nowadays.
Since the first release (5,6), GEPAS has avoided the temp-
tation to become a list of as many methods as possible and
evolved really to cope with new challenges that have emerged
in the field of microarray data analysis. Much work has been
invested in the implementation of a useful workflow. GEPAS
provides the user with an integrated environment in which
modules can be found for different types of analysis that
respond to real analysis demands. Modules are connected in
such a way as to avoid improper use of the tools.
From a technical point of view, GEPAS has been designed
with the intention of taking full advantage of the properties of
Nucleic Acids Research, 2005, Vol. 33, Web Server issue W619
the web: connectivity, cross-platform compatibility and remote
usage. The modular architecture allows the addition of new
tools and facilitates the connectivity of GEPAS from and to
other web-based tools.
With >76 000 experiments analysed during the last year and
a daily average of almost 300 uses, GEPAS can be considered
a consolidated tool in the field of microarray data analysis.
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ABSTRACT
Summary: We present a web server for Diagnosis and Nor-
malization of MicroArray Data (DNMAD). DNMAD includes
several common data transformations such as spatial and
global robust local regression or multiple slide normalization,
and allows for detecting several kinds of errors that result from
the manipulation and the image analysis of the arrays. This tool
offers a user-friendly interface, and is completely integrated
within the Gene Expression Pattern Analysis Suite (GEPAS).




DNA array technologies (Schena et al., 1996) allow the sim-
ultaneous monitoring of the expression of thousands of genes.
Experiments usually involve measuring the expression levels
of genes under several conditions corresponding to different
samples, different doses of a certain drug or different stages
during an individual’s lifetime.
Ideally, DNA microarray techniques allow us to focus on
changes in gene expression levels that are solely due to dif-
ferences between the samples. However, it is widely accepted
that other factors such as differences in labelling efficiency,
physical properties of the dyes, differences in hybridization,
changes in scanner settings, etc. can introduce systematic
variation aside from that due to the expression levels of genes
in each sample (Yang et al., 2002).
Therefore, to obtain accurate and precise results from the
analysis of microarray data, normalization of data is essen-
tial. Here, we describe a web-based tool for Diagnosis and
Normalization of spotted cDNA MicroArray Data (DNMAD).
2 MOTIVATION
Within print-tip group location normalization has proven
to be an effective method in normalizing microarray data
(Yang et al., 2002), but the use of most currently available
implementations requires prior training on using a statistical
∗To whom correspondence should be addressed.
package such as R (http://www.R-project.org), which could
represent a relatively high investment especially if the only
aim behind such training is to normalize microarray data.
Despite the importance of normalization, there are not
many bioinformatic Web tools available to perform normal-
ization procedures, and the few that exist, e.g. SNOMAD
(Colantuoni et al., 2002) or Multi microarray normalization
(http://genome1.beatson.gla.ac.uk/Rweb/anova.html), do not
offer certain options that would make the process more effi-
cient such as the use of files coming directly from the scanner
or the possibility of entering more than one slide at a time.
In addition, connectivity and data exchange between tools
is also important. Web tools integrated within a suite for gene
expression pattern analysis, as opposed to individual Web
tools, allow users to perform the whole analysis without hav-
ing to manipulate file formats to make them compatible with
the tools used for each individual step. Also, server-based
solutions benefit from the server processing capacity (greater
than that of personal computers), that allow the user to process
more data simultaneously. To allow for efficient handling of
requests from many users, the DNMAD service is controlled
by a queue system.
The aim of this tool is to provide the scientific community
with an easy to use, fully featured web interface for microar-
ray data normalization that is completely integrated within
the freely available Gene Expression Pattern Analysis Suite
(GEPAS) (Herrero et al., 2003a).
3 WEB INTERFACE
This application uses R (R Core, 2004, http://www.R-
project.org) and the Bioconductor package limma (Smyth
et al., 2004, http://www.bioconductor.org), with some cus-
tom modifications, to carry out the normalization procedures.
The web interface is a Perl CGI script that communicates with
R using the CGIwithR (Firth, 2004, http://cran.r-project.org)
package. The server accepts a set of GenePix files as input,
either compressed as a single file (.tar.gz, .zip or .tar.bz2) or as
uncompressed GenePix files coming directly from the scan-
ner. These files must adhere to the original standard file format
from GenePix, although customized files containing only the
3656 Bioinformatics vol. 20 issue 18 © Oxford University Press 2004; all rights reserved.
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appropriate columns of data (Block, Column, Row, Name,
ID, F635 Mean, B635 Median, F532 Mean, B532 Median
and Flags) can also be used if GenePix software has not been
used to scan the arrays, or if custom modifications have been
made to the data. These columns constitute the minimal set
of columns required to perform the normalization. The lay-
out of the array must be introduced into the interface along
with the data files. Other options, such as the use of flags (for
excluding certain spots from the normalization) or background
subtraction, can also be selected in the web interface.
The default normalization method is ‘print-tip loess’, as
implemented in Yang et al. (2002). This method consists
of a robust local regression for each print-tip group of the
array. This method can only be used if the following assump-
tions are met: (1) the number of points to normalize must
be large in each print-tip group; (2) very few genes should
be differentially expressed (i.e. the expression of the two co-
hybridized mRNA samples should be similar for the majority
of the spots of the array); and (3) there should be an approx-
imately equal number of up- and downregulated genes in each
print-tip group.
If these assumptions cannot be met for each print-tip group,
it is possible to use, instead, ‘global loess’, where the local
robust regression is carried out over the whole array instead
of for each print-tip group (Yang et al., 2002).
4 RESULTS
The output page contains information regarding the type of
normalization followed, errors and warnings, plots for inter-
preting the results and for diagnosis and links to download the
normalized data or to enter the hub of GEPAS (Herrero et al.,
2003a), via the Preprocessor module (Herrero et al., 2003b).
A summary of all options selected for normalization is
shown at the top of the output page. This information is
also attached to the results file that contains the normal-
ized log2 ratios of expression. Furthermore, a collection of
plots and images are provided in order to show plate effect,
printing effects and potential problems occurring during the
elaboration of the array and the hybridizations, in the sample
preparations, in the scanning of the arrays, etc.
These plots include: (1) boxplots for all the arrays and for
each array showing individual print-tip groups, to assess the
need for normalization for a particular array; (2) MA-plots
with the regression curve for each print-tip group, in order to
observe the efficiency of the normalization; and (3) diagnostic
plots.
Diagnostic plots are compositions of 10 different plots, and
they should help the user to detect problems in the arrays
(Smyth et al., 2003, http://www.bioconductor.org). These
plots include: (1) histograms of the raw pixel intensities (log2)
of the red and green mean foreground that help to identify
problems in the scanner settings or in the hybridizations;
(2) density plots of the log2 intensities for both channels,
displayed in sidewise panels for all the arrays and for each
array; and (3) images of the arrays including the red and green
background, and the unnormalized and normalized ratio val-
ues, which should help to identify spot damaged arrays or
spatial patterns. All plots and images can be downloaded along
with an HTML document to browse through them.
As the server accepts multiple arrays, and given that these
multiples arrays can show differences between their scales,
slide-scale normalization is provided. This method, imple-
mented as in Yang et al. (2002), reduces differences in the
scales of the arrays that are being normalized. After slide-scale
normalization, plots and images are provided again, allowing
the user to decide if the slide-scale procedure is valuable for
the particular data.
Finally, links to download the normalized data [normalized
expression ratios in log2 scale and the A values (the ‘average
signal’ or 0.5 ∗ (log2 R + log2 G))] are displayed, to enable
data storage. A direct link to the Pre-analysis module of the
Preprocessor (Herrero et al., 2003b) is also provided, allow-
ing the user to continue with analysis using the GEPAS suite
(Herrero et al., 2003a, 2004), such as for clustering genes, or
to identify differentially expressed genes, without having to
perform any kind of format adjustment to the data.
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ABSTRACT
We have developed a web tool, PupaSNP Finder
(PupaSNP for short), for high-throughput searching
for single nucleotide polymorphisms (SNPs) with
potential phenotypic effect. PupaSNP takes as its
input lists of genes (or generates them from chromo-
somal coordinates) and retrieves SNPs that could
affect the conserved regions that the cellular machin-
ery uses for the correct processing of genes (intron/
exon boundaries or exonic splicing enhancers), pre-
dicted transcription factor binding sites (TFBS) and
changes in amino acids in the proteins. The program
uses themapping of SNPs in the genome provided by
Ensembl. Additionally, user-defined SNPs (not yet
mapped in the genome) can be easily provided to
the program. Also, additional functional information
from Gene Ontology, OMIM and homologies in other
model organisms isprovided. In contrast toother pro-
grams already available, which focus only on SNPs
with possible effect in the protein, PupaSNP includes
SNPs with possible transcriptional effect. PupaSNP
will be of significant help in studies of multifactorial
disorders, where the use of functional SNPs will
increase the sensitivity of identification of the
genes responsible for the disease. The PupaSNP
web interface is accessible through http://pupasnp.
bioinfo.cnio.es.
INTRODUCTION
Single nucleotide polymorphisms (SNPs) are the simplest and
most frequent type of DNA sequence variation among indi-
viduals and they represent one of the most powerful tools
for the analysis of genomes (1). Owing to their widespread
distribution, SNPs are particularly valuable as genetic markers
in the search for disease susceptibility genes, drug response-
determining genes, and so on. In the past decades, linkage
analysis has been very successful in the identification of
genes responsible for mendelian diseases. Nevertheless, direct
application of linkage analysis to the case of complex diseases,
in which several genes with weaker genotype–phenotype cor-
relations are involved, has resulted in more modest success
(2). Now, it is believed that improved genotyping methods in
combination with the proper design strategies could bring the
genetics of complex diseases to a point of success comparable
to where mendelian genetics now firmly resides (3).
There are examples documented in which alleles of more
than one gene contribute to the same disease. It is generally
believed that multigenic diseases reflect disruptions in the
proteins that participate in a protein complex or a pathway
(4). Typically, SNPs have been used as markers; that is, the
real determinant of the disease was not the SNP itself but some
other mutation in linkage disequilibria with it.
The use of functional SNPs could be an important factor for
increasing significantly the sensitivity of association tests. In
fact, several complex genetic disorders such as Alzheimer’s
disease (5) and Crohn’s disease (6) have been associated with
functional SNPs, lending credence to strategies giving priority
to candidate markers based on predictable function. The latest
build of NCBI’s dbSNP (http://www.ncbi.nlm.nih.gov/SNP/
snp_summary.cgi) contains 5 772 564 SNPs, with 2 356 957 of
them validated. This means that human variation has been
screened to an average resolution of 1 SNP for every 566 nt.
There is also curated information on SNPs in HGVbase (7).
These figures suggest that the possibility of finding the real
determinant of a disease among the characterized SNPs can
be seriously considered. In fact, dbSNP build 117 contains
24 483 SNPs located in coding regions that produce amino
acid change, affecting a total of 9791 different genes. Several
estimate suggest that, overall, only 20% of them could damage
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the protein (8). Much attention has been focused on the
possible phenotypic effects of SNPs that cause amino acid
changes. The volume of available information together with
the development of more sophisticated methods of protein
structure prediction has led to different attempts to relate
the effect of amino acid changes to structural distortions
and, consequently, possible phenotypic effect. Following
this, two main different approaches have been taken: on the
one hand is the study of conservation of residues in homo-
logous proteins (9) including more sophisticated approaches
taking into account the phylogenetic history (10) and, on the
other hand, there is the study of changes in the stability
(11,12) and other properties of the protein due to changes
of amino acids (8,13).
Nevertheless, there are different ways in which the func-
tionality of a gene product can be affected without requiring a
amino acid change in the protein. There is increasing evidence
that many human disease genes harbour exonic or non-coding
mutations that affect pre-mRNA splicing (14). Alternative
splicing produced by mutations in intron/exon junctions, or
in distinct binding motifs, such as exonic splicing enhancers
(ESEs), to which different proteins involved in splicing bind,
is the basis of different diseases. In fact, it has been estimated
that 15% of point mutations that result in human genetic dis-
eases cause RNA splicing defects (15). For example, a silent
mutation in exon 14 of the APC gene is associated with exon
skipping in a Familial Adenomatous Polyposis (FAP) family
(16), and there are many more examples [see Table 2 in (14)].
Also, alterations in the level of expression of gene products
can cause diseases. Different SNPs are associated with altera-
tions in gene expression (17) and, in some cases, it is known
that they alter some regulatory sequence motif. For example, a
regulatory polymorphism in the programmed cell death 1 gene
(PDCD1), which alters a binding site for the runt-related tran-
scription factor 1 (RUNX1) located in an intronic enhancer, is
associated with susceptibility to systemic lupus erythematosus
in humans (18). It has also been reported that polymorphisms
in the gelatinase A promoter region are associated with dimin-
ished transcriptional response to estrogen and genetic fitness
(19). A recent large-scale screening over a set of 16 chromo-
somes, found SNPs in the promoters regions of 35% of the
genes, and experimental evidence suggested that around one-
third of promoter variants may alter gene expression to a
functionally relevant extent (20). Therefore, the inclusion of
other possible causes of loss of functionality in gene products,
beyond the simple estimation of the possible phenotypic effect
of an amino acid change, increases considerably the number of
SNPs with potential phenotypic effect to be considered for the
design of experiments.
Classical statistical linkage tests need a large number of
cases if the number of genes to be tested is high. It has
only recently been recognized that reliable identification of
genetic variants that affect gene regulation is still a challenge
in genomics and is expected to play an important role in the
molecular characterization of complex traits (21). Another
important consideration when analysing multigenic traits is
the information available on the genes. Information allows
a more targeted approach, by focusing initially on genes
whose functionality is related to the disease studied.
Genome surveys based on the information contained in
dbSNP show that there are 361 SNPs mapped in splice sites
of introns, 1 387 506 in introns and 242 842 in untranslated
regions affecting 336 16 306 and 14 198 genes, respectively. A
number of these SNPs could be disease determinants.
With the idea of extracting as much information as possible
form SNPs with putative phenotypic effect, we have devel-
oped PupaSNP Finder (Putative Phenotypic Alterations caused
by SNPs; PupaSNP for short). This tool retrieves all the SNPs
present in a set of genes of interest that potentially affect the
functionality of the gene product. This list is combined with
functional information obtained from Gene Ontology (GO)
annotations (22). Genes can be directly retrieved from geno-
mic locations or, alternatively, can be taken from a list pro-
vided by the user. This corresponds to two typical problems:
(i) traits mapped to a given chromosomal region or (ii) traits
associated with a given class of genes (e.g. a signalling path-
way). Genome coordinates of genes and SNPs are taken from
the Ensembl annotation (23).
METHODS
Finding SNPs with potential phenotypic effect
PupaSNP operates with a collection of entries from dbSNP
mapped to the Golden Path genome assembly, as implemented
in human section of Ensembl (http://www.ensembl.org). As
previously mentioned, PupaSNP uses a list of genes and gen-
erates a report in which all the SNPs with possible phenotypic
effect are listed. The genes can be selected directly by their
location in a region of the genome, or just provided as a list
(e.g. genes belonging to a given pathway, involved in a parti-
cular biological function). Genomic regions can be selected
either by defining a range of chromosome coordinates or by
directly choosing the cytoband of interest. The engine finds all
the genes located within the specified region as well as their
promoter regions using Ensembl APIs. In the case of a user-
defined list, Ensembl is used to extract their complete intron/
exon structure as well as the promoter regions.
The potential effects on the phenotype taken into account
are at both transcriptional and gene product levels.
These include alterations in (i) transcription factor binding
sites, (ii) intron/exon border consensus sequences, (iii) ESE
sequences, which are the binding sites for specific serine/
arginine-rich (SR) proteins involved in the splicing machinery
(24,25) and (iv) the exons that cause an amino acid change.
Additionally, the GO terms (22) associated with the genes can
be obtained. This is very useful in the case of looking for genes
in a chromosomal region, because it can help to discard genes
definitively not involved in the disease studied, based on the
annotations.
Transcription factor binding sites. In the search for SNPs
with potential phenotypic effect, 10 000 bp upstream of the
genes, belonging to the promoter region of each gene in the
list, are scanned for the presence of possible transcription
factor binding sites (TFBSs). The program MatchTM (26),
version 1.10, from the Transfac1 database (27), version pro-
fessional 7.3, was used for this purpose. SNPs located within
these motifs are considered to have a putative phenotypic
effect in the expression of the gene. The options used for
the program MatchTM were (i) group of matrices: vertebrates,
(ii) use high quality matrices only and (iii) cutoff selection for
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matrix group: to minimize false positives. This cutoff was
obtained by exploring the third exon sequences with the
weight matrices and was chosen to reduce the number of
random putative sites found by the program (26).
Although the scan is done in a region 10 000 bp upstream
from the start of the gene, the number of bases to be taken into
account in the study is customizable. Obviously, the closer to
the start of the gene, the more likely the binding site is to be
authentic.
Intron–exon boundaries. Ensembl APIs were used to extract
the intron/exon organization of the genes and the correspond-
ing sequences. The two conserved nucleotides at each side of
the splicing point, which constitute the splicing signal (14),
were then located and all the SNPs altering these signals are
recorded.
Exonic splicing enhancers. Mutations that deactivate or acti-
vate exonic splicing enhancer sequences may result in exon
skipping, malformation, and so on. ESEs also appear to be
important in exons that normally undergo alternative splicing.
Different classes of ESE consensus motifs have been
described, but they are not always easily identified. We
have developed a script that scans exon sequences to identify
putative ESEs responsive to the human SR proteins SF2/ASF,
SC35, SRp40 and SRp55, by using the weight matrices avail-
able for them (28). A score is obtained related to the likelihood
that the site found is a real ESE. Only ESE sites with scores
over the threshold [see (28) and http://exon.cshl.org/ESE/
ESEmatrix.html for details] are taken into account in the ana-
lysis. Threshold values, above which a score for a given
sequence is considered to be significant, are set as the median
of the highest score for each sequence in a set of 30 randomly
chosen 20 nt sequences (from the starting pool used for func-
tional assays for ESE identification; see http://exon.cshl.org/
ESE/ESEmatrix.html). If an SNP disrupts one of these
sequences, the new score, corresponding to the mutated
sequence, is also calculated. Strong differences between the
two score values suggestmore drastic effects caused by the SNP.
Changes at aminoacid level and functional implications. SNPs
that result in a change of amino acid are likely to cause some
phenotypic effect and, consequently, are all listed. Since the
main purpose of the tool is to cover possible transcriptional
effects of the SNPs and there are a number of tools already
available for the prediction of phenotypic effects due to muta-
tions in amino acids (see Introduction) PupaSNP only lists
them. To help in the identification of possible effects we label
SNPs that disrupt any functional motif as listed in Interpro (29),
a resource that compiles information on protein families,
domains and functional sites. The coordinates of the Interpro
motifs within the exons of the genes are extracted from
Ensembl and cross-referenced with the SNPs coordinates.
Additional functional information. Since PupaSNP finder
works with lists of genes in order to select the best SNP
candidates for further use in association analysis, it is very
helpful to have functional annotations of the genes. This
allows the assignment of priorities based also on the informa-
tion available on the genes. Information is obtained from (i)
Gene Ontology annotations, obtained through the FatiGO
engine (30) (available at http://fatigo.bioinfo.cnio.es), (ii)
OMIM (Online Mendelian Inheritance in Man), which con-
stitutes a comprehensive, authoritative and timely knowledge
base of human genes and genetic disorders (31) and (iii) homo-
logies to other organisms, obtained directly from Ensembl.
Gene Ontology is a tree structure (called a directed acyclic
graph) in which terms describing three fundamental ontologies
(molecular function, biological process and cellular compo-
nent) have descendants with more detailed descriptions. Thus,
descending the hierarchy of GO implies moving towards terms
with more detailed descriptions of the ontologies, but, at the
same time, there are fewer genes with annotations at such
detail. FatiGO works by climbing up the hierarchy to a
selected parent level (30) to optimize the number of genes
with annotation and the detail of the annotation. Thus, the
identification of common parent functions or processes is
easier. In this way, the consideration of the SNPs in a func-
tional context can help to understand the potential biological
implications of the SNPs and genes studied.
RESULTS
SNPs with possible phenotypic effect
We analysed a total of 24 037 human genes corresponding to
the annotations in Ensembl build 34 (version 18.34.1), which
contains the mapping of dbSNP 117. By scanning with the
MatchTM program the 10 000 bp upstream promoter regions of
the genes, 2 587 478 transcription factor binding sites, corre-
sponding to 330 different Transfac weight matrices (27), were
found. After mapping the SNPs in the promoter regions,
71 444 TFBSs were found to be disrupted by a total of
57 412 SNPs (some SNPs affect more than one TFBS at the
same time). A total of 19 010 genes presented at least 1 pre-
dicted TFBS disrupted by a SNP, which constitutes a consid-
erable proportion of the total number of genes. The coverage
in terms of both SNPs and TFBS predictions was good: only
for 54 genes was no single SNP found in the 10 000 bp 50-
upstream region, and only for 2 genes could no predicted
TFBS be found (ENSG00000116119, or KV2A_HUMAN,
which is the IG KAPPA CHAIN V-II REGION CUM, and
ENSG00000174994, or AK057375, which seems to be a DNA
binding protein). In a number of cases, SNPs affect overlap-
ping TFBSs, which could have a stronger effect still in the
phenotype. There are even 2 SNPs that simultaneously affect
15 TFBSs.
The four conserved bases that define intron–exon bound-
aries were mutated by 844 SNPs, affecting to a total of
598 genes.
Over eight million ESE motifs were found, covering all the
genes studied. A total of 138 746 SNPs were found to disrupt
ESE sequences. These SNPs affect a total of 17 312 genes.
These results suggest that, in the search for SNPs with
potential phenotypic effects, regulatory SNPs or SNPs affect-
ing splicing should not be neglected.
The web interface
Input data. PupaSNP has been designed for high-throughput
screening of functional SNPs. Thus, the input consists of a list
of genes. The list can be directly provided as a collection of
gene identifiers (Ensembl IDs, or external IDs, which include
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GenBank, Swissprot/TrEMBL and other gene IDs supported
by Ensembl) or can be specified by means of a chromosomal
location (cytobands or chromosomal coordinates). In the latter
case, PupaSNP extracts all the genes contained in the specified
location. Ensembl coordinates are used to extract the genes.
Only Ensembl annotated genes, but not predictions, are
extracted.
User-defined SNPs. Alternatively, the user can input SNPs
not in the database in a very straightforward manner and
take advantage of the tools for predicting their potential phe-
notypic effect. A text file containing the descriptions of the
SNPs must be generated. Each line describes one unique SNP
with the following tab-delimited data: SNP name, gene
(Ensembl ID or external ID), position with respect to the
start of the translation and alleles, e.g.
MySNP01 ENSG00000000003 -1830 A/G
MySNP02 ENSG00000157873 421 C/G
This describes two SNPs: the first in the gene
ENSG00000000003 (tetraspanin 6, or TSPAN6), 1830 bp
away from the transcription start point, with polymorphisms
consisting of a change of an A for a G; and the second in gene
ENSG00000157873 (tumor necrosis factor receptor-like 2,
TNFRSF14), 421 bp within the transcripted region, which
corresponds to the first exon of the gene.
The web interface. Aweb interface to PupaSNP is available at
http://pupas.bioinfo.cnio.es/. Lists of genes can be defined
by chromosome position, which can be specified in terms
of cytoband units or in absolute chromosomal position (as
mapped in the corresponding Ensembl assembly). The up-
stream region makes reference to the number of bases
upstream in which TFBSs will be searched for (with a
upper limit of 10 000 bp). Also, lists of genes can be uploaded
or just pasted into the box. PupaSNP finds all the SNPs map-
ping to locations that might cause a loss of functionality in the
genes. Functional information for the genes can also be
obtained from OMIM and from Gene Ontology. Information
on homologous genes can also be retrieved. Finally, SNPs do
not need to be annotated in the genome to be included in the
query tool. The user can specify a list of SNPs using a gene as
reference. In this way the use of absolute coordinates, which
can easily change between assembly versions, is avoided in
favour of the use of coordinates relative to genes, which tend to
be more stable. Results include SNPs in a the promoter region
of the genes, SNPs located at intron boundaries, SNPs located
at exonic splicing enhancers and coding SNPs located at Inter-
pro domains. Figure 1 shows part of the results provided by the
program for the SNPs with possible phenotypic effect on genes
in the p36.33 cytoband of chromosome 1. Figure 1C is espe-
cially interesting because it shows how the scores obtained by
the motif scanning method can be used to assess the possible
impact of the polymorphism on the recognition of the ESE
motif by the cellular machinery.
Both the SNPs and the genes found are linked to the
Ensembl Genome Browser.
Experimental validation
The validation status of the SNPs is, in some cases, a much
more important factor for their selection than their possible
functional role. Such information is scarce: 2 359 534 out of
5 798 183 SNPs in dbSNP build 118 have been validated,
which constitutes 40%. However, only 160 466 have estimates
of population frequencies and only 94 867 have a phenotype
associated. To obtain a sense of the reliability of the SNPs
annotated with ‘no-info’, a set of SNPs was sought for a list of
candidate modifier genes related to a phenotype exhibited by
MEN2 (Multiple endocrine neoplasia, type IIA) patients
(OMIM, #171400), all of them RET mutation carriers.
MEN2 is an autosomal dominant syndrome of multiple endo-
crine neoplasms, with variable clinical expression even
between members of the same family. This fact cannot be
explained only by a mutation in a major susceptibility gene,
but suggests a role for genetic modifiers, which may also work
through quantitative effect.
In most of cases, it was necessary to validate the putative
SNPs identified by PupaSNP because there was no information
about validation status. To validate SNPs and estimate their
allele frequency, 48 non-related individuals from the Spanish
population were used. The specific primers used to amplify the
fragments of interest by PCR (polymerase chain reaction)
were designed using the OLIGO 4.1 program. When possible,
the primers were selected and designed to amplify a fragment
(200–500 bp) that allowed us to investigate several SNPs at the
same time. As a denaturing high-performance liquid chroma-
tograph (dHPLC) system (WAVE, Transgenomics Limited,
Crewe, UK) was used for the initial SNP screening, the frag-
ments of interest had a homogeneous GC content across dif-
ferent domains from the DNA fragment to obtain a consistent
melting profile. The Navigator software was used for data
handling and optimization of the dHPLC system. After nor-
malization, each PCR product that exhibited a change in the
chromatogram profile was characterized by sequence analysis.
These PCR products were purified using an E.Z.N.A. Cycle-
Pure Kit (Omega Bio-tek, USA) according to the man-
ufacturer’s instructions, and sequenced using an automatic
sequencer ABI PRISMTM 3700 (Applied Biosystems. Perkin
Elmer, USA). The reaction was carried out in 4 ml of a Big Dye
terminator cycle sequencing Kit (Perkin Elmer, USA), 10 pmol
of the sense/antisense primer, 5% DMSO and 6–12 ng of
amplified DNA. Although the results obtained here do not
pretend to be capable of general extrapolation to the entire
database, we have found that 24 out of 28 SNPs assayed
proved to be authentic and polymorphic in the Spanish popu-
lation, which constitutes a good rate.
DISCUSSION
Typically, SNPs have been used as markers to search for the
real determinant of a disease in linkage disequilibria with it. As
previously mentioned, the use of functional SNPs, which may
be the real disease determinants, could be an important factor
in increasing the sensitivity of association tests.
Despite the obvious importance that alterations in the reg-
ulation, expression level or splicing of genes can have for the
phenotype, these have long been ignored in the most common
approaches to finding functional SNPs, which have instead
focused more on the possible effect of polymorphisms causing
amino acid changes. Apart from the databases mentioned
above (dbSNP and HGVbase), there are a number of resources
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available over the net collecting information on phenotypes
associated with SNPs, such as The Human Gene Mutation
Database (http://www.hgmd.org) at the University of Wales,
which classifies SNPs according the lesion they cause
(missense substitutions, splice variants, and so on) (32) and
PicSNP, a catalogue of non-synonymous SNPs obtained from
the human genome assembly (33). However, these are mainly
specialized catalogues collecting information on SNPs rather
than tools for their selection.
PupaSNP constitutes a tool for selecting SNPs with putative
phenotypic effects designed for high-throughput experiments.
It deals with lists of genes, instead of focusing on individual
genes. In addition, more information on different possible
motifs with regulatory function has been included. For exam-
ple, SNPs in ESE had never previously been included in any
catalogue.
Multigenic diseases are generally associated with disrup-
tions in proteins that participate in a protein complex or a
pathway (4). The inclusion in PupaSNP of information regard-
ing the participation of genes in signalling cascades or in
pathways or in protein complexes will be considered in the
near future. Databases containing protein interaction data,
such as DIP and BIND (see http://www.hgmp.mrc.ac.uk/
GenomeWeb/prot-interaction.html), can be an important
source of information to be considered in the search for
SNPs affecting multigentic traits.
Despite the fact that PupaSNP is more focused on
SNPs with possible effects at transcriptional level, the
inclusion of an algorithm for improving the predictions of
the effect of SNPs in the proteins, such as FoldX (12),
would provide, within the same framework, both types of
result.
Minimum SNP set selection allows the user to optimize
the number of SNPs required to represent haplotype diversity,
thus reducing the cost of genotyping by assaying the mini-
mum number of SNPs required. The inclusion of information
on linkage disequilibrium or on haplotype blocks can assist in
a more efficient selection of SNPs. Some programs, such as
HapScope (34), include information on haplotypes and use
them to select minimum subsets of SNPs. Another important
issue is the reliability of the SNPs. As previously mentioned,
only 40% of the SNPs in dbSNP have been validated, and
only for 5% are population frequencies are available. This
means that most of the SNPs found in any kind of selection
will lack information on their possible presence in the
population of interest as a manageable polymorphism. Even
though our results suggest a high rate of authenticity, even for
the SNPs labeled as ‘no-info’, they must be treated carefully
Figure 1. A selection of results from PupaSNP. (A) List of genes and the corresponding transcripts with the SNPs mapping to the different regions, which include
coding and 50- and 30-untranslated regions. For coding SNPs, the position within the transcript and the change produced (if any) is reported. (B) SNPs located in the
promoter regions (in the example, a limit of 4000 bp was chosen). Disruptions of predicted TFBSs are listed. The validation status of the SNPs (‘no-info’,
‘by-submitter’, ‘by-frequency’, ‘by-cluster’; see dbSNP web page) is also provided. (C) SNPs located at exonic splice enhancers. The scores make reference to the
closeness of the site to the motif. If the polymorphism gives a site with a worst score, this would, generally speaking, probably imply worst recognition of the site by
the cellular machinery and, consequently, a putative alteration in the normal splicing process. When the cursor is over the gene name, additional information is
displayed.
W246 Nucleic Acids Research, 2004, Vol. 32, Web Server issue
and cannot be directly extrapolated to the entire database.
As population frequencies are included in the database,
these data could be of interest for use as part of the selection
process of SNPs
PupaSNP will be the tool used in the first step of the pipeline
for the study of polymorphisms at the Spanish National
Genotyping Centre (CeGen). For this reason it has been deve-
loped to cope with high-throughput experimental designs.
PupaSNP takes as input lists of genes (or generates them
from chromosomal coordinates) and provides results which
integrate all the information available as well as obtained
by means of predictions of SNPs with possible functional
consequences.
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